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Abstract 
Hearing loss is a common sensory deficit that affects more than 275 million 
people worldwide. Identifying and understanding the genetic causes which 
underlie hearing loss can lead to improved diagnostic and treatment strategies. 
The biological function of Vitelline Membrane Outer Layer 1 homolog (chicken) 
(VMO1) is of particular interest as the mRNA transcript was previously found to 
be uniquely expressed and highly abundant in the mouse inner ear. 
The aim of this research was to design, clone, express and purify a recombinant 
VMO1 protein containing a His Tag using the VMO1 gene amplified from human 
cell lines. The VMO1 gene was cloned into the pET28b(+) expression system and 
bacterial cells were manipulated to express the recombinant VMO1 protein 
through IPTG induction. The resulting recombinant protein was then purified 
using a nickel affinity gel. Finally, a commercial VMO1 antibody was tested and 
validated using the purified recombinant VMO1 protein using western blot 
analysis.  
Bioinformatics analysis was undertaken to develop primers to amplify cDNA of 
two isoforms of the VMO1 gene in human cell lines, isoform 1 and isoform 3. 
Both isoforms of the VMO1 gene were found to be expressed in two commercial 
in vitro human cancer cell lines; monocytic leukaemia and breast cancer. 
Following amplification, the isoforms were sub cloned into T-tailed vectors, with 
isoform 1 being successfully ligated into the pET28b(+) expression vector. 
Sequencing data confirmed the amplified cloned PCR inserts were VMO1 
transcripts, and the predicted translated sequence was in-frame with the His Tag, 
resulting in a recombinant protein that was 20 kDa in size.  
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Expression of the recombinant VMO1 protein was attempted using three bacterial 
expression strains with successful expression of a 20 kDa protein occurring in the 
Rosetta
™
 (DE3) pLysS strain. The recombinant VMO1 protein formed inclusion 
bodies within bacterial cells following over expression. Western blot analysis of 
non purified protein samples showed that the 6X His antibody recognised a 
20 kDa recombinant protein as expected. However, the commercially available 
VMO1 antibody detected two bands approximately 20 and 35 kDa in size. 
In the future, it is recommended that optimisation of recombinant protein folding 
methodology, large scale protein induction and purification of the VMO1 protein 
be completed. In addition, it is recommended to validate the VMO1 antibody by 
testing in vitro human cancer cell lines for the expression of VMO1 protein. Once 
the specificity of the VMO1 antibody has been demonstrated by western blot 
analysis, functional assays could be performed to determine the biological 
function of VMO1. This may provide further insight into the function of VMO1 in 
the mammalian inner ear and the role it may play in hearing.  
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CHAPTER ONE 
Introduction and Literature Review  
1.1 Introduction 
Hearing loss (HL), in the form of moderate to profound deafness, is a common 
sensory deficit thought to affect more than 275 million people worldwide (Hilgert, 
Smith, & Van Camp, 2009). It can be caused by the partial or complete loss of 
sound perception. The aim of this thesis is to express and purify a recombinant 
Vitelline Membrane Outer Layer 1 homolog (chicken) (VMO1) protein that can 
be used for validation of commercially available antibodies and elucidation of 
function of the protein through biochemical assays. This protein was first 
discovered in the chicken egg as part of the vitelline membrane. This membrane 
plays an integral part in keeping the egg white and developing embryo in the yolk 
separate during early embryogenesis. Furthermore, the VMO1 protein has been 
found to be uniquely expressed in the inner ear of the mouse where it is localised 
to the Reissner's membrane, a two-layered membrane that prevents mixing of the 
endolymphatic and perilymphatic fluids of the cochlea. The role of VMO1 in the 
inner ear is unknown. However, it is considered a good candidate for functional 
investigation studies based on its unique localisation.  
This literature review will discuss in depth the definition of hearing loss as it is an 
issue that affects a large number of people around the world and in New Zealand. 
In addition to this, the structure of the mammalian ear will be explained in detail 
for the understanding of how external sound is able to be received by the brain 
through the ear. Hearing loss (HL) is a complex disorder which can be caused by 
environmental, genetic, or a combination of both factors. Understanding of the 
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genetic causes behind hearing loss can provide better insight into treatment 
strategies. Finally, the biology of VMO1 will be discussed. 
1.2 Hearing Loss 
It is estimated that one in 500 newborns are affected by HL with that rising to 2.7 
per 1000 by the age of 5 years and 3.5 per 1000 during adolescence. In New 
Zealand, data collected by Greville_Consulting (2006) from censuses in 1991/92, 
1996/97, and 2001/02 indicated that the prevalence of HL is around 400,000 
people. Hearing loss also affects the aging population as a condition known as 
presbycusis. This term refers to all conditions leading to HL in elderly people and 
is characterised by reduced hearing sensitivity and speech interpretation, and 
slowed processing of sound. This disorder is of high prevalence causing both 
social and health problems with about 40% of the over 65 year old population 
being affected. Untreated presbycusis can lead to people feeling isolated and 
depressed due to the effects it has on communication with others. However, it can 
be treated with the use of hearing aids or cochlea implants but cannot be reversed 
due to the loss of sensory cells in the inner ear during the natural aging process 
(Gates & Mills, 2005; Huang & Tang, 2010). An unaffected person is able to hear 
within the range of 20 to 20,000 Hertz (Hz) (Rosen & Howell, 2011). Humans are 
most sensitive to frequencies that are between 2,000 and 5,000 Hz. Loudness of 
sound is measured in decibels (dB) with HL defined as mild (30-50 dB), moderate 
(50-70 dB), severe (70-90 dB), or profound (>90 dB) (Lammens, Verhaert, 
Devriendt, Debruyne, & Desloovere, 2013). 
1.2.1 Classification of Hearing Loss 
HL can be classified by the abnormalities present in the mammalian ear, age of 
onset, if it affects one or both ears, or is caused for genetic or environmental 
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factors. Abnormalities in the outer and middle ears are classified as conductive 
HL. This dysfunction prevents sound from reaching the inner ear for processing. 
Sensorineural HL occurs when there is an abnormality in the inner ear or the 
vestibulocochlear nerve. Also, mixed HL can occur when both conductive and 
sensorineural HL is present in the individual.  
In addition, HL can be further categorised as prelingual or postlingual. If HL is 
present before speech development in a toddler, it is defined as prelingual. This 
type of HL can have profound effects on the individual's ability to develop a 
spoken language and affect educational progress (Bitner-Glindzicz, 2002). In 
comparison, postlingual HL occurs after speech development with the most 
common example being age-related HL in the older population (Hilgert et al., 
2009). Furthermore, HL can be unilateral, or affecting one ear, or bilateral where 
it affects both ears. HL can be caused by a number of environmental factors 
including noise, physical trauma, bacterial or viral infections, ototoxic compounds, 
such as the antibiotic gentamicin (Turnidge, 2003), and the natural aging process 
(Gates & Mills, 2005).  
HL can be further classified as acquired hearing loss (AHL) or genetic hearing 
loss (GHL). GHL is present at birth and responsible for more than 50% of 
prelingual deafness (Smith, Shearer, Hildebrand, & Van Camp, 2014) whereas 
AHL occurs after birth due to result of an illness or injury. It is estimated that at 
least two thirds of prelingual HL is thought to have a genetic cause with the 
remaining cases being caused by environmental factors. The genetic causes of HL 
can be further classified as syndromic or non-syndromic. Non-syndromic deafness 
is thought to account for 60-70% of inherited HL, with autosomal recessive 
inheritance being the most common cause. In addition to this, 10-15% have an 
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autosomal dominant cause with the remaining being X-linked, mitochondrial, or 
chromosomal (Bitner-Glindzicz, 2002). When HL is inherited, it is mostly 
monogenetically caused. Syndromic HL is where the HL is associated with other 
medical disorders such as Usher syndrome and Pendred syndrome (Hilgert et al., 
2009; Martini, Calzolari, & Sensi, 2009; Petit, Levilliers, & Hardelin, 2001).  
1.2.2 Genetics of Hearing Loss 
A number of deafness loci have been identified and been named DFN accordingly. 
They are then sequentially numbered based on order of discovery. The first locus 
mapped was DFNA1 in 1992 (Leon, Raventos, Lynch, Morrow, & King, 1992). 
GHL can be inherited as a Mendelian trait and as such, can be inherited as 
autosomal dominant (DFNA), autosomal recessive (DFNB), and X-linked 
(DFNX). GHL can also be inherited through mutations to mitochondria (MTT). 
Figure 1 shows 80 genes and loci that have been identified in the human genome 
as playing a role in HL. They are colour-coded based on the inheritance traits they 
show.  
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Currently, over 130 non-syndromic deafness genes have been identified (Van 
Camp & Smith, 2005), with more than 1000 mutations relating to deafness-
causing genes being reported (Shearer, Hildebrand, Sloan, & Smith, 2011). One 
such DFNA gene is Pou class 4 homeobox 4 (POU4F3), which is a located on the 
DFNA15 locus positioned at chromosome 5q31-q33. Twelve members of a five-
generation Libyan family were diagnosed with progressive HL that segregated as 
an autosomal dominant trait (Vahava et al., 1998). Onset of HL occurred between 
18 – 30 years of age. Following genome-wide screening, the human ortholog of 
Figure 1: Genes in the human genome that have been identified as playing a role 
in hearing loss. They are grouped by colour according to the inheritance pattern. 
SHL and NSHL stand for syndromic hearing loss and non-syndromic hearing loss, 
respectively. When a gene has been implicated as the cause for both of these types of 
hearing loss, a light blue line is used. All other classifications represent genes that 
cause non-syndromic hearing loss. Autosomes are numbered 1 through to 22 and the 
sex chromosomes are identified as X and Y. (Adapted from Dror and Avraham 
(2010). 
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the mouse deafness gene Pou3f4 was found located on chromosome Xq21.1. This 
gene is expressed in postmitotic auditory hair cells and a targeted deletion results 
in a deaf mouse. The human ortholog, POU3F4, codes for a transcription factor 
that binds DNA at two sites, the POU domain and the POUH domain. The gene is 
made up of two exons and upon sequencing of the gene in affected members of 
this family; it was found that an eight base pair deletion occurred in exon 2. This 
led to a translational frameshift with four missense amino acids and a premature 
stop codon in the POUH domain of the protein thus affecting its function (Bird & 
Friedman, 2012; Vahava et al., 1998).  
Furthermore, DFNX1 through to DFNX5 are five loci that have been mapped to 
the X chromosome that are linked to non-syndromic HL. Mutations to only three 
genes have been reported; phosphoribosyl pyrophosphatase synthetase (PRPS1), 
POU3F4, and small muscle protein (SMPX). Recessive mutations in the DFNX2 
locus are the most common of those that are X-linked. However, these alleles are 
only responsible for a small part of non-syndromic HL. DFNX2 mutations are 
characterised by rapidly progressive HL and hearing is affected due to the fixation 
of the stapes footplate in the middle ear (Figure 2). This prevents sound from 
properly travelling to the inner ear due to lack of movement by the ossicles (Bird 
& Friedman, 2012; Choi et al., 2013).  
The diagnosis of HL caused by genetic mutations has recently become available 
with the advancement of technology. Before now, technology was limited due to 
time and cost constraints. Therefore, due to advancements in technology and 
growing knowledge, new loci and genes responsible for HL will be identified 
(Shearer & Smith, 2012).  
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1.3 The Mammalian Ear 
The mammalian ear, as an organ, plays an important sensory role in the body, 
aiding in the detection of sound as well as playing a part in balance (Dror & 
Avraham, 2010). In particular, the human ear is able to hear frequencies between 
20 Hertz (Hz) and 20,000 Hz (Hudspeth, 1997). The structure of the ear is 
composed of three compartments; the outer ear, the middle ear, and the inner ear 
(Figure 2).  
 
1.3.1 The Outer and Middle Ear 
The outer ear consists of the auricle and the external auditory canal. The outer ear 
transmits sound waves from the environment, through the middle ear and into the 
inner ear. Sound waves are transferred to the middle ear through the tympanic 
membrane (ear drum). The middle ear is a hollow space consisting of the 
Eustachian tube which links the middle ear to the nasopharynx and equalises the 
air pressure of the middle air to environmental air pressure (Hidir, Ulus, 
Karahatay, & Satar, 2011). Of importance in the middle ear are the three 
Figure 2: Anatomy of the human ear. The three compartments of the ear are shown; 
outer (orange), middle (pink) and inner (blue) (adapted from Encyclopaedia Britannica). 
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ossicles, or bones; malleus, incus, and stapes. They act together to direct 
sound towards the oval window of the cochlea at the start of the inner ear.  
1.3.2 The Inner Ear 
The inner ear is a fluid-filled organ which turns sound waves into electrical 
stimuli which can be interpreted by the brain via the cochlear nerve. It is 
composed of a membranous labyrinth within a cavity of the bony labyrinth 
(temporal bone) and divided into two systems; the auditory system and the 
vestibular system (Figure 4A). The auditory system consists of the snail-shaped 
cochlea which allows for detection of noise whilst the vestibular system contains 
the three semicircular ducts, the utricle and saccule, all of which aid in balance 
(Dror & Avraham, 2010). The base, or beginning, of the cochlea is where high-
range frequencies (20,000 Hz) are transduced whereas the apex of the cochlea 
allows for transduction of low frequencies (200 Hz). From the base to the apex of 
the cochlea, frequencies are tonotopically arranged (Figure 3). As a result, high 
frequency sounds cause maximum vibrations to the basilar membrane at the base 
whereas low frequency sounds are detected by the apex of the basilar membrane 
with mid-range frequencies detected between the base and apex.  
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A cross-section of the cochlea shows that it is divided into three fluid-filled 
sections known as scalae (Figure 4A). The scala media, or cochlear duct, contains 
endolymph, a fluid with a high concentration of potassium ions (K
+
) (about 
150 mM) and a very low concentration of sodium ions (Na
+
) (1 mM). This ionic 
composition is similar to intracellular fluid and remains similar across mammals 
(Raphael & Altschuler, 2003). The scala media is surrounded by the scala 
vestibuli (vestibular duct) and scala tympani (tympanic duct), both of which 
contain perilymph. In comparison to endolymph, the perilymph has a high 
concentration of Na
+
 (145 mM) and low K
+
 (3.5 mM) (Petit et al., 2001). 
1.3.3 Organ of Corti 
Within the scala media is the organ of Corti (OoC) which is responsible for the 
detection of sound. The OoC is located on the basilar membrane, which separates 
the scala media from the scala tympani, and below the tectorial membrane 
(Figure 4A). The OoC contains two types of hair cells; a single row of inner hair 
cells (IHC) and three rows of outer hair cells (OHC). These hair cells play a large 
role in the translation of mechanical stimuli into an electrical signal that can be 
Figure 3: Arrangement of frequencies detected along the 
cochlea from the base to the apex. Frequencies are 
tonotopically distributed from high frequency to low 
frequency (adapted from Encyclopaedia Britannica). 
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interpreted by the brain. On the apical surface of the hair cells are filaments called 
stereocilia. They are densely packed into hair bundles with between 20 and 50 
stereocilia present per IHC depending on the mammalian species (Raphael & 
Altschuler, 2003). They connect to adjacent stereocilia via apical tips and interact 
with neighbouring stereocilia using side-links. The stereocilia of the OHC are 
connected to the tectorial membrane at the Kimura's membrane, a thickening on 
the lower surface of it (Richardson, Lukashkin, & Russell, 2008). When sound 
waves enter the oval window from the middle ear, they are converted to liquid 
waves within the inner ear (Petit et al., 2001). The liquid waves in the inner ear 
causes the basilar membrane to vibrate with movements travelling longitudinally 
across it (Ghaffari, Aranyosi, & Freeman, 2007). This vibration is transferred to 
the OoC and the hair cells that line it. The movement of the hair bundles causes 
mechanoelectrical transduction (MET) channels on the tips of the stereocilia to 
open. This leads to an influx of K
+
 and calcium ions (Ca
2+
) into the stereocilia 
which depolarises the hair cells. This causes the release of a neurotransmitter from 
the hair cells and leads to an electrical signal being sent to the cochlear nerve.  
1.3.4 Reissner's Membrane 
Reissner's membrane is located between the scala media and scala vestibuli, 
keeping the endolymph and perilymph separate respectively (Figure 4B). The 
membrane is two cell layers thick with epithelial cells located on the 
endolymphatic side and mesenchymal cells on the perilymphatic side. These cell 
layers are separated by a basement membrane (Duvall & Rhodes, 1967; Yeh, Tsai, 
Lee, Hsu, & Tran Ba Huy, 1997). The membrane is a nonvascular structure in a 
number of animals including humans, however the rabbit is an exception to this 
(Johnsson, 1971). Reissner's membrane forms an ionic barrier, controlling the 
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movement of ions across it. In addition to this, three different types of ion 
channels have been discovered on Reissner's membrane, located on the epithelial 
cells (Raphael & Altschuler, 2003; Yeh et al., 1997). Firstly, stretch-activated 
nonselective cation (SAcat) channels were found to be permeable to Ca
2+
 and are 
thought to play a role in changing the electrochemical composition in endolymph. 
Secondly, voltage-sensitive Chloride (Cl
-
) channels were found to be abundant in 
the Reissner's membrane. Although it remains unknown what triggers a Cl
-
 
channel response, it has been demonstrated that they work in response to the cell 
influx of Ca
2+
 that occurs at stretch-activated channels (Kotera & Brown, 1993), 
one of the other channels found on the membrane. Lastly, K
+
-selective channels 
were also found on the epithelial cells of the membrane however they rarely 
occurred (Yeh et al., 1997). This suggests that the Reissner's membrane plays a 
role in regulating the ionic composition of the endolymph which is important for 
the transduction of sound waves into electrical signals.  
The next section will discuss the biology of the VMO1 protein. This gene was 
discovered to be exclusively expressed in Reissner's membrane of the mouse inner 
ear (Peters et al., 2007).  
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1.4 Vitelline Membrane Outer Layer 1 Protein 
The human Vitelline Membrane Outer Layer 1 homolog (chicken) (VMO1) gene 
was named after its similarity to chicken VMO1, a protein that was identified in 
the vitelline membrane (VM) of the chicken egg.  
Figure 4: Anatomy of the mammalian inner ear. (A) The auditory and vestibular 
system that make up the inner ear (adapted from Wikipedia). (B) Cross-section of 
the cochlea in the inner ear showing the three fluid compartments; scala vestibuli, 
cochlear duct (orange), scala tympani, and location of the hair cells in the organ of 
Corti (green) (adapted from Encyclopaedia Britannica).  
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1.4.1 VMO1 in the Vitelline Membrane of the Chicken Egg 
The VM of a hen's egg is a membrane separating the yolk from the egg white 
(Figure 5). Two layers are present in the VM, with the outer layer being thicker 
than the inner layer. Found between these two layers is a thin sheet known as the 
continuous layer. The VM plays an important role during early embryonic 
development as it encloses the yolk and provides a base for the expansion of the 
embryo which eventually ruptures as the embryo expands in size (Bellairs, 1963; 
Jensen, 1969). The VM acts as a semi-permeable membrane which allows certain 
materials, such as water and egg albumen, to pass through it (Romanoff & 
Romanoff, 1949). The inner layer of the VM is laid down around the yolk while it 
is still in the ovary of the hen and the outer layer is formed around it following 
ovulation as it passes down the oviduct (Cook, Bellairs, Rutherford, Stafford, & 
Alderson, 1985). The inner layer is consisted of several kinds of glycoproteins 
(GP); soluble proteins GP-I, GP-II, GP-III, and the insoluble protein GP-IV. The 
outer layer is constructed of large macromolecules called ovomucin. To these 
macromolecules, the soluble proteins, lysozyme, VMO1 and VMO2, are bound 
(Kido et al., 1995; Kido, Morimoto, & Kim, 1992). 
The primary structure of VMO1 was determined by Back, Bain, Vadehra, and 
Burley (1982) as a basic protein of 163 amino acids in size. The VMO1 protein 
has a calculated molecular weight of 17,979 Daltons (Da). The mRNA that 
encodes for VMO1 has been found to be expressed in the hen oviduct, a region 
joining the infundibulum to the magnum. However, mRNA expression was not 
reported in other regions of the hen reproductive system (Kido et al., 1995). 
Although the function of VMO1 in the VM is unknown, it was found that the 
protein shares similar activity to lysozyme. Kido et al. (1995) found that VMO1 is 
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able to synthesise N-acetylchitooligosaccharides from hexasaccharides of N-
acetylglucosamines. This is similar to the transferase activity of lysozyme. 
 
 
 
 
 
 
1.4.2 Protein Structure of Chicken VMO1 
The protein structure of chicken VMO1 was determined by Shimizu et al. (1994) 
using the multiple isomorphous replacement (MIR) method. Using this method, 
the crystal structure was determined at 3 angstrom (Å) resolution and allowed for 
the main chain of VMO1 to be traced in an electron density map. Amino acid 
analysis using Circular dichroism (CD) spectroscopy, proton nuclear magnetic 
resonance (NMR) and differential scanning calorimetry (DSC) by Kido et al. 
(1995) was used to determine the primary structure of VMO1. Their study showed 
that VMO1 contained high amounts of glycine, serine and other basic amino acid 
residues. Furthermore, carboxymethylation was used to test for presence of free 
cysteine resides. If free residues were present, carboxymethyl-cysteine (Cm-Cys) 
Figure 5: Structure of the chicken egg showing the location of the 
vitelline membrane. The VM separates the egg yolk (yellow and white 
yolk) from the egg white (inner thin, outer thin and outer thin white) 
(adapted from http://www.tonis.at/en/das-ei/interesting-facts/the-structure-
of-a-chicken-egg.html). 
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would be formed. However, no Cm-Cys were found, therefore it was thought all 
cysteine residues were forming disulfide bridges in the protein structure. In 
addition, the amino acid analysis found there was no methionine present in the 
protein, which may be removed post-translationally. 
The ribbon representation of VMO1 shows that the secondary structure of the 
protein is made up of six long beta (β) strands and eight short β-strands 
(Figure 6A). The presence of β-sheets were determined using both proton NMR 
and X-ray crystallography (Kido et al., 1995; Shimizu et al., 1994). This structure 
means the protein is classified as a β-protein. The β-strands were found to sit anti-
parallel to one another and grouped into three β-sheets in a so-called Greek key 
motif formation, named after the Greek art style. As shown in Figure 6B, the first 
sheet consists of two long and three short β-strands. The second sheet was found 
to differ slightly from the first, with two long and two short β-strands. It was also 
discovered that hydrogen bonds were formed between the main chain atoms and 
side-chain atoms, Serine (Ser) 86, Ser 88 and Ser 130 in the second sheet. The 
third sheet was comprised of three short β-strands from the N-terminal region of 
the amino acid sequence and two long β-strands from the C-terminal region. All 
together, the three β-sheets folded to form a molecule shaped like a flower vase 
with the dimensions of 30 Å x 30 Å x 45 Å. 
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The internal region of the folded protein structure is filled with side chains of 
hydrophobic amino acids such as phenylalanine, isoleucine, leucine and valine. In 
addition to this, hydrogen bonds were found at the top and bottom of this structure. 
The three β-sheets were held together by three disulfide bridges between cysteine 
(Cys) residues at the positions Cys26 - Cys57, Cys79 - Cys110, and Cys133 - 
Cys161 (Shimizu et al., 1994). Proton NMR found that the structure of the protein 
was stable at 70°C which was normal for the β-prism shape of the VMO1 protein. 
Although the protein structure has been widely studied and determined, the 
function of VMO1 remains unknown.  
1.4.3 VMO1 in Reissner’s Membrane of the Mouse Ear 
Massively parallel signature sequencing (MPSS) is a technique used for 
identifying mRNA which is only expressed at low levels in certain cell types. This 
Figure 6: Schematic diagram of VMO1 protein structure. (A) Ribbon representation 
of VMO1 drawn using MOLSCRIPT. The three β-sheets are represented by three 
different colours; green (1
st
), blue (2
nd
) red (third). (B) Diagram of VMO1 showing the 
formation of the three β-sheets and the direction of the β-strands. Colours used for 
different strands correspond to the same colours used in Figure 6A (adapted from 
Shimizu, Vassylyev, Kido, Doi, and Morikawa (1994)).  
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method tags each mRNA with a signature near the poly(A) tail, allowing for 
detection of each product present. This technique was used to generate libraries 
from inner ear tissues dissected from postnatal day (PD) 7 and 8 aged mice. Three 
tissue types were used for making the libraries; mouse organ of Corti (MoCR), 
mouse vestibular epithelium (MoVB), and mouse stria vascularis (MoSV). 
Interestingly, Vmo1 was found to be the second most abundant signature present. 
Additionally, the top ten signatures unique to the inner ear libraries were all 
present in the MoVB library. A majority of these signatures are from genes that 
are known to play a role in inner ear function. These included otogelin, in which a 
mouse mutant model was found to be deaf, and Col9al, in which a mouse 
knockout model had progressive hearing loss. (Peters et al., 2007).  
Using real-time PCR (RT-PCR), Vmo1 was found to be expressed in the mouse 
inner ear but not in the mouse liver, kidneys, pancreas, retina, brain, or testes 
(Peters et al., 2007). In addition to this, in situ hybridisation using an anti-sense 
probe for Vmo1 showed that it localised to the RM in the mouse inner ear (Figure 
7A). Furthermore, Vmo1 was not detected in 87 other mouse tissue types that 
were part of the Mouse Reference Transcriptome (MRT) project. From this data, 
the authors were able to conclude that Vmo1 was the first example of a transcript 
expressed exclusively on the Reissner's membrane.  
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As a result of this data, Vmo1 is of interest as a candidate in human hearing loss 
and related disorders due to the unique location and level of its expression in the 
mammalian inner ear. In particular, Meniere's disease, a chronic illness 
characterised by episodes of vertigo, tinnitus, and hearing loss, this disorder is 
thought to be caused in part by the rupturing of the extended RM. This is a result 
of a build up of endolymph in the scala media leading to a feeling of pressure in 
the inner ear and deafness. This rupturing leads to the symptom of vertigo 
(Kitajima, Watanabe, & Suzuki, 2011; Nakashima et al., 2007; Sajjadi & 
Paparella, 2008; Valk, Wit, & Albers, 2006).   
1.4.4 Identification and Characterisation of VMO1 in Other Organisms  
Since the identification and characterisation of VMO1 in the chicken egg, a 
number of homologues and paralogues have been discovered, including the 
human homologue.  
Figure 7: In situ hybridisation of cross sections show localisation of Vmo1 to the 
Reissner's membrane in mice. (A) The antisense probe for Vmo1 showing positive 
mRNA expression (white) on RM. (B) Sense probe for Vmo1 showing no expression in 
RM (adapted from Peters et al. (2007). 
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Bioinformatics analysis of VMO1 by Forrester-Gauntlett (2013) showed that the 
human (Homo sapiens) and mouse (Mus musculus) are conserved at the amino 
acid level with 71.8% identity and 80.2% similarity. In addition to this, the mouse 
and chicken (Gallus gallus) had 47.1% identity and 60.3% amino acid similarity. 
There was a high level of identity shared with the amino acids responsible for the 
formation of the chicken VMO1 3-D structure and all eight cysteine residues for 
disulfide bonds in the chicken VMO1 protein were in identical places in both the 
mouse and human VMO1 protein. 
Within humans, VMO1 has been identified using SELDI-ToF and proteomic 
studies of urine samples from individuals. One such study by Alves et al. (2013) 
found VMO1 following tandem mass spectrometry (MS/MS) analysis of urine 
samples from individuals with renal cell carcinoma (RCC). Although the authors 
did not purify VMO1, they suggested that it was a secreted protein. In addition to 
this find, Olivieri et al. (2014) compared urine samples from patients with 
bilateral aldosterone-producing adenomas to healthy subjects. Two types of these 
adenomas were used in the study; Aldosterone producing adenoma (APA) and 
bilateral adrenal hyperplasia (BAH). Protein analysis was performed using 
nanoHPLC-MS/MS, a type of mass spectrometry, to determine proteins present in 
the samples. This method was also used to detect the amount of protein present 
between differing cohorts. VMO1 was found to be down-regulated by 3.57-fold in 
APA patients compared to the control cohort. It was also down-regulated 2.63-
fold in APA patients compared to BAH patients. The reasoning behind this study 
was to identify biomarkers for diagnosis of differing bilateral aldosterone-
producing adenomas in patients. 
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In addition to chickens, mice and humans, VMO1 has also been identified in 
several other species. One such study by Chen et al. (2011) investigated the tears 
of camels during summer and winter to identify seasonal variations between 
proteins present. Briefly, camel tears from 50 healthy camels were collected and 
pooled in summer and winter. Proteins were separated using SDS-PAGE and 
proteins that showed differing expression levels between the two seasons were 
excised from gels and analysed using MALDI-ToF/ToF-MS for identification 
purposes. As a result, VMO1 was identified and found to increase in expression in 
summer compared to winter samples. The presence of VMO1 was further 
validated using western blot with a rabbit anti-human VMO1 polyclonal antibody. 
In a follow-up study by Shamsi et al. (2011), tears were collected from healthy 
camels, sheep, cows, and humans. MALDI-ToF analysis resulted in a 21 kDa 
protein that was identical to the human VMO1 in camel tears. Following 
validation using western blot with the aforementioned antibody, VMO1 was also 
identified in sheep tears but not in cow or human tears. The authors believe that 
although VMO1 was not detected in cow tears, it may still be present. This is 
due to there being sufficient changes in the cow VMO1 sequence that would 
prevent it from binding to the antibody. Finally, it was thought that VMO1 
plays a special role in the tear film, keeping the ocular surface healthy. 
RNA Sequencing (RNA-Seq) is a new generation sequencing technology used for 
analysing quantititative RNA expression at a given time. This methodology has 
been used to investigate the whole transcriptome of normal and noise-traumatised 
cochlear sensory epithelia (CSE) in rats. Rats were exposed to 120 dB for 
two hours and tissue samples collected a day later for RNA extraction. RNA-Seq 
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analysis found VMO1 had a 51.77-fold increase in expression in noise-
traumatised rats compared to the control group (Patel et al., 2013).  
Two species of catfish, Blue catfish (Ictalurus furcatus) and Channel catfish 
(Ictalurus punctatus) are both species used in aquaculture. As a result, studying 
their health is important for sustaining healthy populations in aquaculture farms. 
RNA-Seq was used to compare changes in the gills and skin following a seven 
day fasting period to these fish species. Fasting is common in aquaculture and can 
increase susceptibility to bacterial infections. Fasted blue catfish were found to 
have a 3.05-fold down-regulation of VMO1 compared to the fed population. 
Other genes found to be down-regulated in fasted fish were involved in immune 
function and metabolism. Fasted channel catfish also showed a 3.55-fold down-
regulation of VMO1 when compared to the fed population. However, the function 
of VMO1 in these fish species remains to be elucidated (Li, Beck, & Peatman, 
2014; Liu, Li, Su, Beck, & Peatman, 2013).  
Venom gland transcriptomics was applied to a diverse group of advanced snake 
species by Fry, Scheib, Junqueira de Azevedo, Silva, and Casewell (2012) to 
identify proteins scaffold types in snake toxins. They found three novel protein 
scaffold types that had not previously been characterised. One of these was the 
VMO1 protein in Macleary's water snake (Enhydris polylepsis). However, the 
function of this protein in the venom was not elucidated. 
Furthermore, six transcripts of vitelline membrane outer layer 1-like protein were 
found in the hepatopancreas of Japanese blue crab (Portunus trituberculatus) by 
Wang, Wu, Liu, Zheng, and Cheng (2014). The protein is synthesised there and 
transported to the developing oocytes via the hemolymph. Therefore, VMO1 
plays a similar role in these crabs to the chicken, preventing the yolk and egg 
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white from mixing in eggs. In addition, VMO1 is localised to the Reissner’s 
membrane in mice (Peters et al., 2007). The Reissner’s membrane is involved in 
keeping endolymph and perilymph fluids in the inner ear from mixing.  
Finally, Alföldi et al. (2011) found VMO1 paralogues present in immature eggs 
from Green anoles (Anolis carolinensis). Three paralogues were identified and 
named VMO1-α, VMO1-β, and VMO1-γ, respectively. Interestingly, VMO1-α 
was found to have 13 members in its family with positive selection acting for 
amino acid substitutes found within the negatively-charged cavity of the protein. 
It is suggested that this region is substrate-binding and modifies the lysozyme-like 
transferase activity that VMO1 has been demonstrated to possess (Kido et al., 
1995). Despite being found in a wide range of tissues in a number of species, the 
function of VMO1 is yet to be elucidated. 
To determine the function of VMO1, a number of molecular strategies can be 
used. The aims of this research thesis are to design, clone and express a 
recombinant VMO1 protein using a bacterial expression system and in addition, 
purify and test the resulting recombinant protein against commercial VMO1 
antibodies using western blot analysis. Thus, this will allow further investigation 
of protein function by the identification of protein partners, and performing 
biochemical assay to test for transferase activity. The next section will describe 
the process of producing the recombinant VMO1 protein and the technology used 
to achieve this. 
1.5 Recombinant DNA Technology 
The term, recombinant DNA technology, refers to a number of techniques that 
allow for the introduction of a gene from one organism into another organism 
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(Pasternak, 2005). Of particular interest to this research, are the experimental 
techniques PCR, DNA cloning, and expression of heterogeneous proteins in 
bacterial cells, that were used for the development and production of VMO1 
protein.  
1.5.1 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) is a molecular technique used to amplify a 
target gene or nucleotide sequence within a DNA sample. The PCR process 
involves the use of enzymes that allow for the duplication of the specific regions 
of DNA, making millions of copies of a sequence during the reaction process 
(Saiki et al., 1988; Verma, Dalal, & Sharma, 2014). Before PCR can be performed, 
a template DNA sample is required. This is generally obtained through the 
isolation of messenger RNA (mRNA) from cells and converted to complementary 
DNA (cDNA) using the enzyme reverse transcriptase. This allows for the exonic 
DNA to be isolated that is expressed in the cells. This cDNA can then be used as a 
template for PCR. For the amplification of a specific target sequence, primers 
which are specific and complementary to the sequence are required. These 
primers will anneal to the DNA template at their target sequence.  
Basically, PCR consists of a number of cycles repeated 25 – 35 times. At the start 
of the PCR, an initialisation step is required that heats the reaction to 94°C – 96°C 
for the activation of the DNA polymerase. Following this step, the cycles begin. 
There are three steps per cycle; denaturation, annealing, and extension. During the 
denaturation step, the reaction is heated to 90°C – 98°C for around 30 seconds to 
separate the double stranded DNA molecules. Following this, the annealing step 
occurs at a temperature that is suitable for the primers. This step allows the 
primers to anneal to their complementary strand of DNA. The DNA polymerase is 
24 
 
able to bind to the segments where the primers have annealed so that the targeted 
DNA region can be amplified. Next is the extension step which allows for optimal 
DNA synthesis for the DNA polymerase. This step synthesises a new DNA strand 
that is complementary to the DNA template the primer has bound to. 
Deoxyribonucleotides (dNTPs) in the reaction mix are added to form the double 
stranded template. After the cycling process has occurred, the reaction is 
concluded with a final extension stage to end the PCR process (Strachan & Read, 
1999).   
PCR was used for this research to amplify the VMO1 gene in cDNA extracted 
from commercial in vitro human cell lines. The PCR product was electrophoresed 
on agarose gels and purified for isolation of the amplified VMO1 gene. The next 
section will briefly describe DNA cloning and how it was applied in this research 
study. 
1.5.2 DNA Cloning 
DNA cloning is a technique where specific cDNA is inserted into a circular 
plasmid vector. This plasmid is then transformed into host cells such as the 
bacterium Escherichia coli (E. coli). To insert the cDNA into the plasmid, the 
plasmid is first digested using restriction enzymes to linearise it. This can create 
either blunt ends, where there are no nucleotide overhangs, or sticky ends where 
there is an overhang of nucleotides on a single strand of the DNA. The gene of 
interest can also be generated with restriction enzyme sites on the end of them that 
are the same as the ones used to digest the plasmid, allowing digestion of the gene 
to create sticky ends on the 5’ and 3’ ends of the gene. This allows the gene to be 
ligated into the plasmid using the enzyme T4 ligase to join the two products 
together (Lodish, 2012).  
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For the purpose of this thesis, the VMO1 gene was ligated into two plasmid 
vectors, pBlueScript II SK (+), a T-tailed cloning vector, and pET28b(+), an 
expression plasmid vector for producing the recombinant VMO1 protein. 
1.5.3 The pET Expression System 
The pET system is a group of plasmids designed for the cloning and expression of 
recombinant proteins in E. coli. The system was first developed by Studier and 
Moffatt (1986). The genes which code for the protein are ligated into the pET 
vector and transformed into the bacterial host cell. The ligated gene is under the 
control of bacteriophage T7 transcription with expression of the gene being 
induced by the T7 RNA polymerase in the cells (Rosenberg et al., 1987; Studier, 
Rosenberg, Dunn, & Dubendorff, 1990). When the plasmid is introduced to a host 
cell with the T7 RNA polymerase gene under lacUV5 control, the expression can 
be induced by introduction of compound Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) which induces the expression of the lacUV5 promoter (Sørensen & 
Mortensen, 2005). 
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1.6 Research Aims and Objectives 
The first aim of this research thesis is to design, clone, and express 
recombinant N-terminal His-tagged VMO1 protein using the pET28b(+) 
bacterial expression system. The second aim is to purify the resulting protein 
using a nickel resin column. Finally, the third aim is to validate a commercial 
VMO1 antibody against the purified protein using western blot methodology 
to show that it is indeed specific, selective and reproducible. This will support 
immunohistochemistry data that suggests VMO1 is a secreted protein in the 
mouse by Forrester-Gauntlett (2013). To accomplish the research aims, the 
following six objectives are required: 
1) Bioinformatics analysis of VMO1 to develop and annotate a graphic 
molecular view of the designed protein construct using primers with 
restriction enzyme overhangs; 
2) Amplify VMO1 mRNA from commercial human cell lines and convert to 
cDNA; 
3) Clone the VMO1 cDNA into the pET28b(+) expression vector;  
4) Express recombinant VMO1 protein in E. coli; 
5) Purify the recombinant VMO1 protein for characterisation and 
determination of function; and 
6) Validate a VMO1 antibody against a range of protein samples including 
purified and non-purified recombinant VMO1 protein using a western blot. 
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CHAPTER TWO 
Methods and Materials 
All methods were carried out in C.2.03 Molecular Genetics Laboratory at the 
University of Waikato (UoW), Hamilton, New Zealand unless otherwise stated. 
Solutions and buffers were prepared using either autoclaved 15 - 18 Megohm-cm 
double distilled deionised water (mQH2O) or double distilled water (ddH2O) 
(Barnstead
™
 double distilled/deionisation system) as listed in Appendix One. 
Buffers and solutions required for Ribonucleic acid (RNA) experiments used 
mQH2O further treated with 0.1% Diethylpyrocarbonate (DEPC). All glassware 
was washed in a Miele dishwasher, autoclaved at 120°C for 15 minutes (min) and 
cooled to room temperature (RT) before use. All centrifugation was carried out on 
Eppendorf Benchtop Centrifuges at RT unless otherwise stated. Absorbance 
readings of the optical density measured at a wavelength of 600 nanometres (nm) 
(OD600) were performed on a Bio-Rad SmartSpec
™
 3000 spectrophotometer. 
Laboratory benches were cleaned with 70% ethanol prior to experiments being 
carried out with aseptic techniques followed. The University of Waikato received 
HSNO approval (GMD101146) from the New Zealand Environmental Protection 
Authority (EPA) in 2011 to develop a range of genetically modified non-
pathogenic microorganisms, cell lines and zebrafish carrying genes coding for 
proteins involved in causation of disease, in the evolution of protein stability and 
cellular functions. The research in this thesis meets these requirements by 
developing a genetically modified organism (GMO) containing the VMO1 gene 
for work towards the elucidation of its protein function. The location and nature of 
the development and the disposal of the approved genetically modified E. coli 
were in accordance with the APP201152 application submitted to the EPA, and 
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controls listed in the GMD101146 approval. Details of this application can be 
found on the EPA website (EPA, 2014). 
2.1 Isolation and Purification of the VMO1 Gene   
Total RNA was isolated from cultured human in vitro cell lines and converted to 
complementary Deoxyribonucleic acid (cDNA) for use with PCR using primers 
designed to amplify the VMO1 genes (Section 2.3). The aim of this first 
experiment was to identify, isolate and purify VMO1 genes to make recombinant 
DNA for cloning purposes.  
2.1.1 Mammalian Cell Culture 
Cells were grown in a dedicated Cell Culture Laboratory and were kindly donated 
by Miss Kirsty Mayall and Dr Greg Jacobson (UoW). Three different human cell 
lines (Table 1) were grown in CELLSTAR
®
 25 mL tissue culture flasks (Greiner 
Bio-One, Austria) containing 10 mL of growth media and antibiotics in a 37°C 
incubator with 5% CO2 atmosphere. Media was changed every two days until cells 
were 90% confluent before either being split to continue growth of the cell line or 
processed for RNA extraction. Human ethics approval was not required from the 
UoW Human ethics committee as these cell lines are commercially available. 
Table 1: Human in vitro cell lines tested for VMO1 gene expression. For each cell line 
listed is the tissue of origin, the components of the media they were grown in and if they 
were adherent or not to the tissue flask. The recipes for the growth media can be found in 
Appendix 1. 
Cell line name Tissue of 
origin 
Growth mode Reference 
A549 Lung 
carcinoma 
Adherent 
monolayer 
Giard et al. 
(1973) 
SUM149PT Breast tissue Adherent 
monolayer 
Elstrodt et al. 
(2006) 
THP1 Monocyte Suspension  
cells 
Tsuchiya et al. 
(1982) 
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2.1.2 RNA Extraction from Human Cell Lines  
All RNA work was performed in a dedicated RNA workspace to prevent 
degradation of RNA by RNases. The area was cleaned with RNase AWAY
™
 (Life 
Technologies, USA) and 70% ethanol prior to use. Sterile RNase- and DNase-free 
filter pipette tips and dedicated auto pipettes were used and samples were stored 
in autoclaved 1.7 mL microcentrifuge tubes (Raylab, NZ).  
Total RNA was extracted from human cell lines using the TriZol
®
 Reagent 
method (Invitrogen, USA). Media was removed from the culture flask containing 
roughly 2x10
6
 cells/mL of either A549 or SUM149PT cells using a sterile 3.5 mL 
Pasteur pipette (Sarstedt, Germany). Two millilitres of TriZol
®
 Reagent was 
added directly to the flasks and swirled briefly to lift the adherent cells from the 
culture flask surface followed by pipetting up and down several times to lyse the 
cells. Media containing THP1 cells was placed in a 15 mL falcon tube (Biologix, 
China) and spun down in a Heraeus
™
 Multifuge 1 S-R centrifuge at 428 x g for 
five min at RT. Media was removed and the pelleted cells were resuspended in 
1 mL of TriZol
®
. A 1 mL aliquot of TriZol
®
 treated cells was transferred to 
1.7 mL microcentrifuge tube for RNA extraction. Samples were then incubated at 
RT for five min to ensure complete dissociation of the nucleoprotein complex. 
Two millilitres of chloroform was added to each tube to remove protein and 
shaken vigorously for 15 seconds (sec) followed by a two min incubation at RT. 
The samples were then centrifuged at 12,000 x g for 15 min at 4°C. The upper 
aqueous phase was removed to a new 1.7 mL microcentrifuge tube and 0.5 μL of 
Glycogen (20 μg/μL) was added as a co-precipitate of RNA. Next, 500 μL of 100% 
isopropanol was added to tubes to precipitate the RNA and incubated at RT for 
10 min. The tubes were then centrifuged at 12,000 x g for 10 min at 4°C to pellet 
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the RNA. The supernatant was removed and 1 mL of 75% ethanol was added to 
each tube to precipitate out the RNA in the solution and remove residual salts. 
Samples were vortexed briefly for 12 sec then centrifuged at 7500 x g for five min 
at 4°C. The supernatant was discarded and the tubes were left to air-dry at RT for 
10 min. The RNA pellet was resuspended in 20 μL of RNase-free DEPC mQH2O. 
RNA samples were then incubated on an Eppendorf Thermomixer
®
 comfort set at 
55°C for 15 min to aid resuspension of the pellet.  
2.1.3 DNase Treatment of Total RNA Extracted from Human Cell Lines 
RNA samples were DNase-treated to remove possible genomic DNA 
contamination from the extraction method. A 5 μL volume containing the reagents 
(ZymoResearch, USA) listed in Table 2 were added directly to the 20 μL RNA 
sample from Section 2.1.2 and incubated in a thermomixer for 15 min at 37°C for 
optimal enzyme activity, 10 min at 65°C to heat inactivate the enzyme, and five 
min on ice to rapidly cool the sample. The purity and concentration of the RNA 
samples was determined using a ThermoScientific
™
 NanoDrop 2000 
spectrophotometer and software. Treated RNA samples were either used directly 
for further downstream applications such as cDNA synthesis or stored at -80°C. 
Table 2: Reagents from the DNase treatment kit (ZymoResearch, USA) used to treat 
RNA of possible genomic contamination 
Reagent Volume (μL) 
10X DNase I buffer 2.50 
DNase I (1 U/μL) 1.25 
0.1% DEPC H2O 1.25 
Total 5.00 
2.1.4 cDNA Synthesis 
RNA was converted into cDNA using the Tetro cDNA Synthesis Kit (Bioline, 
USA) so the resulting double stranded cDNA template could be used for 
downstream PCR reactions. All cDNA synthesis reactions were performed in 
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sterile RNase- and DNase-free PCR tubes (Axygen, USA). Reagents were thawed 
on ice and the 5X RT buffer was vortexed briefly to ensure it was completely 
dissolved. The reaction was prepared as shown in Table 3 to a total volume of 
20 μL and mixed gently by pipetting up and down. Oligos (dT)18 primers, rather 
than Random Hexamers, were used to target the poly-A tail of mRNA so only 
mRNA was converted to cDNA rather than total RNA. PCR tubes were then 
placed in a Bio-RAD T100 Thermal Cycler for incubation at 45°C for 30 min to 
anneal the Oligos (dT)18 primers to the mRNA and for optimal Reverse 
Transcriptase activity. Samples were then exposed to 85°C for five min to 
deactivate Reverse Transcriptase. The samples were cooled on ice for five min. A 
negative control for each RNA sample was prepared which contained no Reverse 
Transcriptase (-RT negative control). No cDNA was expected to be synthesised in 
this reaction and therefore was used as a measure of genomic contamination to the 
extracted RNA samples. 
Table 3: Reagents used for 20μL cDNA synthesis reaction.  
Reagent RNA sample -RT Negative control 
Total RNA  
(15.4 – 97.2 ng/μL)  
2 μL 2 μL 
Oligos (dT)18 primer 1 μL 1 μL 
10mM dNTPs 1 μL 1 μL 
5X RT Buffer 4 μL 4 μL 
Ribosafe RNase Inhibitor 
(10U/μL) 
1 μL 1 μL 
Tetro Reverse Transcriptase 
(200U/μL) 
1 μL - 
mQH2O 10 μL 11 μL 
Total 20 μL 20 μL 
2.2 Primer Design 
Oligonucleotide primers were designed for PCR, cloning, and DNA sequencing 
using Geneious version 7.1.7 (Biomatters, http://www.geneious.com) unless 
otherwise stated. Primers were synthesised by Integrated DNA Technologies Ltd 
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(IDT) and reconstituted in 1X TE buffer (10mM Tris-HCl, 1mM EDTA, pH 8) to 
a final concentration of 100 µM and stored at -20°C. Working stocks were diluted 
to 5 µM using mQH2O and also stored at -20°C. Primers used for the purpose of 
this research are listed in Table 4. Three sets of primer pairs (SH1-3) including a 
Forward (F) and reverse (R) specific for human VMO1 were designed using the 
NCBI reference sequences as described below. 
2.2.1 SH1F and SH1R 
SH1F and SH1R primers were designed to amplify the complete VMO1 isoform 1 
gene (NCBI: NM_182566) and allow ligation into a cloning vector for expression 
of recombinant VMO1. The location of the binding of this primer set is shown on 
Figure 8. SH1F contained a BamHI restriction enzyme site at the 5’ end whilst 
SH1R contained an EcoRI restriction enzyme site near the 5’ end. Extra 
nucleotides were added so the cleavage site would not be close to the end of the 
product. This was based on recommendations from New England BioLabs (1999). 
This allowed for digestion of the PCR product using these enzymes to create 
complementary sticky ends for ligation into the pET28b(+) and pBlueScript II SK 
(+) vectors. This primer set predicted a PCR product size of 691 base pairs (bp) 
due to the addition of an adenine base to each 3’ end of the PCR product by the 
enzyme Taq Polymerase during PCR. This allowed the PCR product to be 
inserted into pBlueScript II SK (+). Once cut with both restriction enzymes, the 
product was estimated to be 685 bp in size. This primer set was also used for 
sequencing reactions for gene confirmation.  
2.2.2 SH2F and SH2R 
SH2F and SH2R primers were designed to amplify the whole VMO1 isoform 3 
gene (NCBI: NM_001144940). Like the primer set, SH1F and SH1R, SH2F 
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contained a BamHI restriction enzyme site and SH2R an EcoRI restriction 
enzyme site to create sticky ends for ligation into vectors. For example, the 
recognition sequence of BamHI is G^GATCC and EcoRl is G^AATTC. The 
position of the binding of these primers is shown on Figure 8 and a PCR product 
formed from these primers was predicted to be 389 bp in size. Once cut with 
BamHI and EcoRl , the resulting product was predicted to be 379 bp.  
2.2.3 SH3F and SH3R 
SH3F and SH3R primers were designed for sequencing of an inner region of the 
VMO1 isoform 1 gene (NCBI: NM_182566), forming a product 438 bp in length. 
The start of SH3F bound to nucleotide 133 and SH3R ended at nucleotide 568, as 
shown in Table 4. 
2.2.4 PCR Positive Controls 
Primers for use as positive controls in PCR were sourced from the C.2.03 
Molecular Genetics Laboratory Primer Database (UoW). There were two primers 
sets that were used as positive controls. Firstly, the housekeeping gene, 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as it has been 
shown to be constitutively expressed across a large number of human tissues 
(Barber, Harmer, Coleman, & Clark, 2005). HCC37F in conjunction with 
HCC38R was designed for human GAPDH and gives a PCR product of 412 bp. 
Secondly, the primers HCC30F and HCC31R were used since they have been 
shown to amplify the VMO1 gene from the commercial cell line, A549 (Crossan, 
2014). 
2.2.5 LMP10F and LMP11R 
LMP10F and LMP11R were obtained from primer stocks in the Molecular 
Genetics Lab (UoW) and were designed to target the T7 promoter and T7 
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terminator of pET28b(+) respectively as the VMO1 gene was ligated between 
these two regions in the vector. This primer set was also used in colony PCR to 
check colonies for the insert of the VMO1 gene into pET28b(+) (Section 2.3.2). 
2.2.6 Primers for Orientation of Cloned PCR Insert 
LMP6F and LMP7R were used in colony PCR (Section 2.3.2) to test the 
orientation of the VMO1 insert into the pBlueScript II SK (+) vector. LMP6F was 
paired with either SH1R or SH2R whilst LMP7R was paired with either SH1F or 
SH2F. If VMO1 isoform 1 was successfully ligated into the pBlueScript II SK (+) 
vector, a band of 789 bp would be observed on an agarose gel following colony 
PCR with SH1R/LMP6F and SH1F/LMP7R. Alternatively, if VMO1 isoform 3 
was ligated into this vector, a product of 516 bp would be observed using 
SH2R/LMP6F and SH2F/LMP6F. 
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Table 4: Primer sequences used for the research detailed in this thesis. The nucleotide sequence of primers with restriction enzyme sites are depicted in bold. 
Primer 
name 
Sequence (5’- 3’) Gene target Melting 
temperature 
(°C) 
Product 
length 
(bp) 
Restriction 
enzymes 
Primer Application 
SH1F CGGATCCCAGACGCTACAGGATGG VMO1 
isoform 1 
63.6 691 BamHI PCR, Colony PCR 
SH1R CCGGAATTCAAGAGGTGGGACTAGCCTCC 64.8 EcoRI 
SH2F CGCGGATCCGATTCACAGACGCTACAG VMO1 
isoform 3 
65.5 387 BamHI PCR, Colony PCR 
SH2R CCGGAATTCAGAAAGCCACTAGGTAGGCG 63.6 EcoRI 
SH3F GGCGACTGGTTTCACATGTGC VMO1 
isoform 1 
inner region 
62.6 438  DNA Sequencing 
SH3R CCAAAGTCTCCCCAGCTCAG 60.0  
LMP6F GTTGTAAAACGACGGCCAGT M13  
  
55.8   DNA Sequencing, 
Colony PCR LMP7R AACAGCTATGACCATG 45.4   
LMP10F TAATACGACTCACTATAGGG T7 Promoter  47.5   DNA Sequencing, 
Colony PCR 
LMP11R GCTAGTTATTGCTCAGCGG T7 
Terminator  
53.4   
HCC30F GGCCTGATTCACAGACGCTA VMO1 57.0 354  PCR positive control 
HCC31R CTCACTCCATTCGCCCCAGC 60.8  
HCC37F CAAGAAGGTGGTGAAGCAGG HeLa 
GAPDH 
56.0 412  PCR positive control 
HCC38R GATGGTACATGACAAGGTGC 53.6  
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Figure 8: VMO1 isoform 1 reference sequence NM_182566 used for designing primer sets SH1F/SH1R and SH3F/SH3R. The restriction enzyme sites of 
BamHI and EcoRI on SH1F/SH1R are also shown in dark green. BamHI has a recognition site of G^GATCC and EcoRI has a recognition site of G^AATTC. 
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Figure 9: VMO1 isoform 3 reference sequence NM_001144940 used for designing primer set SH2F/SH2R. The restriction enzyme sites on 
SH2F/SH2R primers are also shown in dark green. BamHI has a recognition site of G^GATCC and EcoRI has a recognition site of G^AATTC. 
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2.3 Polymerase Chain Reaction 
PCR was performed using reagents from Solis BioDyne (Estonia) (Table 5). To 
avoid contamination, master mixes for PCR were prepared in a dedicated PCR 
cabinet that was UV-treated before each use. Also, dedicated pipettes and sterile 
DNase- and RNase-free filter tips were used. Next, 18 μL of master mix was 
aliquoted into sterile 200 µL PCR tubes (Axygen, USA) with F and R primers 
(Table 4) added to a final concentration of 0.25 µM. Lastly, 1 μL of cDNA was 
added as template. 
Table 5: Final concentration of reagents used in PCR 
Reagent Final concentration Individual amounts per 
reaction (μL) 
10X Buffer B1 (Tris-HCl and 
(NH4)2SO4) 
1X 2 
25 mM MgCl2 1.5 mM 1.2 
10 mM dNTPs 200 μM 0.4 
5 U/μL HOT FIREPol® DNA 
Polymerase 
0.05 U/μL 0.2 
mQH2O ̶ up to 20 μL 
 
cDNA extracted from several cell lines were used as the template for 
amplification and to test for presence of the VMO1 gene. PCR was carried out in a 
Bio-Rad T100 Thermal Cycler using the conditions outlined in Table 6. The 
primer set of HCC37F and HCC38R was used as a positive control for PCR 
(Section 2.2.4). In addition, each PCR was carried out with negative controls 
which contained primers and no template cDNA to test for possible contamination. 
The template cDNA was substituted with mQH2O.  
 
  
39 
 
Table 6: PCR cycle setting for amplification of DNA  
Step Temperature Time 
HOT FIREPol
® 
DNA Polymerase activation 95°C 15 min 
Cycling x 30 Denaturing 95°C 30 sec 
Annealing 60°C 30 sec 
Extension 72°C 1 min 
Final extension 72°C 5 min 
 
Following PCR, the amplified products were stored at RT until being loaded onto 
an agarose gel for analysis. 
2.3.1 Gradient PCR 
Gradient PCR was performed to optimise PCR reactions with primer sets and 
determine the best annealing temperature for primer sets. This was carried out 
using the same process as described in Section 2.3 with differing rows of the Bio-
Rad T100 Thermal Cycler set to temperatures between 52°C and 62°C. 
2.3.2 Colony PCR 
Colony PCR was performed on bacterial colonies following transformation of 
ligated vector DNA. This was to test colonies for presence of PCR inserts in 
cloned vectors or to check the orientation of the PCR insert in the cloned vector. 
A number of primers were used for colony PCR, as shown in Table 4. Colonies 
were selected from plates using a sterile toothpick and dipped into a 200 μL PCR 
tube containing a final concentration of 1X Buffer B1 (Tris-HCl and (NH4)2SO4), 
1.5 mM MgCl2, 200 μM of dNTPs, 0.05 U/μL HOT FIREPol
®
 DNA Polymerase 
and 0.25 μM of primers. The sterile toothpick was then streaked out onto Luria 
broth (LB) agar plates containing selective antibiotics. Colony PCR was 
performed as per Table 6. Following PCR, the reactions were loaded onto agarose 
gels for analysis. 
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2.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to separate out fragments of DNA for 
analysis, purification and quantification, and was carried out in a dedicated gel 
electrophoresis room as Ethidium bromide, a known carcinogen, was used in the 
process of making gels. Two agarose gel methods were used for the purpose of 
this MSc research; low melting point and agarose. In general, gels were cast and 
run using an Owl
™
 Separation System. DNA samples were mixed with 2 µL of 
6X Loading Dye and loaded into the gel well. Following electrophoresis, gels 
were photographed using a COHU High Performance CCD camera and Scion 
Image – Release Beta 4.0.2 software (Scion Corporation). Molecular DNA 
ladders were used to determine the size of fragments within gels. Weight per 
volume (w/v) concentrations of gels was based on the size of the fragments being 
electrophoresed and further applications (Table 7). 
Table 7: Weight per volume (w/v) agarose gels and the purpose each percentage gel 
was used for. 
Percentage gel  Amount of agarose added to 35 mL 
of 1X TAE buffer 
Nucleic Acid Analysis 
0.9% 0.315 g Plasmid  
1% 0.35 g Plasmid  
2% 0.70 g PCR  
 
2.4.1 Low Melting Point Agarose Gels for DNA Purification 
SeaPlaque
®
 GTG
®
 agarose powder (Lonza, USA) was weighed out in a weigh 
boat (0.315-0.7 g) and added to a 250 mL flask containing 35 mL of 1X TAE 
electrophoresis buffer (40 mM Tris-Acetate, 1 mM EDTA, pH 8). This 0.9-2% 
agarose is suitable for the separation of DNA fragments between 100 bp to 
23,000 bp and has a melting temperature of ≤65°C. The flask was then gently 
swirled and placed in a 650 W microwave where it was heated on medium heat 
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for one min. The flask was swirled again and microwaved until crystals of agarose 
were completely dissolved. The solution was cooled by running the flask under 
cold tap water before adding 2 µL of 10 mg/mL Ethidium bromide and swirling to 
mix. The solution was poured into a balanced gel caster. A comb containing 6 
wells that were 9 mm in width each was inserted into the solution and the gel was 
left to set at RT before use. The agarose gel was placed in the electrophoresis 
apparatus and covered with 1X TAE buffer. Agarose gels were run for 30 min at 
90 V before being placed on a Safe Imager
™
 Transluminator (Invitrogen, USA) to 
visualise the DNA products under blue light and prevent DNA damage. 
Fragments were purified from the gel using the protocol outlined in Section 2.5. 
2.4.2 Agarose Gels  
Agarose gels were made using HyAgarose
™
 LE Agarose (Hydragene, USA) 
powder which was weighed out in a weigh boat and added to 35 mL of 1X TAE 
buffer in a flask. This agarose was used since it is common reagent in the 
laboratory that has low electroendosmosis and a standard melting point (≤88°C) 
resulting in high resolution sharp DNA bands or high clarity and a low 
background. The amount of agarose added differed depending on the size of the 
fragments being run on the gel, as shown in Table 7. The flask was microwaved 
on medium heat to dissolve the agarose powder. Once dissolved, the mixture was 
cooled by running the flask under cold water and 2 µL of 10 mg/mL Ethidium 
bromide was added to allow visualisation of DNA fragments. The mixture was 
poured into an Owl
™
 Gel casting system with a two combs containing twelve 
0.75 cm width wells placed in it and left to set at RT. Gels were run for 30 min at 
90 V in 1X TAE buffer and viewed under UV light.  
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2.5 Purification of VMO1  
Low melting point gels were visualised on a Safe Imager Transluminator 
(Invitrogen, USA). Using a molecular ladder for reference, the DNA fragment of 
the correct size was cut from the gel using a scalpel and placed into a 1.7 mL 
microcentrifuge tube and weighed. Using the ZymoClean
™
 Gel DNA Recovery 
Kit (ZymoResearch, USA), three volumes of Agarose Dissolving Buffer was 
added per volume of gel fragment and incubated at 55°C for 10 min, shaking at 
700 rpm in an Eppendorf Thermomixer comfort. The dissolved solutions were 
loaded into a provided Zymo-Spin Column and placed into a provided Collection 
tube. The solutions were centrifuged at 16000 x g for 30 sec and the flow-through 
in the Collection tube was discarded. A total volume of 200 µL of DNA Wash 
Buffer was added to the columns and centrifuged at 16000 x g for 30 sec. This 
step was repeated once more before placing the Zymo-Spin Column into a new 
1.7 mL microcentrifuge tube and 20 µL of mQH2O was added to the column 
matrix. This was then centrifuged for 30 sec at 16000 x g to elute the DNA. DNA 
quality was analysed using the NanoDrop 2000 Spectrophotometer and 
accompanying software. Following extraction, DNA was stored at -20°C or used 
for digestion using restriction enzymes. 
2.5.1 Cloning VMO1 into a T-tailed Vector 
Following isolation of the PCR product using the Gel Recovery Kit, the VMO1 
PCR products for isoform 1 and isoform 3 were digested overnight at 37°C, 
mixing at 700 rpm in an Eppendorf Thermomixer comfort, using the restriction 
enzymes, BamHI and EcoRI (Roche, USA). A total reaction volume of 40 µL was 
made as shown in Table 8. Following digestion, the BamHI/EcoRI digested 
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amplified DNA was purified to remove residual enzymes and salts prior to 
ligation into vectors.  
 Table 8: Reaction mixture used for restriction digestion of VMO1 PCR products 
Reagent Volume (µL) 
Purified PCR product 20 
10X Buffer 3   2 
100X BSA (10 mg/mL)   1 
EcoRI (10U/μL)   2 
BamHI (10U/μL)   2 
mQH2O 13 
Total Volume 40 µL 
 
2.5.2 Purification of Digested DNA  
Following digestion of the VMO1 products, the ZymoClean
™
 Genomic DNA 
Clean and Concentrator Kit
™
 (ZymoResearch, USA) was used to purify out the 
amplified DNA from reagents in the restriction digest. In a 1.7 mL 
microcentrifuge, 200 µL of DNA Binding Buffer was mixed with each of the 
40 µL double digest reactions and transferred to a provided Zymo-Spin Column in 
a collection tube. This was centrifuged at 16000 x g for 30 sec and the flow-
through was discarded. Next, 200 µL of DNA Wash Buffer was added to the 
columns and centrifuged at 16000 x g for 30 sec. This step was repeated and then 
the column was transferred to a new 1.7 mL microcentrifuge tube. Finally, 15 µL 
of prewarmed (55°C) mQH2O was added to the column matrix, incubated for one 
min at RT before centrifuging for 30 sec at 16000 x g to elute the DNA. The 
purified, digested VMO1 PCR products were run on a 2% 1X TAE agarose gel to 
estimate the concentrations of the DNA. A total volume of 5 µL of each product 
was mixed with 2 µL of 6X Loading Dye and run on the gel with 5 µL of 100 bp 
DNA ladder (GenScript, USA) at 90V for 30 min. The brightness of the bands 
was compared to the DNA ladder whose bands were of known concentrations. 
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These concentrations were used for the Ligation calculation (Equation 1). This 
was so the ligation reaction was performed with a molar ratio of 1:3 vector to 
insert of the known DNA sizes present. The next step was to ligate the purified 
VMO1 insert into a cloning vector. 
 
 
 
2.6 Ligation of Purified VMO1 into pBlueScript II SK (+) Cloning Vector 
Purified VMO1 was ligated into the pBlueScript II SK (+) vector for means of 
DNA sequencing and subcloning before being cloned into the pET28b(+) 
expression vector. pBlueScript II SK (+) is a cloning vector of 2961 bp and the 
vector map can be found in Appendix Two. The pBlueScript II SK (+), kindly 
donated by Dr Ray Cursons (UoW), was digested using an EcoRV enzyme to 
create a linearised blunt vector. This was then tailed using dideoxythymidine 
triphosphate (ddTTP). This created a vector with a single 3’-overhanging thymine 
on each of the blunt ends. A 10 µL ligation reaction was prepared in 200 µL PCR 
tubes as per Table 9. Briefly, the T4 DNA Ligase buffer (Fermentas Thermo 
Scientific, USA) was mixed by pipetting up and down with the purified VMO1 
insert DNA, digested vector DNA and mQH2O before being mixed with T4 DNA 
Ligase (Fermentas Thermo Scientific, USA). The reaction was left overnight at 
4°C to increase the number of transformants.   
  
Equation 1: Ligation calculation used for determining the concentration of PCR 
product required for a molar ratio of 1:3 vector to insert. Size is measured in bp 
𝑛𝑔/µ𝐿 𝑃𝐶𝑅 𝑖𝑛𝑠𝑒𝑟𝑡 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 =
𝑛𝑔/µ𝐿 𝑉𝑒𝑐𝑡𝑜𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑥 𝑃𝐶𝑅 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑠𝑖𝑧𝑒
𝑉𝑒𝑐𝑡𝑜𝑟 𝑠𝑖𝑧𝑒
 𝑥 3 
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Table 9: Reagents used for ligation of VMO1 isoforms into vectors. 
Reagent Volume (µL) 
1X T4 DNA Ligase Buffer (40 mM Tris-HCl, 10 mM MgCl2, 10 
mM DTT, 0.5 mM ATP) 
 1 
Purified Vector DNA (5 ng/µL)  5 
Purified VMO1 PCR product (30 ng/µL)  1 
mQH2O  2 
T4 DNA Ligase (5 Weiss units/µL)  1 
Total Volume 10 µL 
 
2.6.1 Preparation of Fresh Chemical Competent E. coli DH5α Cells 
Escherichia coli (E. coli) DH5α were prepared for chemical transformation of 
pBlueScript II SK (+) and pET28b(+) vectors containing either VMO1 isoform 1 
or isoform 3. E. coli DH5α were streaked out on a LB agar plate and grown 
overnight at 37°C. Two colonies were selected for inoculation of 10 mL of LB 
broth and grown at 37°C shaking at 800 rpm in a Ratek Orbital Mixer Incubator 
until the culture appeared turbid. Once turbidity was reached, 1.5 mL amounts of 
culture were removed and spun down for one min at 16000 x g and the 
supernatant removed. Pellets were then resuspended in 100 µL of CaCl2/PEG 
solution (0.1 M CaCl2 and 1% PEG 8000) and stored on ice until required for 
transformation.   
2.6.2 Chemical Competent Transformation 
Following preparation of chemical competent DH5α, the whole ligation reaction 
(10 µL) was added to the cells and flicked to mix. Cells were left on ice for 
30 min with intermittent flicking every five min. Cells were heat shocked in a 
water bath set to 42°C for one min then placed on ice for one min. Following this, 
1 mL of LB broth prewarmed to 37°C was added and cells were left to grow for 
an hour to allow expression of antibiotic resistance gene(s) at 37°C shaking at 
300 rpm in an Eppendorf Thermomixer
®
 Comfort.  
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2.6.3 Selection for Colonies Containing pBlueScript II SK (+) with the VMO1 
Insert 
Prior to transformation, LB agar plates containing ampicillin (100 mg/mL) were 
spread with 4 µL of 2% 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-
Gal) and 40 µL of 20% Isopropyl β-D-1-thiogalactopyranoside (IPTG). 
Ampicillin was used to select for growth of colonies containing the vector 
whereas X-Gal and IPTG were used for blue and white colony screening. The 
gene of interest was cloned into the multiple cloning site (MCS) of the lacZ, a 
gene in pBlueScript II SK (+) which is responsible for producing the α-peptide of 
β-galactosidase. The plasmid was transformed into E. coli DH5α which contains 
the gene for production of the ω-peptide for β-galactosidase. If both peptides are 
produced, the β-galactosidase enzyme is formed and can be detected by X-Gal. 
This can be cleaved by β-galactosidase to form 5-bromo-4-chloro-indoxyl which 
oxidises to 5,5'-dibromo-4,4'-dichloro-indigo, a blue coloured pigment. However, 
the cloning into this site disrupts the production of the a-peptide of the β-
galactosidase protein. Following growth for an hour (Section 2.6.2), cells were 
spun down for one min at 16000 x g and resuspended in 100 µL of LB broth 
before being spread out on the plates containing IPTG/X-Gal. Plates were grown 
overnight at 37°C. White colonies were selected for colony PCR (Section 2.3.2) to 
check the orientation of the insert in the vector using primers described in 
Section 2.2.6. The transformation efficiency could not be calculated due to a low 
volume of unknown concentration of pBlueScript II SK (+) vector. However, it 
was noted that the DNA was detected on an agarose gel (Dr. Ray Cursons, 
personal communication, 12 June, 2014).  
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2.7 pET28b(+) Expression Vector 
A frozen glycerol stock of (E. coli) DH5α containing pET28b(+) was obtained 
from communal stocks in the -80°C freezer (UoW). It was streaked out on a LB 
agar plate containing the antibiotic kanamycin at a final concentration of 30 µg/μL. 
The plates were left to grow overnight upside down in a 37°C oven. A single 
colony was selected from the agar plate to inoculate 10 mL of LB broth 
containing a final concentration of 30 µg/μL kanamycin and left to grow 
overnight at 37°C in a Ratek Orbital Mixer incubator on speed setting 8. A 
plasmid map of pET28b(+) can be found in Appendix Two. 
2.7.1 Extraction and Purification of pET28b(+) 
The pET28b(+) vector was extracted from E. coli DH5α using the Zyppy Plasmid 
Miniprep kit (ZymoResearch, USA) and the manufacturers guidelines. This 
protocol can extract up to 25 μg of plasmid DNA. For this procedure, all 
centrifugation was performed at 16000 x g. A 1.5 mL volume of overnight 
bacterial culture was transferred to a 1.7 mL microcentrifuge tube and centrifuged 
for 30 sec, and the supernatant discarded. The pellet was resuspended in 600 µL 
of 1X TE buffer pH 8. The 7X Lysis Buffer was preheated to 37°C for 30 min to 
dissolve the mixture before adding 100 µL to the resuspended cell pellet. It was 
mixed by inversion six times to ensure complete cell lysis. A 350 µL volume of 
pre-chilled Neutralisation Buffer was added to the tube and quickly mixed (within 
two min) by inversion to ensure complete neutralisation of the reaction. As a 
result, a yellow precipitate formed and was centrifuged for four min. 
Approximately 900 µL of the supernatant was transferred to the provided Zymo-
Spin IIN column, taking care to avoid disturbing the pellet of cellular debris. The 
column was placed into a provided Collection tube and centrifuged for 15 sec. 
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The flow-through in the Collection tube was discarded and the column placed 
back in the original tube. Then, 200 µL of Endo-Wash Buffer was placed in the 
column and centrifuged for 30 sec before adding 400 µL of Zyppy Wash Buffer 
and centrifuging for one min. The column was transferred to a new 1.7 mL 
microcentrifuge tube and 30 µL of prewarmed 55°C mQH2O was added directly 
to the column and left to incubate at RT for one min. Finally, the column was 
centrifuged for 30 sec to elute the plasmid DNA. The concentration and purity of 
plasmid DNA was determined using the NanoDrop 2000 Spectrophotometer 
software. The purity of the DNA sample is determined by the 260/280 ratio, and 
those around ~1.8 are considered pure enough for downstream applications. It was 
then stored at -20°C or digested by restriction enzymes for later applications.  
2.7.2 Restriction Digest of pET28b(+) 
The pET28b(+) vector was digested using two restriction enzymes, BamHI and 
EcoRI (Roche, USA). These enzymes were used to create a linearised vector with 
compatible sticky ends for ligation of the amplified VMO1 gene. The two 
enzymes selected were within the MSC of pET28b(+) at position 192 and 198 
(Appendix Two). Four reactions were set up according to Table 10. Both enzymes 
were tested individually as well as a double digest to check that the digestion 
activity was complete. A negative control was also used as a comparison of non-
digested DNA. Following an overnight digest in an 37°C Eppendorf Thermomixer 
comfort which was shaking at 700 rpm, 5 µL of each reaction was then mixed 
with 2 µL of 6X Loading Dye and loaded onto a 0.9% 1X TAE gel (Section 2.4). 
A 5 µL volume of 1 kB Plus DNA Ladder (Invitrogen, USA) was also loaded 
onto the gel. 
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Table 10: Reaction mixes for digestion of pET28b(+) using restriction enzymes. 
Reagent Negative 
control 
Double digest BamHI EcoRI 
pET28b(+) () 5 µL 12.5 μL 5 µL 5 µL 
Buffer 3 1 µL 2.5 μL 1 µL 1 µL 
100X BSA 
(10mg/mL) 
1 µL 1 μL 1 µL 1 µL 
BamHI (10U/μL) - 2.5 μL 1 µL - 
EcoRI (10U/μL) - 2.5 µL - 1 µL 
mQH2O 13 µL 29 µL 12 µL 12 µL 
Total 20 µL 50 µL 20 µL 20 µL 
 
The double restriction enzyme digest of pET28b was seen as a single product on 
the gel of 5362 bp. In addition to this, a linearised product was present on the gel 
in the single digest reactions. This allowed for positive confirmation that the 
digest had worked. Following this confirmation, the remaining 35 µL volume of 
the double digest was mixed with 2 μL of 6X Loading Dye and loaded onto a 1% 
1X TAE low melting point gel. Following electrophoresis (Section 2.4.1), a 
5362 bp band was gel purified using the ZymoClean
™
 Gel DNA Recovery Kit 
(ZymoResearch, USA).   
2.7.3 Ligation of Purified, Digested pBlueScript II SK (+) -VMO1 Insert into 
BamHI/EcoRI Digested pET28b(+) Vector 
White colonies containing ligated pBlueScript II SK (+) and VMO1 gene were 
selected and analysed using colony PCR to detect for the insertion in the correct 
orientation (Section 2.4.1). Positive clones were grown in 10 mL of LB and 
ampicillin (50 μg/μL) broth and the vector DNA purified out as per Section 2.7.1. 
The cloned VMO1 gene of approximately 693 bp was cut from pBlueScript II 
SK(+) vector using the restriction enzymes BamHI and EcoRI to confirm the PCR 
results prior to DNA sequencing. The restriction digest product was then run on a 
2% 1X TAE low melting point agarose gel and purified (Section 2.4.1) before 
being ligated into BamHI/EcoRI digested pET28b(+) as per the protocol below.  
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2.8 Transformation of Ligated Vectors into Bacterial Competent Cells 
Ligated vectors containing the VMO1 insert were transformed into bacterial cells 
through either electroporation or chemical transformation. Positive controls were 
used where possible for calculation of the transformation efficiency. The equation 
for working out the transformation efficiency is shown in Equation 2. Colonies on 
the plate were counted and entered into the equation. The amount of DNA added 
for the transformation was either determined by the concentration provided by the 
manufacturer as a positive control or by NanoDrop. Transformations are 
considered of high quality when the cells are worked out as 10
10
 transformants/μg 
for electrocompetent cells and 10
7
 transformants/μg for general cloning purposes.  
 
                    
# 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑜𝑛 𝑝𝑙𝑎𝑡𝑒
𝑛𝑔 𝑜𝑓 𝐷𝑁𝐴 𝑝𝑙𝑎𝑡𝑒𝑑
 × 1000 𝑛𝑔/𝜇𝑔 = transformants/µg  
Equation 2: Calculation for determining the transformation efficiency following 
transformation of vectors into competent cells.  
 
2.8.1 Preparation of Electrocompetent Cells 
Electrocompetent cells were produced as they have higher transformation 
efficiency rates than chemical competent cells (Hanahan & Glover, 1985). E. coli 
DH5α was sourced from glycerol stocks stored at -80°C and streaked out on a LB 
agar plate and grown overnight at 37°C. The following day, a single colony was 
used for inoculation of 10 mL of LB broth and grown overnight at 37°C at 
200 rpm in a Ratek Orbital Mixer Incubator. The 10 mL overnight culture was 
used to inoculate 1 L of LB broth and incubated at 37°C until the OD600 reached 
exponential growth phase between 0.5 and 0.7 before being chilled on ice for 
15 min. Centrifugation was carried out on a benchtop Heraeus Multifuge 3SR 
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Plus at 4°C for 15 min at 4500 rpm to pellet the bacterial cells. The culture was 
centrifuged in cooled, sterile centrifuge buckets and the supernatant was poured 
off. The pellet was resuspended in 1 L of sterile, chilled 10% glycerol then 
centrifuged at 4°C for 15 min at 4500 rpm. The glycerol was poured off and the 
pellet was resuspended in 500 mL of fresh 10% glycerol before being re-
centrifuged as before. The glycerol was once again poured off and the pellet 
resuspended in 20 mL of fresh 10% glycerol. Following a final centrifugation, the 
pellet was resuspended in 3 mL of 10% glycerol and 50 µL aliquots were made in 
prechilled 1.7 mL microcentrifuge tubes on ice. The 50 μL aliquots were briefly 
frozen in liquid nitrogen before being stored at -80°C. 
2.8.2 Transformation of pET28b(+) and VMO1 using Electroporation 
Electrocompetent E. coli DH5α (Section 2.8.1) and E. coli BL21 (DE3) strains 
were used for electroporation. Electrocompetent cells were thawed at RT before 
being placed on ice. In a prechilled 1.7 mL microcentrifuge tube, 40 µL of 
electrocompetent cells were mixed with 2 µL of ligated reaction DNA 
(Section 2.7.3). This volume was transferred to a pre-chilled sterile 0.2 cm Bio-
Rad Gene Pulser
®
 Cuvettes. The cuvettes were placed on ice to cool. Right before 
electroporation, the mixture was transferred to the cuvette and tapped lightly to 
ensure the mixture was at the bottom of the cuvette. The cuvette was wiped with a 
paper towel to remove any ice and placed in the safety chamber slide of the Bio-
Rad Gene Pulser
™
 which was set to 25 µF and 2.50 kV, and the pulse controller 
set to 200Ω. The cuvette was pulsed once at the setting above. Immediately after 
electroporation, 1 mL of LB broth warmed to RT was added to the cuvette and the 
cells gently resuspended. This was then transferred to a 1.7 mL microcentrifuge 
tube and incubated for one hour at 37°C, shaking at 300 rpm to allow for the 
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expression of antibiotic resistant genes. The cells were then plated onto 
prewarmed LB agar plates containing kanamycin (30 μg/μL) for selective growth 
of bacterial cells containing the vector. The transformations were plated in serial 
dilutions of 1:10 of 10 μL of transformed cells diluted in 90 μL of fresh LB broth, 
100 μL of undiluted cells, and the remaining cells spun down and resuspended in 
100 μL of fresh LB broth prior to plating. The plates were grown upside down 
overnight in a 37°C oven. The white E. coli DH5α colonies were tested for 
presence of the VMO1 insert in the correct orientation using colony PCR. Positive 
clones were then grown in 5 mL of LB broth containing kanamycin (30 μg/μL) 
and the vector purified out for DNA sequencing, or transformation into protein 
expression bacterial strains; E. coli BL21 (DE3), E. coli BL21 (DE3) pLysS, or 
Rosetta
™
 (DE3) pLysS. 
2.8.3 Transformation of pET28b(+) into E. cloni
®
 EXPRESS Chemically 
Competent Cells 
The pET28b(+) vector containing VMO1 isoform 1 was transformed into E. cloni
®
 
EXPRESS BL21 (DE3) pLysS cells (Lucigen, USA). Prior to transformation, LB 
agar plates containing chloramphenicol (34 μg/μL) and kanamycin (30 μg/μL) 
were prewarmed at 37°C in an oven. LB agar plates containing chloramphenicol 
(34 μg/μL) and ampicillin (50 μg/μL) were also prewarmed in a 37°C oven for the 
transformation of the positive plasmid control, pUC19 (10 pg), provided with the 
kit. pET28b(+) containing PhoH2 (sourced from Dr Emma Andrews, UoW) was 
used as positive control for protein expression and also prepared for 
transformation. The E. cloni
®
 cells were removed from the -80°C freezer, thawed 
on ice and 40 µL of cells were aliquoted into each sterile pre-chilled 14 mL tube 
(Greiner Bio-One, Austria) on ice. For chemical transformation, the cells were 
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mixed with 1 µL of vector and stirred briefly for three seconds using a pipette tip. 
The mixture was incubated on ice for 30 min before being heat shocked in a 42°C 
water bath for 45 sec. The tubes were incubated on ice for two min before adding 
960 µL of RT Expression Recovery Medium (Lucigen, Austria) to the cells. The 
tubes were placed in a Ratek Orbital Mixer Incubator at 250 rpm for one hour at 
37°C to express the antibiotic genes. Following this growth, 200 µL was spread 
out on the appropriate antibiotic plates and grown overnight at 37°C. Single white 
colonies were selected for protein expression induction.  
2.8.4 Transformation of pET28b(+) into Rosetta
™
 (DE3) pLysS Competent 
Cells 
Transformation of DNA into competent Rosetta
™
 (DE3) pLysS cells (Novagen, 
USA) was performed as per manufacturer’s instructions. Cells were removed 
from the -80°C freezer and thawed on ice and 20 μL of cells were aliquoted into 
sterile, prechilled 1.7 mL microcentrifuge tubes on ice. One microlitre of purified, 
isolated pET28b (+) containing the VMO1 isoform 1 insert (Section 2.7.3) was 
pipetted into the tube and gently mixed by swirling using the pipette tip. In 
addition to this, a test plasmid control (1 pg) provided by the manufacturer was 
transformed into the competent cells as they had been displayed to produce more 
than 2 x 10
6
 colonies/μg plasmid when plated. This reaction was placed on ice for 
five min before heating tubes in a 42°C waterbath for 30 sec. Tubes were then 
placed back on ice for two min before adding 80 μL of SOC media provided by 
the manufacturer. Tubes were placed in an Eppendorf Thermomixer
®
 comfort set 
at 37°C, shaking at 300 rpm for one hour. Following this, 40 μL of the 
transformation was pipetted onto a LB agar plate containing chloramphenicol 
(34 μg/μL) and kanamycin (30 μg/μL) and spread with a sterile glass rod. Also, 
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40 μL of the control transformation was plated onto a LB agar plate containing 
ampicillin (50 μg/μg) and chloramphenicol (34 μg/μL) and spread using a glass 
rod. Plates were placed upside down in a 37°C oven to grow overnight. Following 
overnight growth, plates were inspected for presence of growth and a single 
colony containing the pET28b (+)/VMO1 construct was selected for downstream 
protein expression applications. In addition, this colony was streaked onto a LB 
agar plate containing appropriate antibiotics so that downstream applications 
could be performed using the same colony or produced into glycerol stocks. 
2.9 DNA Sequencing 
DNA Sequencing was carried out by the University of Waikato DNA Sequencing 
Facility using an Applied Biosystems 3130xl Genetic Analyser. The purpose of 
sequencing was for confirmation of the VMO1 nucleotide sequence as well as 
checking the orientation of the insertion of the gene into the recombinant vectors, 
pBlueScript II SK (+) and pET28b(+). Sequencing was also used to confirm the 
VMO1 gene was in frame in the vector(s) for protein expression and that there 
were no stop codons present in the open reading frame of the translated nucleotide 
sequence. Sequencing was carried out using primers provided by the Facility or 
those listed in Table 4. Primers were provided to the UoW DNA Sequencing 
Facility at a final concentration of 5 μM in 0.1% DEPC mQH2O. Vectors 
containing the VMO1 gene that were at a concentration of 150 μg/μL, determined 
by a NanoDrop 2000 Spectrophotometer, were sent for sequencing. The resulting 
sequences were analysed using Geneious version 7.1.7 
(Biomatters, http://www.geneious.com). 
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2.10 Recombinant VMO1 Protein Expression 
Recombinant protein expression was optimised using two different bacterial 
strains and concentrations of IPTG. Firstly, pET28b(+) containing the VMO1 
isoform 1 gene was transformed into electrocompetent E. coli BL21 (DE3), and 
then into commercial E. cloni
®
 EXPRESS BL21 (DE3) pLysS cells for protein 
expression of the recombinant VMO1 protein. This bacterial strain contains the 
pLysS plasmid that encodes for the T7 lysozyme. This lysozyme lowers the 
background expression levels of genes that are under the T7 promoter. This does 
not inhibit the expression of the target gene following induction with IPTG. In 
addition, a positive pET28b(+) plasmid control for protein expression was 
included. This construct was developed and obtained as extracted vector DNA 
from Dr Emma Andrews (UoW) and contains the PhoH2 from Mycobacterium 
smegmatis. It was used as it had previously been demonstrated to express at the 
same conditions as the conditions used for this thesis, producing a protein of 
approximately 50 kiloDalton (kDa) in size and was transformed into the E. coli 
BL21 (DE3) pLysS cells (E Andrews, personal communication, October 2014).  
2.10.1 Small-scale Time Course Protein Expression Analysis using E. coli 
BL21 (DE3) 
A single colony from a transformed agar plate (Section 2.8.2) was selected for 
inoculation of 2 mL of LB broth with kanamycin (30 μg/μL). The culture was 
grown at 37°C shaking at 200 rpm in a Ratex Orbital Mixer Incubator until the 
OD600 was between 0.6 and 1. The culture was spun down for 30 sec at 16000 x g 
and the supernatant removed and the pellet resuspended in 2 mL of fresh LB broth 
and kanamycin (30 μg/μL). Three 14 mL tubes were set up containing 5 mL of LB 
broth and kanamycin (30 μg/μL). To each tube, 200 µL of the resuspended 
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bacterial cells was added and incubated at 37°C in a 250 rpm shaking incubator 
until the OD600 measured between 0.4 and 0.6. To two of the culture tubes, 
100 mM IPTG was added to the final concentrations of 0.4 mM and 1 mM, 
respectively. IPTG binds to the lac repressor, allowing genes under the lac operon 
to be transcribed. One tube was reserved as a control for uninduced cells where no 
IPTG was added. Following this, the culture tubes were placed in a 37°C shaking 
incubator at 250 rpm with 500 µL aliquots taken at certain time points (0 hr, 3 hr, 
6 hr, 24 hr) for whole cell extraction. These 500 µL aliquots of culture were 
transferred to 1.7 mL microcentrifuge tubes, spun down for five min at 5000 x g 
at 4°C and then the media was removed. The bacterial cell pellet were 
resuspended and lysed in 50 µL of Cracking Buffer. Next, 50 µL of 2X SDS 
Loading Buffer was added and the sample boiled for five min at 99°C. Samples 
were stored on ice until PAGE gel analysis to observe protein bands in non-
induced and induced samples (Section 2.11). 
In order to determine if the expressed recombinant protein was soluble or 
insoluble, 1 mL of whole extract cell sample was centrifuged at 5000 x g for 
five min at 4°C and the media removed. The cell pellet was resuspended in 
100 µL of 5X TE buffer (pH 8). Samples were sonicated using a Misonix 
Sonicator
®
 Ultrasonic Liquid Processor XL2020 with the microtip probe. The 
sonicator was tuned to manufacturer's instructions before placing the probe in the 
sample. The sonicator was set to Continuous mode and power setting 1. Samples 
were sonicated six times for 20 sec pulses with 20 sec between pulses to prevent 
overheating of the protein samples. Following sonication, the samples were spun 
at 4°C for five min at 16000 x g to pellet out the insoluble fraction. To process the 
soluble fraction, 50 µL of the supernatant was transferred to a new 1.7 mL 
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microcentrifuge tube and 50 µL of 2X SDS Loading Buffer was added. The 
remaining supernatant was discarded from the insoluble fraction and the pellet 
resuspended in 50 µL each of Cracking Buffer and 2X SDS Loading Buffer. The 
soluble and insoluble fraction samples were then boiled for five min at 99°C prior 
to being run on a SDS-PAGE gel and finally stored at -20°C. 
2.10.2 Protein Expression using E. cloni
®
 EXPRESS BL21 (DE3) pLysS 
Protein expression of VMO1 isoform 1 was performed in a similar manner to that 
of the E. coli BL21 (DE3) except two changes were made to the LB media. Firstly, 
filter sterilised 20% glucose was added to the LB broth to a final concentration of 
1%. Glucose was used to control non-specific expression. Secondly, 
chloramphenicol was added to the LB broth to a final concentration of 34 μg/μL 
to select for the pLysS plasmid. A final concentration of 1mM IPTG was used for 
protein expression induction and aliquots were taken at varying time points and 
protein samples were processed for whole cell extracts and soluble and insoluble 
fractions. Samples were pelleted by centrifugation at 5000 x g for five min at 4°C 
and media was removed and stored at -80°C if samples could not be analysed 
immediately.  
2.10.3 Small-scale Time Course Protein Expression Analysis using Rosetta
™
 
(DE3) pLysS 
A single colony was selected from a LB agar plate containing chloramphenicol 
(34 μg/μL) and kanamycin (30 μg/μL) and used to inoculate 5 mL of starter LB 
broth containing chloramphenicol (34 μg/μL) and kanamycin (30 μg/μL). The 
starter broth was grown overnight shaking at 200 rpm at 37°C. The following day, 
200 μL was used to inoculate two 14 mL tubes of LB broth containing the 
aforementioned antibiotics. The tubes were grown shaking at 200 rpm at 37°C 
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until the OD600 reached between 0.4 and 0.6, then IPTG (0.4 mM) was added to 
one of the tubes to induce protein expression whilst the other tube was used as a 
control. A 0.5 mL sample was taken at time point zero hours from both tubes for 
analysis of protein expression in the whole cell lysate. The tubes were placed back 
in a Ratek Orbital Mixer Incubator at 200 rpm at 37°C for 24 hours. At the 
24 hour point, 0.5 mL samples were taken from each tube for proteins present in 
the whole cell lysate and 1 mL samples were taken for fractionated protein 
samples. All samples were spun at 5000 x g for five min at 4°C to pellet cells and 
supernatant was discarded. Whole cell sample pellets were resuspended in 50 µL 
of Cracking buffer before adding 50 µL of 2X SDS Loading buffer. The 
fractionated sample pellets were resuspended in 100 µL of 5X TE buffer and 
sonicated as per Section 2.10.1. Sonicated samples were centrifuged once again at 
5000 x g for five min at 4°C to pellet the sample. Following this, 50 µL of 
supernatant was removed to a new 1.7 mL microcentrifuge tube and mixed with 
50 µL of 2X SDS Loading buffer with the rest of the supernatant discarded. The 
pellet was resuspended in 50 µL of Cracking buffer before adding 50 µL of 
2X SDS Loading buffer. Samples were boiled for five min at 99°C on an 
Eppendorf Thermomixer
®
 comfort set prior to loading 10 µL onto an SDS-PAGE 
gel for protein separation.  
2.11 SDS-PAGE Gel 
Denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was used for separation of proteins in whole cell lysates and fractionated 
samples of bacterial cells. This was to determine the presence of recombinant 
VMO1 protein expression in bacterial cells. Protein samples were run on three 
types of gels; premade commercial 10% Mini-PROTEAN
®
 TGX Stain-Free
™
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Gels (Bio-Rad Laboratories, Inc, USA), premade commercial 12% Express PAGE 
Gels (GenScript), or 12% hand cast PAGE gels which are recommended for 
separating out proteins between 20 and 150 kDa (Thermo Fisher Scientific Inc, 
2014).  
Hand cast gels were made as described in Table 11 with a 4% stacking gel used to 
focus the protein bands and a 12% separating gel for separation of proteins based 
on molecular weight. Gels were cast using a Hoefer
™
 Dual Gel Caster with glass 
plates, spacers and combs. The glass plates were cleaned with detergent then left 
to dry. They were cleaned again using 70% ethanol and a small amount of 
Beckman vacuum grease silicon (USA) was spread evenly along the bottom of the 
plates to help create a vacuum seal with the caster. The glass plates with the 
spacers were then placed in the gel caster. The 12% separating gel was prepared in 
a 50 mL falcon tube (Biologix, China) with the Ammonium persulfate (APS) and 
Tetramethylethylenediamine (TEMED) added last just before gels were cast to 
cause the polymerisation of acrylamide. The reagents were mixed gently together 
before being transferred between the glass plates using a sterile 3.5 mL transfer 
pipette (Sarstedt, Germany). A layer of 2-butanol was added to the top of the gel 
once it was poured to exclude air from the top of the gel and help with 
polymerisation of the gel. Once the gel was set, the 2-butanol was poured off and 
rinsed using ddH2O. The 4% stacking gel was prepared and added to the top of the 
separating gel and a comb containing 10 teeth was added to the stacking gel and 
left to set.  
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Table 11: Reagents required for preparing 12% SDS-PAGE hand cast gels with a 4% 
stacking gel. Volumes are sufficient to make two gels. 
Reagent Volume 
12% Separating gel 4% Stacking gel 
22.2% Acrylamide/0.6% Bis (37:1) 10.81 mL  2.00 mL 
1 M Tris/HCl pH 6.8 − 6.54 mL 
3 M Tris/HCl pH 8.8 2.50 mL − 
mQH2O 6.28 mL 1.25 mL 
10% SDS 200 μL 100 μL 
10% APS 180 μL 100 μL 
TEMED   26 μL   10 μL 
2.11.1 Gel Electrophoresis 
Gel electrophoresis of pre made gels was carried out using the Mini-PROTEAN
®
 
Tetra Cell (Bio-Rad Laboratories, Inc, USA) and hand cast gels in a Mini 
PROTEAN
®
 3 Cell (Bio-Rad Laboratories, Inc, USA). The glass plates containing 
the gels were placed in the electrophoresis tanks and covered with 1X Tris-
Glycine running buffer (0.025 M Tris-HCl, 0.192 M Glycine, 0.1% SDS, pH 8.5). 
The premade 12% gels were run using 1X MOPS running buffer (GenScript, USA) 
Gel combs were removed and the wells rinsed with the running buffer. Protein 
samples (10 μL) were loaded into the wells and 5 μL of either Precision Plus 
Protein
™
 Unstained Standards (Bio-Rad Laboratories, Inc, USA) or PAGE-
MASTER Protein Standard Plus (GenScript, USA) protein ladder was added to 
one of the wells for determination of protein sizes. The SDS-PAGE gel was 
electrophoresed at 200 V for 45 min until the dye front was approximately a 
centimetre above the bottom of the gel. The gel was then used for visualisation of 
protein using Coomassie Blue staining or Bio-Rad Gel Doc
™
 EZ System. 
Alternatively, the gel was used for western blotting analysis (Section 2.13). 
2.11.2 SDS-PAGE Gel Visualisation  
Premade 10% gels were visualised using a Bio-Rad Gel Doc
™
 EZ System using 
the stain-free plate. The gel was removed from between the glass plates and 
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placed on the stain-free plate. The plate was then placed in the Gel Doc
™
 system 
and the gel imaged using the Image Lab
™
 Software (Bio-Rad, USA) according to 
the manufacturer’s instructions. 
Hand cast gels were visualised using Coomassie Blue R250. The gel was removed 
from the glass plates and placed into a container and covered with fixing solution 
(10% acetic acid, 50% methanol in ddH2O) for ten minutes at RT. The fixing 
solution was removed, and then Coomassie Blue R250 was added to cover and 
stain the gel overnight, shaking on an Orbital shaker (Bellco Glass Inc., USA) at 
speed setting four. The following day, the Coomassie Blue R250 was removed 
and the gel rinsed with ddH2O before being covered with fixing solution to 
destain the gel on the shaker for two hours set as above. Once destained, the gel 
was placed on an Ilford A3 Light Box and photographed for analysis using a 
COHU High Performance CCD camera and Scion Image – Release Beta 4.0.2 
software. 
2.12 Bradford Assay for Estimation of Protein Concentration 
A quick Bradford Assay was performed using Bio-Rad Protein Assay Dye 
Reagent Concentrate and Bovine serum albumen (BSA) as a standard. Differing 
concentrations of BSA were made up in 1X PBS from a stock solution of 
10 mg/mL Purified BSA (Roche, USA) as per Table 12. Bio-Rad Protein Assay 
Dye Reagent Concentrate was diluted to 1:4 in mQH2O. This protein assay was 
used based on the change in colour in response to the concentration of protein 
added to it as the dye binds to basic and aromatic amino acid residues. Using a 
96 well plate, 100 µL of the diluted assay reaction was added to a row of the plate 
and 1 μL of the differing BSA concentrations were added to each well in 
ascending concentration order. In the next row, 1 μL of protein samples of 
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unknown concentrations were mixed with 100 μL of diluted assay reaction. The 
colour changes were visually compared to the BSA standards for estimation of 
protein concentration. This was used for quickly estimating the amount of protein 
to be loaded onto the SDS-PAGE gels for western blots. A more precise 
measurement can be obtained by measuring the wavelength at 585 nm.  
Table 12: Concentrations of BSA standards made up for the quick Bradford Assay.  
Conc. 
(mg/mL) 
0 0.1 0.25 0.5 1 2 4 6 8 10 
BSA (10 
mg/mL) 
0 1 2.5 5 10 20 40 60 80 100 
1X PBS 
pH 8 
100 99 97.5 95 90 80 60 40 20 0 
 
2.13 Western Blot for Detection of Recombinant VMO1 Protein 
Following confirmation of presence of recombinant VMO1 protein expression 
using SDS-PAGE gels to separate out proteins, the samples were run on premade 
commercial 12% Express PAGE gels and electrophoresed for 30 min at 200 V in 
a Mini-PROTEAN
®
 Tetra Cell (Bio-Rad Laboratories, Inc, USA) using 
1X MOPS running buffer (GenScript, USA). Ten microlitres of protein sample 
were loaded into wells as well as 4 mg/mL BSA, mouse ear protein extract kindly 
donated by Miss Blaise Forrester-Gauntlett, and a purified R343A protein, kindly 
donated by Dr Emma Andrews, which contains a His Tag for positive control with 
the 6X His Tag antibody (Catalogue number: GTX115045) as it has been 
previously demonstrated to work (E Andrews, personal communication, January 
2015). In addition, 5 μL of each WB-MASTER Protein Standard and PAGE-
MASTER Protein Standard Plus (GenScript, USA) protein ladders were both 
loaded into wells for determination of protein size. The WB-MASTER Protein 
Standard is specifically designed for western blotting as the proteins present in the 
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ladder contain IgG banding sites that can bind to primary and secondary 
antibodies so it can be visualised on the membrane along with the samples.  
Followed gel electrophoresis of samples, gels were removed from their encasing 
and rinsed in ddH2O. Separated proteins on the gels were transferred to a 
Polyvinylidene Difluoride (PVDF) membrane (Amersham LIFE SCIENCE, UK) 
using the eBlot
™
 Protein Transfer System (GenScript, USA). The hydrophobic 
PVDF membrane was dipped into 100% methanol for activation then placed in 
ddH2O for one min to rinse. Next, the membrane was placed in eBlot
™
 
Equilibrium Buffer for five min. The transfer stack was set up according to 
manufacturer’s instructions. The eBlot™ Anode Pad was placed on the anode plate 
and the pre-wet membrane was placed on top of it. Air bubbles were carefully 
removed from between the membrane and the anode pad using the supplied 
shovel. Following this, the gel was placed on top of the membrane and air bubbles 
carefully removed. The Gel Window was placed on the gel to cover the margin of 
the membrane. Next, the eBlot
™
 Cathode Pad was placed over the gel and the lid 
was closed on top of it. The eBlot
™
 Protein Transfer System was run for 
seven min as recommended for transferring proteins less than 80 kDa in size.  
The transferred membranes were placed in containers containing 10% Blocking 
solution and placed on an orbital shaker at setting four at RT for an hour. The 
membranes were then rinsed using three washes of 1X Tris Buffered Saline 
Tween (TBST) for 15 min each. Next, two antibodies, 6X His Tag antibody 
(GeneTex Inc., USA, Catalogue number: GTX115045) and VMO1 antibody 
[N1C3] (GeneTex Inc., USA, Catalogue number: GTX106683) were made up to a 
final ratio of 1:1000 in 10% Blocking solution to a final volume of 2 mL. The 
mixture was pipetted over the membrane and placed on an orbital shaker at 4°C 
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overnight to incubate. The following day, antibodies were removed from the 
membranes and three washes of 15 min with 1X TBST were performed on an 
orbital shaker at RT. The membranes were incubated for one hour at RT with the 
secondary antibody, goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology Inc., 
USA, Catalogue number: sc-2004), made up to a final ratio of 1:5000 in 
10% Blocking solution. The membranes were washed three times for 15 min each 
again with 1X TBST on an orbital shaker at RT before having a final wash in 
1X TBST for one hour at RT. Membranes were then rinsed in 1X TBS for 15 min 
on the orbital shaker at RT.  
Proteins were detected on the membranes using the SuperSignal
®
 West Femto 
Maximum Sensitivity Substrate (ThermoScientific, USA) kit. This kit is an 
ultrasensitive enhanced chemiluminescent (ECL) substrate for low-femtogram 
level detection during western blot analysis. It allows for detection of proteins on 
the membranes that have been probed with primary and secondary antibodies. For 
the reaction to occur, equal amounts of SuperSignal
®
 West Femto Stable Peroxide 
Buffer and SuperSignal
®
 West Femto Luminol/Enhancer Solution were combined 
in a tube and mixed briefly. The reaction was then added to the membranes in 
equal amounts straight after mixing and placed in a dark cupboard for two min to 
allow for the reaction to occur.   
2.13.1 Chemiluminescent Development and Detection of Proteins  
Following the reaction of the SuperSignal
®
 West Femto Maximum Sensitivity 
Substrate with the membrane, the membrane was developed using the FujiFilm 
Intelligent Dark Box II with the FujiFilm LAS-1000+ camera and accompanying 
software. The camera was cooled to -25°C before use. The camera was set on 
chemiluminescence and the light source set to EPI. The membrane was placed on 
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a black tray in the machine and whilst the door was open, the brightness was 
adjusted using the FujiFilm LAS-1000+ software. The door was closed and an 
image taken using the manual setting with the software. The membrane was 
exposed to chemiluminescence for 45 sec to allow development of the image and 
the resulting image was saved using the accompanying software. 
2.13.2 Ponceau S Staining of Western Blot Membrane 
After chemiluminescent imaging, membranes were stained using Ponceau S Stain 
in order to detect proteins present on the membrane. Membranes were covered 
with the stain for five min and placed on an Orbital shaker (Bellco Glass Inc., 
USA) on setting 4 at RT. The dye was then poured off and the membrane covered 
with Ponceau S Destaining solution and placed back on the orbital shaker for 
10 min to remove residual stain. The destaining solution was then poured off and 
membranes were visualised for presence of proteins in each sample. 
2.14 Small Scale Purification of Recombinant VMO1 Protein 
A 5 mL culture flask of Rosetta
™
 (DE3) pLysS containing the pET28b (+) and 
VMO1 construct was induced with IPTG and grown for 24 hours as per 
Section 2.10.3 for expression of the recombinant VMO1 protein. A final 
concentration of 1.0 mM IPTG was added for protein induction. Following the 
24 hour incubation, the culture was spun down at 5000 x g for five min at RT to 
pellet the cells. The supernatant was removed and the pellet resuspended in 
500 μL of NaCl-free Lysis buffer and 500 μL of 2X cOmplete, Mini, EDTA-free 
Protease Inhibitor solution (Roche, Germany). Samples were then sonicated using 
a Misonix Sonicator
®
 Ultrasonic Liquid Processor XL2020 with the microtip 
probe as per Section 2.10.1. Following sonication, the samples were treated with 
5 μL of DNase I, RNase-free and 100 μL of 10X Reaction Buffer 
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(ThermoScientific
™
, USA). The samples were incubated for 30 min at 37°C in an 
Eppendorf Thermomixer
®
 comfort. The samples were then centrifuged at 
5000 x g at 4°C for five min to collect the inclusion bodies. The supernatant was 
removed and saved for analysis. The inclusion bodies pellets were resuspended in 
1X Binding buffer with Urea for the protein purification.  
2.14.1 Purification of Recombinant VMO1 Protein using HIS-Select
® 
Nickel 
Affinity Gel  
The HIS-Select
®
 Nickel Affinity Gel (Sigma-Aldrich, USA) was used for 
purification of the recombinant VMO1 protein from the insoluble fraction. The 
affinity gel solution was mixed gently by inversion before pipetting 50 μL of it 
into a 1.7 mL microcentrifuge tube. It was spun in a centrifuge at 5000 x g for 
30 sec at 4°C and the liquid was removed. Next, 250 μL of mQH2O was added 
and spun at 5000 x g for 30 sec at 4°C and liquid removed. This step was repeated 
to rinse the solution of the storage buffer than contains ethanol. Next, 200 μL of 
Equilibration Buffer was added and mixed well with the affinity gel. This mixture 
was spun at 5000 x g for 30 sec at 4°C. The supernatant was removed and 
discarded before adding 100 μL of the resuspended insoluble fraction. This 
solution was mixed well and centrifuged at 5000 x g for 30 sec at 4°C. The 
supernatant was saved from this step. Next, the affinity gel was washed with 
500 μL of Wash Buffer by mixing briefly then centrifuging at 5000 x g for 30 sec 
at 4°C. The supernatant was collected and saved before repeating the step, again 
collecting the supernatant. The protein was then eluted from the affinity gel using 
50 μL of Elution Buffer at pH 6.0. This was mixed well with the gel and 
centrifuged at 5000 x g for 30 sec at 4°C. The supernatant was collected and the 
step repeated to collect another supernatant sample. Following this, the affinity 
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gel was eluted again using 50 μL of Elution Buffer at pH 4.5. This is because 
recombinant proteins with a histidine tag will not elute at pH 6.0, so it is advised 
to try a lower pH such as pH 4.5. The solution was mixed well before centrifuging 
at 5000 x g for 30 sec at 4°C. The supernatant was collected and the step repeated 
to collect another supernatant sample. All collected supernatant samples were 
processed for analysis with western blot with antibodies.  
2.14.2 Western Blot of Protein Purification for Detection 
Supernatant samples were collected from the protein purification using the HIS-
Select
®
 Nickel Affinity gel. Fifteen microlitres of sample was mixed with 15 μL 
of 2X SDS Loading Dye. Finally, a western blot was undertaken as described in 
Section 2.13 to identify purified recombinant VMO1 protein and validate the 
specificity of the VMO1 antibody against a range of protein samples. 
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CHAPTER THREE 
Results 
This chapter outlines the results obtained using molecular methods for the 
amplification of VMO1 mRNA, the cloning and expression of recombinant 
VMO1 protein, the validation of antibodies against the recombinant protein using 
western blotting, and finally, the purification of the recombinant VMO1 protein 
using HIS-Select nickel affinity gel.  
3.1 Primers for Amplification of Human VMO1 
Primers that targeted the full length mRNA of VMO1 isoforms 1 and 3 were 
designed using Geneious version 7.1.7 and synthesised by IDT Ltd. The primer 
set SH1F and SH1R were designed to target the VMO1 isoform 1 gene and the 
primer set SH2F and SH2R were designed to target the VMO1 isoform 3 gene. 
Primers were tested on cDNA synthesised from RNA extracted from two human 
cell lines, SUM149PT and THP1. The cDNA was kindly donated by Miss Hannah 
Crossan (UoW).  
3.1.1 Validation of Previous Findings  
The primer set of HCC30/31 was tested on two cell lines to validate the results 
found by Crossan (2014). Ten PCR reactions were set up as per Table 5 and 
Table 6 and the resulting amplicons were run on a 2% 1X TAE agarose gel 
stained with Ethidium bromide for 30 min at 90 V.  
Figure 10 shows the agarose gel electrophoresis results of this PCR. Lanes 1 and 8 
were loaded with the 100 bp DNA ladder for the determination of band sizes. 
Amplification of VMO1 from SUM149PT cDNA resulted in two bands (Lane 2). 
A faint band at approximately 350 bp which corresponds with the expected 
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amplified VMO1 product of 354 bp in size and a band of nearly 800 bp in size 
which could be possible genomic DNA contamination or non-specific 
amplification. However, there is a band present around 800 bp in size in the -RT 
negative control (i.e., template from cDNA synthesis reaction with no reverse 
transcriptase added). Therefore, results suggest that the SUMP149PT RNA 
sample was contaminated with genomic DNA. No bands were present in the 
negative PCR control (Lane 4). This is an indication that the PCR master mix 
made contained no DNA contamination from exogenous sources.  
The positive PCR control primer set HCC37/38 amplifies GAPDH, a 
consecutively expressed gene in humans. The product size of this gene using these 
primers is 412 bp which can be seen as a very bright band in lane 5 as expected. 
Lane 6 was a negative reverse transcriptase reaction using the HCC37/38 primers 
and no bands were present, indicating no genomic contamination. Lane 7 was a 
negative control in the PCR reaction and contained no bands of amplified DNA as 
expected due to no cDNA template being present for amplification.  
In comparison, no bands were observed from PCR reactions using THP1 cDNA 
and HCC30/31 primers (Lane 9). The negative PCR control shows that there was 
no DNA contamination (Lane 10) whereas the GAPDH positive control (Lane 11) 
resulted in a bright band of expected size and a smaller fainter band present of 
unknown origin. Lane 12 was a negative PCR control with no THP1 template 
cDNA present. Therefore, no bands were expected to be present, as shown in this 
lane, due to no DNA being present for amplification. 
In conclusion, VMO1 gene is expressed in SUM149PT and not THP1 cells. 
Therefore, our data is not in agreement with Hannah Crossan 2014.  
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Figure 10: Amplification of VMO1 and GAPDH from SUM149PT and THP1 cell 
lines. PCR products were run on a 2% 1X TAE agarose gel for 30 min at 90 V. 
Lanes 1 and 8: 100 bp DNA ladder (GenScript, USA); Lane 2: SUM149PT cDNA 
with HCC30/31; Lane 3: SUM149PT cDNA -RT negative control with HCC30/31; 
Lane 4: Negative PCR control with HCC30/31; Lane 5: SUM149PT cDNA with 
HCC37/38; Lane 6: SUM149PT -RT negative control with HCC37/38; Lane 7: 
Negative PCR control with HCC37/38; Lane 9: THP1 cDNA with HCC30/31; Lane 
10: Negative PCR control with HCC30/31; Lane 11: THP1 cDNA with HCC37/38; 
Lane 12: Negative PCR control with HCC37/38. 
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3.1.2 Gradient PCR 
The primer pairs of SH1F/1R and SH2F/SH2R were tested using gradient PCR in 
order to optimise the PCR protocol for amplification of the expected product size 
and determine the best annealing temperature. Figure 11 shows the results of the 
gradient PCR where ranges of annealing temperatures from 55 to 62°C were 
investigated. Lanes 2 through to 4 contain PCR products run at the annealing 
temperature of 55.5°C. Lane 2 contained the primer set of SH1F/1R and only 
contained a faint band below 100 bp in size which is indicative of primer dimers, 
a common by-product of PCR. This is where the primers in the reaction have 
attached to one another where complementary bases are present. This leads to 
amplification of the primer dimer by the Taq polymerase. This indicated that this 
temperature was too low for this primer set to anneal to the cDNA and allow 
amplification of the VMO1 isoform 1 gene. Lane 3 contained the PCR products of 
primer set SH2F/2R. It shows a faint band of the expected PCR product size of 
VMO1 isoform 3 of 387 bp as well as a very faint band below 100 bp of primer 
dimers. Lane 4 is a negative control for the SH1F/1R primer set and contains no 
cDNA in the reaction therefore it would be expected to see no bands for 
amplification of DNA. However, there are bands present below 100 bp from 
primer dimer formation. Lanes 5 through to 7 contain PCR products run at the 
annealing temperature of 57.1°C. Lane 5 contains SH1F/1R in the PCR mix and 
shows no bands other than primer dimers below 100 bp. This indicates that this 
temperature is not ideal for amplification of the VMO1 isoform 1 gene. Lane 6 
contains SH2F/2R and has no bands other than primer dimers. Therefore, this 
primer set did not amplify the VMO1 isoform 3 gene. Lane 7 is a negative control 
PCR containing the SH2F/2R primer set and no template cDNA to amplify. 
Therefore, it is expected that there are no bands present however there are primer 
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dimers present below 100 bp. Both lanes 8 and 9 had annealing temperatures of 
60.4°C. Lane 8 contains the primer set SH1F/1R. Multiple bands are present in 
this lane however the VMO1 isoform 1 gene, with an expected size of 691 bp, is 
present in the lane as the brightest band. It is unsure what the other bands present 
in the lane are without isolating them and sequencing them but they may be 
caused by non-specific binding of the primer set to the cDNA. Lane 9 contains the 
primer set of SH2F/2R and shows multiple bands present. However the brightest 
band in the lane corresponds with the expected size of the VMO1 isoform 3 gene. 
Lanes 10 and 11 had an annealing temperature of 62.0°C and used the primer sets 
of SH1F/1R and SH2F/2R respectively. Lane 10 also shows multiple bands 
present including primer dimers with the expected product of 691 bp being the 
brightest band in the lane. Lane 11 shows multiple bands with the brightest band 
being the expected product of 387 bp in size.  
Following the results of the gradient PCR, the annealing temperature of 60°C was 
selected for the primer sets SH1F/1R and SH2F/2R for future PCR applications.  
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3.1.3 Unexpected PCR Results. 
PCR was performed to amplify the VMO1 isoform 1 and 3 genes using the primer 
pairs SH1F/1R and SH2F/2R. The PCR cycle performed was per Table 6. 
Figure 12 shows the results of this PCR run on an agarose gel. Lane 1 contains the 
100 bp DNA ladder (GenScript, USA). Lane 2 contains the SUM149PT cDNA 
amplified by primer set HCC37/38 which targets the GAPDH gene. A band at the 
expected size, 412 bp, was present in the agarose gel. Therefore, the positive 
control was successful and the components of the reaction and the thermal cycler 
conditions were configured properly and working efficiently. In addition, both 
negative controls worked, showing that no DNA was produced when there was no 
reverse transcriptase present in the cDNA synthesis reaction (Lanes 3, and 9) or 
no DNA template added (Lanes 4, 7 and 10). Lanes 5 though to 7 used the primer 
set SH1F/1R to amplify the VMO1 isoform 1 gene in SUM149PT cDNA. Lane 5 
Figure 11: Gradient PCR of amplified SUM149PT cDNA with SH1F/1R or 
SH2F/2R primer pairs. Products were run on a 2% 1X TAE agarose gel for 30 min at 
90 V. Lane 1: 100 bp DNA ladder (GenScript, USA). The following primer pair and 
annealing temperature was used; Lane 2: SH1F/1R at 55.5°C ; Lane 3: SH2F/2R at 
55.5°C; Lane 4: Negative PCR control using SH1F/1R at 55.5°C;Lane 5: SH1F/1R at 
57.1°C; Lane 6: SH2F/2R at 57.1°C; Lane 7: Negative PCR control using SH2F/2R at 
57.1°C; Lane 8: SH1F/1R at 60.4°C; Lane 9: SH2F/2R at 60.4°C ; Lane 10: SH1F/1R at 
62.0°C. 
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contained the cDNA synthesised and a PCR product of 691 bp was predicted to be 
in this lane. However, there were no bands present in the gel despite the primers 
demonstrating working in Figure 11. Lanes 8 through to 10 were PCR products 
from the reaction using the primer set SH2F/2R designed to amplify the VMO1 
isoform 3 gene. A product of 387 bp was expected to be amplified by these 
primers (Lane 8). However, no band was visible suggesting that the primers had 
not amplified the gene.  
 
 
 
The results of this PCR suggest that the primer sets SH1F/1R and SH2F/2R did 
not amplify their targeted genes in the reaction. This result suggests that the 
VMO1 gene is not expressed in the SUM149PT cell line, compared to mRNA 
which was provided by Crossan (2014).  
Figure 12: PCR amplification of SUM149PT cDNA. PCR products were run on a 
2% 1X TAE agarose gel for 30 min at 90 V. Lane 1: 100 bp DNA ladder (GenScript, 
USA); Lane 2: Positive PCR control with HCC37/38; Lane 3: SUM149PT cDNA 
negative RT control with HCC37/38; Lane 4: Negative PCR control with HCC37/38; 
Lane 5: SH1F/1R; Lane 6: SH1F/1R; Lane 7: Negative PCR control with SH1F/1R; 
Lane 8: SH2F/2R; Lane 9: SUM149PT cDNA negative RT control with SH2F/2R; 
Lane 10: Negative PCR control with SH2F/2R. 
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3.2 Multiple Human Cell Line Testing for Expression of the VMO1 Gene 
Following the results of the PCR amplification of SUM149PT cDNA using the 
primer sets SH1F/1R and SH2F/2R, it was decided to extract a new batch of RNA 
from three mammalian cell lines and test the newly synthesised cDNA for the 
presence of VMO1 gene expression. The cell lines selected were A549, a lung 
carcinoma derived cell line, THP1 and SUM149PT.  
3.2.1 RNA Concentration and Purification using NanoDrop 
Following isolation of RNA from the three different cell culture lines, samples 
were measured using a ThermoScientific
™
 NanoDrop 2000 Spectrophotometer 
and accompanying software (Table 13). The RNA was DNase-treated as per 
Section 2.1.3 prior to testing the quality and quantity using the NanoDrop. RNA 
was tested to determine concentration and purity to decide if it was suitable for 
downstream applications such as cDNA synthesis. The 260/280 absorbance ratio 
of RNA is generally accepted as being pure when it is around 2.0. In addition to 
this, the 260/230 absorbance ratio was determined by the NanoDrop. This ratio 
indicates the presence of contamination from organic compounds such as phenol 
and TriZol used during the extraction process. As a result of these values, a low 
260/230 ratio can be caused by glycogen used as a coprecipitate during RNA 
extraction. 
Table 13: Concentration and purity of RNA extracted from human cell lines. The 
260/230 and 260/280 ratios were used for determining purity and presence of 
contamination in the samples following extraction.   
Cell line 260/230 260/280 Concentration (ng/μL) 
A549 0.79 1.80 97.2 
SUM149PT 0.69 1.68 87.0 
THP1 0.68 1.39 15.4 
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In conclusion, RNA was extracted from three human cell lines ranging from 15.4 
to 97.2 ng/μL and contained impurities. Based on these results, RNA was 
converted to cDNA using the Tetro cDNA Synthesis Kit (Bioline, USA) as per 
Section 2.1.4. 
3.2.2 cDNA Concentration and Purification using NanoDrop 
Following cDNA synthesis, the samples were tested for their concentration using 
a ThermoScientific
™
 NanoDrop 2000 Spectrophotometer and accompanying 
software (Table 14). The 260/280 ratio was determined by reading the spectra of 
the samples at 260 nm and 280 nm respectively. This measure is a good indication 
of DNA purity as nucleic acids have a maximum absorbance at 260 nm and 
proteins at 280 nm. However, it is noted that the resulting cDNA samples were 
not purified and therefore residual salts, RNA, dNTPs and primers may interfere 
with the reading output. Table 14 shows that THP1 cDNA had a very low 
concentration in relation to the other two samples. This is due to differences in the 
concentration of the RNA template (Table 13) in the 2 μL volume.  
Table 14: Concentration and purity of cDNA converted from mRNA extracted from 
human cell lines. The 260/230 and 260/280 ratios were used for determining purity and 
presence of contamination in the samples following extraction. 
Cell line 260/230 260/280 Concentration (ng/μL) 
A549 1.99 1.60 1185.3 
SUM149PT 1.58 1.31 2022.1 
THP1 1.07 1.24 204.0 
 
Following determination of cDNA quantity using the NanoDrop, the samples 
were used for PCR amplification with a number of primer sets. 
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3.2.3 PCR Amplification of cDNA Extracted from Human Cell Lines  
PCR was performed on each of these cell lines using the protocol as per 
Section 2.3 using the primer sets SH1F/1R, SH2F/2R, HCC30/31, and HCC37/38. 
The results of the PCR amplification of these cell lines are shown in Figure 13. 
The 100 bp DNA ladder (GenScript, USA) was loaded into the first well of each 
row on gel for determination of product sizes in the gel. The extracted cDNA 
from THP1 was loaded into lanes 2 – 6 on the gel. The THP1 cDNA was 
amplified with SH1F/1R and produced a PCR product of 691 bp as shown in lane 
2. There was also an unknown PCR product of approximately 1000 bp produced 
as shown by a fainter band in lane 2. Amplification of the THP1 cDNA by 
SH2F/2R produced multiple products as shown in lane 3; however the expected 
product of 387 bp was present. A band at 691 bp in this lane suggests that this 
primer set may also amplify the VMO1 isoform 1 gene. The amplification of the 
cDNA by HCC30/31 also produced a number of products including the predicted 
354 bp product of the VMO1 gene (Crossan, 2014). Amplification of the GAPDH 
gene by HCC37/38 was performed as a positive control and produced the 
predicted product as shown in lane 5. 
The SUM149PT cDNA was amplified with the same primers as above. These 
PCR products were loaded in lanes 6 through to 11. The SH1F/1R primers did not 
produce any PCR products and this was shown in lane 6 as there were no bands 
present in the gel. SH2F/2R also failed to amplify the cDNA as shown in lane 7. 
In addition to this, the primer set HCC30/31 was tested against the SUM149PT 
cDNA as it had previously been demonstrated to work with this cell line (Crossan, 
2014). However, this failed to produce the expected product of 354 bp as shown 
in lane 8. The GAPDH gene was amplified by primer set HCC37/38 as a positive 
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control for this cell line and the product was loaded into lane 9, producing a very 
bright band of 412 bp in size as expected. Lane 10 was a negative control of the 
cDNA synthesis reaction using the HCC37/38 primer set with no template DNA 
present and no products were expected to be amplified and the lane should not 
have contained bands. However, there is a faint band of a similar size to the 
GAPDH gene product of 412 bp which was loaded into the lane next to it. This 
suggests that the product has contaminated the next lane, causing the band to be 
visible. Lane 11 was the negative PCR control using the SH2F/2R primer set with 
no cDNA present to test for contamination. As expected, there were no PCR 
products produced as there were no bands present in the gel.  
The A549 cDNA was tested with the SH1F/1R primers to determine if the VMO1 
isoform 1 gene would be amplified. The PCR of this was loaded into lane 12 and 
no bands were detected on the gel suggesting that VMO1 is not expressed in the 
A549 cell line. This was the same for the SH2F/2R primer set loaded into lane 14 
and the HCC30/31 primer set loaded in lane 15. Neither of these primer sets 
showed amplification of products. The GAPDH gene was amplified in the A549 
cDNA and produced a product of the expected size, as shown in lane 16 with a 
very bright band. The negative A549 cDNA synthesis control was amplified using 
primer set HCC37/38 and loaded into lane 17 and no bands were present 
indicating no DNA was present in the reaction as expected. A negative PCR 
control was performed using HCC30/31 and was loaded into lane 18 and did not 
produce any products as expected.  
Finally, the previously provided SUM149PT cDNA sample was amplified using 
the same primers as above. The PCR products produced by SH1F/1R was loaded 
into lane 19 and showed the amplification of a number of products. The expected 
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product of 691 bp was present in this sample showing that amplification of the 
expected gene occurred. The amplification by SH2F/2R was loaded into lane 20 
and produced a faint band of the expected product size, 387 bp. In addition, an 
unknown PCR product of around 800 to 900 bp was present on the gel. The 
amplification of the cDNA by HCC30/31 was loaded into lane 21 and showed the 
expected product at 354 bp as a faint band as well as a brighter unknown product 
around 800 bp in size. The GAPDH gene was amplified by HCC37/38 as a 
positive control for the PCR reaction and produced the expected product as seen 
as a very bright band in lane 22. The negative cDNA synthesis control was tested 
using primer set HCC37/38 and no bands were expected to be present in the gel. 
However, there was a product approximately 500 bp in size suggesting that the 
RNA contained genomic DNA contamination. Therefore, it is recommended that 
a DNase treatment is applied to future RNA extractions to remove genomic DNA. 
Finally, a negative PCR control was performed using HCC37/38 and no products 
from this reaction were detected on the gel as expected.  
The results of this PCR indicate that the VMO1 isoforms 1 and 3 genes are 
expressed in THP1 cell lines. Also, our results suggest that VMO1 is not 
expressed in the lung and breast. 
The resulting positive THP1 PCR products were loaded onto a low melting point 
gel and bands of the expected size were cut from the gel for purification 
(Section 2.5.2). These purified products were used for ligating into the pET28b(+) 
vector as per Section 2.3.7. 
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3.3 Digestion of pET28b Vector using Restriction Enzymes 
The pET28b(+) vector was digested overnight at 37°C using the BamHI and 
EcoRI enzymes. Four reactions were set up; a negative control with no restriction 
enzymes, a double digest, and two tubes each containing one each of the enzymes. 
Figure 14 shows the agarose gel results of the digest. Multiple bands are observed 
for the negative control (Lane 2) due to the differing conformations of plasmid 
DNA from top to bottom on the gel; nicked/relaxed circle, linear, supercoiled, and 
Figure 13: PCR amplification of cDNA from human cell lines A549, SUM149PT, 
and THP1 using primers designed to amplify VMO1 genes. Annealing temperature 
was 60°C. PCR products were run on a 2% 1X TAE agarose gel for 30 min at 90 V. 
Lanes 1 and 13: 100 bp DNA ladder (GenScript, USA); THP1 cDNA: Lane 2: SH1F/1R; 
Lane 3: SH2F/2R; Lane 4: HCC30/31; Lane 5: HCC37/38. SUM149PT cDNA: Lane 6: 
SH1F/1R; Lane 7: SH2F/2R; Lane 8: HCC30/31; Lane 9: HCC37/38; Lane 10: negative 
RT control with SH2F/2R; Lane 11: Negative PCR control with SH2F/2R. A549 cDNA: 
Lane 12: SH1F/1R; Lane 14: SH2F/2R; Lane 15: HCC30/31; Lane 16: HCC37/38; Lane 
17: Negative RT control with HCC37/38; Lane 18: Negative PCR control with 
HCC30/31. Provided SUM149PT cDNA (Crossan, 2014): Lane 19: SH1F/1R; Lane 20: 
SH2F/2R; Lane 21: HCC30/31; Lane 22: HCC37/38; Lane 23: Negative RT control with 
HCC37/38; Lane 24: Negative PCR control with HCC37/38. 
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circular, single stranded DNA. Despite the pET28b(+) vector being 5368 bp in 
size, these four conformations will migrate through the gel at differing speeds and 
show bands at different places relative to size in comparison to the DNA ladder. 
Lane 3 shows the pET28b(+) vector which has been digested with both BamHI 
and EcoRI. This digest cuts out a small section of six base pairs from the vector, 
making a linear product of 5362 bp in size with sticky overhangs for cloning in of 
the VMO1 DNA. Both lanes 4 and 5 show pET28b(+) digested with either BamHI 
or EcoRI respectively. This was performed to show that the enzymes worked 
individually. Lane 5 shows multiple bands which is due to incomplete digestion of 
the entire vector in the reaction by the EcoRI enzyme. Therefore, some of the 
conformations of the plasmid DNA can be seen.  
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Figure 14: Restriction enzyme digest of pET28b(+) using EcoRI and 
BamHI. Products were run on a 0.9% 1X TAE agarose gel for 30 min at 
90 V. Lane 1: 1KB+ DNA Ladder (Invitrogen, USA); Lane 2: Control 
digest containing no enzymes; Lane 3: Double digest containing both 
enzymes; Lane 4: Digest using BamHI; Lane 5: Digest using EcoRI.  
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The next step was to load the remaining 45 µL double digested pET28b(+) sample 
on a 1% TAE LMP agarose gel stained with 2 µL of Ethidium bromide. The gel 
was run for 30 min at 90 V before being viewed on a Safe Imager
™
 
Transluminator (Invitrogen, USA) to prevent damage to the DNA present in the 
gel. The band was cut from the gel and recovered using the ZymoClean
™
 Gel 
DNA Recovery Kit and purified using the ZymoClean
™
 Genomic DNA Clean and 
Concentrator Kit
™
. The resulting product was run on a gel to estimate the 
concentration of the product for ligation of the vector with purified VMO1 DNA 
(Figure 15).  
3.4 Estimation of concentration of products  
Amplified VMO1 isoforms 1 and 3 were recovered from a LMP gel using the 
ZymoClean
™
 Gel DNA Recovery Kit and digested overnight at 37°C using the 
restriction enzymes, BamHI and EcoRI. This was performed to create sticky 
overhangs on the DNA fragments for cloning into the pET28b(+) vector. 
Following this, the digested reactions were purified using the ZymoClean
™
 
Genomic DNA Clean and Concentrator Kit
™ 
leaving 15 µL of each purified 
product. Wells were loaded with 5 μL of product mixed with 2 μL of 6X Loading 
dye. The 100 bp DNA ladder (GenScript, USA) was used for estimation of 
concentration of products and determination of size. GenScript states that their 
500 bp indicator in the ladder has a concentration of 20 ng/µL and all other bands 
having a concentration of 10 ng/µL. Products were run on a 2% 1X TAE agarose 
gel for 30 min at 90 V (Section 2.5.2).  
Figure 15 shows the gel that was used for the estimation of the concentrations of 
each of the products run on it. These estimations were used to calculate the 
Ligation calculation (Equations 3 and 4). Lane 1 was loaded with the 100 bp DNA 
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ladder (GenScript, USA). Lane 2 was loaded with the purified digested VMO1 
isoform 1 PCR product. This was estimated as having a concentration of 25 ng or 
5 ng/µL based on the volume loaded onto the gel. Lane 3 was loaded with purified 
digested VMO1 isoform 3 PCR product. This was also estimated as having a 
concentration of 25 ng or 5 ng/µL. Lane 4 was loaded with the purified, digested 
pET28b(+) vector. This was estimated to have a concentration of 150 ng or 
30 ng/µL based on the brightness of the band in comparison to the 500 bp 
indicator in the DNA ladder. These estimations were used for calculations for the 
ligation reaction. 
 
 
 
3.4.1 Ligation  
Estimations of DNA concentrations of purified products were used for the 
calculation of amount of product (Equations 3 and 4) needed for the ligation 
 1     2      3    4     
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Figure 15: Estimation of concentration of purified products for ligation 
calculations. The purified products were loaded on a 2% 1X TAE agarose gel and run 
for 30 min at 90 V. Lane 1: 100 bp DNA ladder (GenScript, USA); Lane 2: Purified, 
BamHI/EcoRI digested VMO1 isoform 1 gene; Lane 3: Purified, BamHI/EcoRI 
digested VMO1 isoform 3 gene; Lane 4: Purified, BamHI/EcoRI digested pET28b(+) 
vector. 
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reaction so that a molar ratio of 1:3 of vector to insert was optimal for cloning 
purposes. The VMO1 isoform 1 gene insert was calculated as requiring 11.6 ng/μL 
for the ligation reaction. As the concentration of this product was estimated at 
5 ng/μL (Figure 15), 3 μL was added to the ligation reaction along with 1 μL of 
the purified, digested pET28b(+). The VMO1 isoform 3 gene was calculated as 
needing 6.5 ng/μL in the ligation reaction and as a result, 5 μL of the product was 
added to the ligation reaction with 1 μL of purified, digested pET28b(+). The 
ligated products were used for transformation into E. coli DH5α using 
electroporation (Section 2.8.2). 
 
 
 
 
 
3.5 Transformation of pET28b(+)/VMO1 Construct into Electrocompetent 
E. coli DH5α 
Following overnight ligation of the VMO1 gene into the pET28b(+) 
(Section 2.7.3), the ligated product was transformed into electrocompetent E. coli 
DH5α and plated onto LB agar plates containing kanamycin. A positive control of 
pET28b(+) was also transformed for calculation of the transformation efficiency 
as per Equation 3. To calculate this efficiency, the numbers of colonies present on 
the LB agar plate were counted. A value higher than 10
9 
is considered as being 
𝑛𝑔/µ𝐿 𝑃𝐶𝑅 𝑖𝑛𝑠𝑒𝑟𝑡 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 =
30 𝑛𝑔/µ𝐿 𝑥 691 𝑏𝑝
5362 𝑏𝑝
 𝑥 3 = 11.6 𝑛𝑔/µ𝐿 
Equation 3: Ligation calculation of the VMO1 isoform 1 gene 
concentration needed to ligate into the pET28b(+) vector.  
𝑛𝑔/µ𝐿 𝑃𝐶𝑅 𝑖𝑛𝑠𝑒𝑟𝑡 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 =
30 𝑛𝑔/µ𝐿 𝑥 387 𝑏𝑝
5362 𝑏𝑝
 𝑥 3 = 6.5 𝑛𝑔/µ𝐿 
Equation 4: Ligation calculation of the VMO1 isoform 3 gene 
concentration needed to ligate into the pET28b(+) vector.  
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high efficiency grade; however the efficiency was calculated as being lower than 
10
6
 which is considered low for electrocompetent cells. Despite having a low 
transformation efficiency of 2.7 x 10
5
, colonies transformed with the 
pET28b(+)/VMO1 isoform 1 construct were present on the LB agar and 
kanamycin plate. A number of these colonies were tested using colony PCR 
(Section 2.3.2) for confirmation that the ligation of the VMO1 gene was successful 
into the pET28b(+) vector. 
3.5 1 Gradient PCR of T7 Primers 
Gradient PCR was performed on purified pET28b(+) vector DNA using the 
primer set LMP10F/11R in order to determine the best annealing temperature. The 
LMP10F primer was designed to anneal to the T7 promoter of the pET28b(+) 
vector and LMP11R to the T7 terminator of pET28b(+), resulting in an amplicon 
of 373 bp in size. These regions were selected to amplify from as the MCS of 
pET28b(+) falls between these two regions and this is where the VMO1 gene has 
been cloned into. The PCR was set up as per Section 2.3.1. 
Figure 16 shows the results of the gradient PCR. Lane 1 was loaded with 5 µL of 
100 bp DNA ladder (GenScript, USA). Lane 2 contained the PCR negative 
control with no template DNA and no bands were expected, as seen, to be present 
as a test for contamination. Lane 3 contained the PCR product with an annealing 
temperature of 52.0°C. As there were no bands present, this indicated that the 
primers did not anneal to the pET28b(+) vector at this temperature. The PCR 
product with an annealing temperature of 54.3°C was loaded into lane 4. This lane 
contained a band at 373 bp, as expected to be seen. However it contained a faint 
band around 250 bp in size of unknown identity. When the PCR had an annealing 
temperature of 55.7°C, there was a band at 379 bp but the band of around 250 bp 
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was also brighter compared to at 54.3°C, as seen in lane 5. The final annealing 
temperature tested was 58.0°C and produced two products of 379 bp and 250 bp, 
however the band at 250 bp was fainter than that at 55.7°C. The annealing 
temperature of 60°C was not tested in this gradient PCR however it was used for 
downstream applications with this primer set to attempt to obtain a single band of 
the correct size when visualised on an agarose gel. 
 
 
 
 
 
3.5.2 Colony PCR of Transformed E. coli DH5α for Confirmation of 
Construct Presence  
White colonies were selected from plates following electroporation to test for 
positive VMO1 isoform 1 inserts using Colony PCR. Briefly, colonies were 
selected using a sterile toothpick and dipped into a tube containing PCR reagents 
Figure 16: Gradient PCR using the primer set LMP10F and LMP11R. LMP10F 
binds to the T7 promoter in the pET28b(+) vector. LMP11R binds to the T7 terminator 
in the pET28b(+) vector. Products were loaded on a 2% 1X TAE agarose gel and run 
for 30 min at 90 V. Lane 1: 100 bp DNA ladder (GenScript, USA); Lane 2: Negative 
PCR control with no template DNA at 52.0°C annealing temperature; Lane 3: Purified 
pET28b(+) vector with LMP10F/11R at 52.0°C annealing temperature; Lane 4: 
Purified pET28b(+) vector with LMP10F/11R at 54.3°C annealing temperature; 
Lane 5: Purified pET28b(+) vector with LMP10F/11R at 55.7°C annealing 
temperature; Lane 6: Purified pET28b(+) vector with LMP10F/11R at 58.0°C 
annealing temperature. 
 1     2     3    4      5     6   
800 - 
1500 - 
500 - 
300 - 
87 
 
and primers designed to target the T7 promoter (LMP10F) and T7 terminator 
(LMP11R) as per Section 2.3.2. In total, 12 colonies were tested for confirmation 
that VMO1 had been ligated into the pET28b(+) vector. The PCR results are 
shown in Figure 17 and shows that the positive control of undigested pET28b(+) 
without an insert amplified with the LMP10F/11R primers, resulting in expected 
PCR product size of 379 bp in size (Lane 2). A single band was obtained by using 
the annealing temperature of 60°C instead of 58°C as this temperature produced 
two products (Figure 16, lane 6). A negative PCR was also performed to test for 
contamination in the PCR reaction. No bands were expected to be present due to 
no template DNA being present for amplification. This reaction was loaded into 
lane 3 and no bands were visualised in the gel, indicating that no contamination 
occurred. All 12 colonies tested via colony PCR resulted in a band at 373 bp 
which indicated that the ligation had been unsuccessful. If the VMO1 isoform 1 
gene had been inserted into the MCS, a product of 1064 bp was expected to be 
amplified in the PCR. The PCR conditions were set to meet this as it is 
recommended that an extension time of 30 sec to one min is used per 1 kB sized 
product (Cheng, Chang, Gravitt, & Respess, 1994). These lanes also contained 
faint bands below 100 bp which could be from DNA present in the bacterial 
colonies or PCR primer dimers.  
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3.6 Ligation and Transformation of the pBlueScript II SK (+)/VMO1 
Constructs into Chemical Competent E. coli  
Following the unsuccessful transformation of the VMO1 isoform 1 gene into the 
pET28b(+) vector, ligation of the gene into a T-tailed pBlueScript II SK (+) vector 
was attempted. In addition to this, the VMO1 isoform 3 gene was also ligated into 
the pBlueScript II SK (+) vector. The ligated products were then transformed into 
chemically competent E. coli DH5α and plated onto an LB agar plate containing 
ampicillin. The plates were also spread with IPTG and X-Gal for blue and white 
colony screening. Plates were grown overnight at 37°C and the next day 
investigated for the presence of white colonies (Figure 18). These colonies were 
selected for Colony PCR using the LMP6F primer which binds to the M13 
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Figure 17: Colony PCR of E. coli DH5α inserted with the pET28b(+) vector to 
check for presence of the VMO1 isoform 1 gene insert. The PCR products were 
loaded on a 2% 1X TAE agarose gel and run for 30 min at 90 V. Primers used were 
LMP10F and LMP11R. Lanes 1 and 9: 100 bp DNA ladder; Lane 2: Positive PCR 
control; Lane 3; Negative PCR control; Lanes 4 – 8 and 10-16: Colonies selected from 
the transformed plate. 
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Forward primer and the LMP7R primer which binds to the M13 Reverse primer in 
the pBlueScript II SK (+) vector.    
 
 
 
 
 
3.6.1 Colony PCR of pBlueScript II SK (+)/VMO1 genes 
White colonies on the LB plates were selected for Colony PCR to test for 
presence of the VMO1 inserts into the pBlueScript II SK (+). The primers selected 
were LMP6F for the M13 Forward primer and LMP7R for the M13 Reverse 
primers. Both these primers anneal to a specific region on the pBlueScript II SK 
(+) vector, on either side of the ligation site (Appendix Two). Ten microlitres of 
PCR product were mixed with 2 μL of 6X Loading dye and loaded into a 2% 
1X TAE agarose gel stained with Ethidium bromide. The gel was run for 30 min 
A B 
Figure 18: Chemical competent E. coli DH5α cells contained the pBlueScript II SK 
(+) vector. Colonies were plated onto LB agar plates containing ampicillin for selected 
growth of colonies containing the vector. The plates were also spread with IPTG and X-
Gal for blue and white colony screening. Following transformation, plates were grown 
upside down at 37°C overnight. Plate A contains colonies transformed with the 
pBlueScript II SK (+) vector containing the VMO1 isoform 3 gene. White colonies were 
selected for Colony PCR using primers LMP6F and LMP7R. Plate B contains colonies 
transformed with the pBlueScript II SK (+) vector containing the VMO1 isoform 1 
gene. White colonies were selected for Colony PCR using primers LMP6F and 
LMP7R. 
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at 90 V to separate out the products then viewed under a UV light and imaged 
(Figure 19).  
The PCR products from white colonies selected from the plate with the 
pBlueScript II SK (+)/VMO1 isoform 1 construct were loaded into lanes 2 through 
to 6. An expected product of 918 bp was seen on the gel as a bright band in all of 
these wells showing that each of the colonies contained the VMO1 isoform 1 gene 
inserted into the vector. These lanes also contained very faint bands above 
1500 bp in size which could be non-specific amplification during PCR. Also, 
primer dimers below 100 bp in size were observed in each PCR reaction.  
The PCR products from white colonies selected from the plate with the 
pBlueScript II SK (+)/VMO1 isoform 3 construct were loaded into lanes 7 through 
to 11. An expected PCR product of 614 bp was seen in all of these lanes, 
confirming that the ligation had been successful. In addition to this, primer dimers 
less than 100 bp in size were present in each of the lanes.  
Following these results, the five positive colonies containing the pBlueScript II 
SK (+)/VMO1 isoform 1 construct and five positive colonies containing 
pBlueScript II SK (+)/VMO1 isoform 3 construct were tested again using Colony 
PCR to determine the direction of the inserted genes. The 3´ A-overhang PCR 
product can ligate into the 3´ T-overhangs vector in either orientation. Therefore, 
it is important that the orientation is known so that the cloned VMO1 insert can be 
digested and ligated into pET28b(+) and the coding of the VMO1 recombinant 
protein is in-frame.  
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3.6.2 Directional Colony PCR using LMP7 and LMP6 
Firstly, the SH1R primer was used in combination with LMP6F as the SH1R 
primer would anneal to the 3’ end of the VMO1 isoform 1 gene and the LMP6F to 
the M13 Forward primer sequence in the pBlueScript II SK (+)/VMO1 isoform 1 
construct. With this primer pair, a band of 789 bp in size is expected. In addition 
to this, the same colonies were tested with SH1F and LMP7R, amplifying from 
the 5’ start of the VMO1 isoform 1 gene and ending at the M13 Reverse primer 
sequence in the pBlueScript II SK (+)/VMO1 isoform 1 construct. This would 
result in the amplification of a of 820 bp band. If the gene was inserted in the 
correct orientation, the start of the VMO1 gene would be closest to the M13 
Forward primer region and the end of it closest to the M13 Reverse primer.  
The same process was repeated to colonies containing the pBlueScript II SK 
(+)/VMO1 isoform 3 construct using SH2F with LMP7R and SH2R with LMP6F.  
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Figure 19: Colony PCR results testing E. coli DH5α transformed with the 
pBlueScript II SK (+) vector ligated with either VMO1 isoform 1 or 3. PCR products 
were run on a 2% 1X TAE agarose gel stained with Ethidium bromide for 30 min at 90 
V. Lane 1: 100 bp DNA ladder (GenScript, USA); Lanes 2 – 6: White colonies tested for 
presence of VMO1 isoform 1 gene in the pBlueScript II SK (+) vector using the primer 
set LMP6F/LMP7R; Lanes 7 – 11: White colonies tested for presence of VMO1 isoform 
3 gene in the pBlueScript II SK (+) vector using the primer set LMP6F/7R. 
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Five positive clones for pBlueScript II SK (+)/VMO1 isoform 1 construct were 
tested via Colony PCR with the SH1R and LMP6F primers. Only three colonies 
resulted in a positive result bright band of 789 bp in size. Thus, indicating that the 
gene was inserted in the correct direction (Figure 20, Lanes 3, 5, and 6). Smearing 
was also present which could be caused by extracellular debris from the colonies. 
The same five colonies were again tested but with the primers SH1F and LMP7R. 
Only three colonies resulted in a positive result bright band of 820 bp in size. 
Thus, indicating that the gene was inserted in the correct direction (Figure 20, 
Lanes 8, 10, and 11). 
The pBlueScript II SK (+)/VMO1 isoform 3 construct was also tested with Colony 
PCR to determine the direction. Lanes 13 through to 17 were loaded with the PCR 
products of amplification of the pBlueScript II SK (+)/VMO1 isoform 3 construct 
with the SH2F and LMP7R primers. The expected product from this amplification 
was 516 bp and can be seen in lanes 13, 14, and 16, indicating that the gene was 
inserted in the right direction in these colonies. Also present in these lanes were 
unknown products of approximately 350 bp. Lanes 15 and 17 contained products 
about 700 bp in size that were also unknown. The same colonies were tested with 
SH2R and LMP6F and these products were loaded into lanes 18 through to 22. 
Lanes 18, 19, and 21 contained products of the expected size of 485 bp. Lane 20 
did not show any amplification. Lane 22 contained faint bands of both 
approximately 700 bp and 150 bp in size that were unknown PCR products.  
In addition to this, the four primer pairs used in this PCR were used as a negative 
control with no template DNA used as a test for the presence of contamination 
(Lanes 24 - 27). All lanes did not show that these PCR contained products, 
showing that the PCR master mix or primers did not introduce contamination. 
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The E. coli DH5α colonies with the pBlueScript II SK (+)/VMO1 isoforms 1 and 3 
that tested positive for the inserts in the correct direction were used to inoculate 
LB broth with ampicillin. The DNA constructs were then extracted from the 
bacterial cells using the Zyppy Plasmid Miniprep kit (ZymoResearch, USA) as 
per Section 2.7.1. The concentration and purity of the purified plasmids was then 
Figure 20: Directional Colony PCR on E. coli DH5α colonies containing the 
recombinant pBlueScript II SK (+) with either VMO1 isoform 1 or 3. PCR products 
were loaded onto a 2% 1X TAE agarose gel stained with Ethidium bromide and run for 
30 min at 90 V. Lanes 1, 12 and 23: 100 bp DNA ladder (GenScript, USA); Lane 2 - 6: 
SH1R and LMP6F; Lanes 7 - 11: SH1F and LMP7R; Lanes 13 - 17: SH2F and LMP7R 
Lanes 18 - 22: SH2R and LMP6F; Negative PCR control: Lane 24: SH1R and LMP6F; 
Lane 25: SH1F and LMP7R; Lane 26: SH2F and LMP7R; Lane 27: SH2R and LMP6F. 
 1     2      3    4      5    6      7     8      9    10   11 
12    13   14   15    16   17   18    19   20   21    22  
 23   24    25  26   27 
1500 - 
1500 - 
1500 - 
500 - 
  500 
- 
500 - 
800 - 
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measured using the NanoDrop (Table 15). The total yield of DNA was between 
5.9 and 14.8 μg, respectively. 
The 260/280 ratio of 1.85 was considered as pure for DNA for pBlueScript II SK 
(+)/VMO1 isoform 1 and 1.79 for pBlueScript II SK (+)/VMO1 isoform 3. 
Therefore, the plasmid samples were sent for sequencing by the Waikato DNA 
Sequencing Facility due to meeting the concentration requirements and having 
negligible contamination. 
Table 15: NanoDrop results for determination of concentration and purity of the 
extracted plasmid sample.  
Sample 260/230 260/280 Total 
Yield (ng) 
Concentration 
(ng/μL) 
pBlueScript II SK 
(+)/VMO1 isoform 1 
1.87 1.85 14,751 491.7 
pBlueScript II SK 
(+)/VMO1 isoform 3 
1.56 1.79 5865 195.5 
 
3.7 DNA Sequencing of the pBlueScript II SK (+) Vectors containing VMO1 
genes 
The Waikato DNA Sequencing Facility uses an Applied Biosystems 3130xl 
Genetic Analyser for the purposes of sequencing the DNA. Sequencing results 
were provided as ab1 files that were uploaded to Geneious version 7.1.7. These 
files were analysed for peak quality in the chromatograms as well as for errors in 
nucleotide calls during the sequencing process. Noise at the start and end of the 
sequences were removed as well. Sequencing was performed using the T7 and T3 
primers provided by the facility on both of the constructs as the genes had been 
inserted between these two regions. Both the sequences for each primer were 
aligned to form consensus sequences for each of the constructs. A sequence length 
of 852 bp was required to cover the whole length of the isoform 1 gene, whereas a 
whole sequence length of 544 bp was required to cover the entire isoform 3 gene. 
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These consensus sequences were then aligned to reference sequences obtained 
from NCBI.  
The sequencing results for pBlueScript II SK (+)/VMO1 isoform 1 are shown in 
Figure 21. Image A shows the results using the T7 primer. The sequence was of 
general good quality; however the sequence was rather short. Image B shows the 
sequencing results using the T3 primer. There was a lot of noise present at the 
start of the sequence which had to be removed before alignment of the T7 and T3 
sequence. This sequence was also shorter than the expected sequence length that 
can be provided by the Applied Biosystems 3130xl Genetic Analyser. Once 
aligned, the consensus sequence was aligned with the reference sequence for 
VMO isoform 1 mRNA (NCBI: NM_182566) using the ClustalW2 alignment tool. 
This alignment is shown in Figure 22. The consensus sequence was not long 
enough to align to the complete reference sequence. Therefore, primers to cover 
the internal region of the gene were later designed to overcome this problem. The 
matches to the reference sequence are indicated with an asterisk symbol (*) under 
the alignment. The pairwise sequence identity score was given as 91.21% which 
indicates that it is the VMO1 isoform 1 gene. 
The sequencing results for pBlueScript II SK (+)/VMO1 isoform 3 are shown in 
Figure 23. Image A shows the results using the T7 primer. The sequence was of 
general good quality with noise at the start of the sequence that was removed prior 
to alignment. Image B shows the sequencing results using the T3 primer. There 
was a lot of noise present at the start of the sequence which had to be removed 
before alignment of the T7 and T3 sequence. Both sequences were of long length, 
providing more detail of the sequence for comparison to the reference sequence. 
Once aligned, the consensus sequence that was formed was aligned with the 
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reference sequence for VMO1 isoform 3 mRNA (NCBI: NM_001144940) using 
the ClustalW2 alignment tool. This alignment is shown in Figure 24. The 
reference sequence was able to align to the whole consensus sequence. The 
pairwise sequence identity score for this alignment was given as 99.47% showing 
that the PCR product inserted into the vector was a very good match to the 
reference and was the VMO1 isoform 3 gene. 
The confirmation that the two inserts into the vector were what they were thought 
to be allowed for downstream applications. The VMO1 isoform 1 gene was 
digested out of the pBlueScript II SK (+) vector using EcoRI and BamHI 
restriction digest enzymes (Section 2.7.3), ligated into the pET28b(+) vector and 
sequenced to ensure that the VMO1 region was covered, no mutations were 
introduced and the protein was in-frame with the His Tag. Alternatively, the 
pBlueScript II SK (+) vector/VMO1 could be resequenced with internal primers 
and alternative sequencing primers such as M13, SK and KS (Appendix Two)  
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A 
B 
Figure 21: DNA Sequence Chromatograms generated by Geneious version 7.1.7.  Image A is the raw sequence data of pBlueScript II SK 
(+)/VMO1 isoform 1 sequenced with the T7 promoter primer provided by the Waikato DNA Sequencing Facility. Image B is the raw sequence 
data of pBlueScript II SK (+)/VMO1 isoform 1 sequenced with the T3 primer provided by the Waikato DNA Sequencing Facility. Both 
sequences were aligned to generate a consensus sequence that was aligned to the reference sequence for VMO1 isoform 1 (NCBI: 
NM_182566).  
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Figure 22: Alignment of sequencing data to the reference sequence for confirmation 
of VMO1 isoform 1 gene. Iso1 refers to the generated consensus sequence of sequencing 
data from sequences shown in Figure 21. RefSeq refers to the reference sequence for 
VMO1 isoform 1 (NCBI: NM_182566). Sequences were aligned using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). * represents identical nucleotides between 
the consensus sequence and the reference sequence.  
 
 
 
 
 
Iso1      TCGAGGTCGACGGTATCGATAAGCTTGATCGGATCCCAGACGCTACAGGATGGAGCGGGG 60 
RefSeq    --------------------------GATC---CCACAGACGCTACAGGATGGAGCGGGG 31 
                                    ****    * ************************ 
 
Iso1      CGNAGGAGCCAAGCTGCTGCCGCTGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGC 120 
RefSeq    CGCAGGAGCCAAGCTGCTGCCGCTGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGC 91 
          ** ********************************************************* 
 
Iso1      ACAGACAGATGGCCGGAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTG 180 
RefSeq    ACAGACAGATGGCCGGAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTG 151 
          ************************************************************ 
 
Iso1      GGGCGACTGGGCCTGGCCTGAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCT 240 
RefSeq    GGGCGACTGGGCCTGGCCTGAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCT 211 
          ************************************************************ 
 
Iso1      CAAGGTGGAGCCTCCCCAAGGCATTCCTGGCGACGACACTGCACTGAATGGGATCAGGCT 300 
RefSeq    CAAGGTGGAGCCTCCCCAAGGCATTCCTGGCGACGACACTGCACTGAATGGGATCAGGCT 271 
          ************************************************************ 
 
Iso1      GCACTGCGCGCGCGGGAACGTCCTAGGCAATACGCACGTG-------------------- 340 
RefSeq    GCACTGCGCGCGCGGGAACGTCCTAGGCAATACGCACGTGGTAGAGTCCCAGTCTGGAAG 331 
          ****************************************                     
 
Iso1      CTGGGGCGAATGGAGTGAGCCGCTGTGGTGCCGCGGCNTGCGCCTACCTAGTGGCTTTCT 400 
RefSeq    CTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCGGCG-GCGCCTACCTAGTGGCTTTCT 390 
          ****************************** ******  ********************* 
 
Iso1      CGCTTCCCGTGGAGGCACCCC--------------------------------------- 421 
RefSeq    CGCTTCGCGTGGAGGCACCCACGACCCTCGGTGACAACACAGCAGCGAACAACGTGCGCT 450 
          ****** *************                                         
 
Iso1      ------------------------------------------------------------ 
RefSeq    TCCGCTGTTCAGACGGCGAGGAACTGCAGGGGCCTGGGCTGAGCTGGGGAGACTTTGGAG 510 
                                                                       
 
Iso1      ------------------------------------------------------------ 
RefSeq    ACTGGAGTGACCATTGCCCCAAGGGCGCGTGCGGCCTGCAGACCAAGATCCAGGGACCTA 570 
                                                                       
 
Iso1      ------------------------------------------------------------ 
RefSeq    GAGGCCTCGGCGATGACACTGCGCTGAACGACGCGCGCTTATTCTGCTGCCGCAGTTGAA 630 
                                                                       
 
Iso1      --------------------------------------------------------- 
RefSeq    CGGCGCCGCCGCCGCCGCTCTCTCCCGGGCCAGGAGGCTAGTCCCACCTCTTGAATT 687 
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A 
B 
Figure 23: DNA Sequence Chromatograms generated by Geneious version 7.1.7.  Image A is the raw sequence data of pBlueScript II SK 
(+)/VMO1 isoform 3 sequenced with the T7 promoter primer provided by the Waikato DNA Sequencing Facility. Image B is the raw sequence 
data of pBlueScript II SK (+)/VMO1 isoform 3 sequenced with the T3 primer provided by the Waikato DNA Sequencing Facility. Both sequences 
were aligned to generate a consensus sequence that was aligned to the reference sequence for VMO1 isoform 3 (NCBI: NM_001144940).  
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Colony PCR of pET28b  
 
 
 
 
 
 
 
 
 
Figure 24: Alignment of sequencing data to the reference sequence for confirmation 
of VMO1 isoform 3 gene. Iso3 refers to the generated consensus sequence of sequencing 
data from sequences shown in Figure 23. RefSeq refers to the reference sequence for 
VMO1 isoform 3 (NCBI: NM_001144940). Sequences were aligned using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). * represents identical nucleotides between 
the consensus sequence and the reference sequence. 
 
 
 
 
 
 
Iso3       GCGGCAACTGTTTGGGGAAGGGCGATCGGTTGCGGGCCTCTTCGCTATTACGCCAGCTGG 60 
RefSeq     ------------------------------------------------------------ 
                                                                        
 
Iso3       CGAAAGGGGGGATGTGCTGCAAGGCGATTAAGTTGGGGTAACGCCAGGGTTTTCCCAGTC 120 
RefSeq     ------------------------------------------------------------ 
                                                                             
 
Iso3       ACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATT 180 
RefSeq     ------------------------------------------------------------ 
                                                                             
 
Iso3       GGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGGAATT 240 
RefSeq     ------------------------------------------------------------ 
                                                                        
 
Iso3       CGATTCGCGGATCCGATTCACAGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTG 300 
RefSeq     ---------GATCCGATTCACAGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTG 51 
                    *************************************************** 
 
Iso3       CTGCC-GCTGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGGCAGATGGCCG 359 
RefSeq     CTGCC-GCTGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCG 110 
           ***** ******************************************* ********** 
 
Iso3       GAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTG 419 
RefSeq     GAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTG 170 
           ************************************************************ 
 
Iso3       GCCTGAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAGGTGGAGCCTCC 479 
RefSeq     GCCTGAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAGGTGGAGCCTCC 230 
           ************************************************************ 
 
Iso3       CCAAGGCATTCCTGGCGACGACACTGCACTGAATGGGATCAGGTTGCACTGCGCGCGCGG 539 
RefSeq     CCAAGGCATTCCTGGCGACGACACTGCACTGAATGGGATCAGGCTGCACTGCGCGCGCGG 290 
           ******************************************* **************** 
 
Iso3       GAACGTCCTAGGCAATACGCACGTGCTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCG 599 
RefSeq     GAACGTCCTAGGCAATACGCACGTGCTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCG 350 
           ************************************************************ 
 
Iso3       GCGGCGCCTACCTAGTGGCTTTCTGAATTCCGGATCAAGCTTATCGATAYCGTCGACCTC 659 
RefSeq     GCGGCGCCTACCTAGTGGCTTTCTGAATT------------------------------- 379 
           *****************************                                
 
Iso3       GAGGGGGGCCCCGGCACCCAGCTTTTGCTCC 690 
RefSeq     ------------------------------- 
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3.8 Transformation of the pET28b(+)/VMO1 Isoform 1 Construct into 
Electrocompetant E. coli DH5α 
Following partial confirmation that the PCR inserts into the pBlueScript II SK (+) 
vectors were the VMO1 genes using DNA sequencing, the inserts were digested 
out using restriction enzymes and gel purified. The inserts were ligated into the 
pET28b(+) vectors then transformed into electrocompetent E. coli DH5α. 
Transformed cells were plated onto LB agar plates with kanamycin to select for 
cells containing the pET28b(+) vector. The transformation efficiency was 
uncalculated due to there being a very high number of colonies on the undiluted 
plate which was greater than 200. Therefore the 1:10 diluted plate was used for 
selecting colonies due to the colonies being easier to select. Sixteen of the 
colonies transformed with the pET28b(+)/VMO1 isoform 1 construct that grew on 
the plate were tested using colony PCR with the primer set LMP10F/LMP11R 
(Figure 25). Sixteen white colonies were tested and three were nine were positive 
(Lanes 2, 4, 7, 12 – 16, and 19) as the expected size of the PCR product of 
1051 bp was observed on the agarose gel. The colonies tested that were amplified 
and loaded into lanes 3, 5, 8, 9, and 18 of the agarose gel showed products of 
around 360 bp in size, indicating that the VMO1 isoform 1 gene had not been 
ligated into the vector. Lanes 6 and 17 did not show bands present indicating that 
the PCR did not work for these colonies. Finally, a negative PCR control loaded 
into lane 20 which showed no presence of amplification indicating that there was 
no contamination in the PCR master mix. 
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After confirmation that the ligation had worked, the positive colony in lane 15 
was selected for growth and extraction of the vector for DNA sequencing. The 
vector was extracted using the Zyppy Plasmid Miniprep (ZymoResearch, USA) 
and the purity and concentration of the extracted plasmid DNA was measured 
(Table 16). The total yield of DNA obtained was 5271 ng. The extracted vector 
met the requirements of concentration for DNA sequencing as listed in 
Section 2.9. The 260/230 ratio indicated that there was negligible contamination 
from organic solvents and the 260/280 ratio indicated the DNA was of high purity.  
 
 
 
  
Figure 25: Colony PCR of electrocompetent E. coli DH5α cells transformed with 
the pET28b(+)/VMO1 isoform 1 construct. PCR products were loaded on a 2% 1X 
TAE agarose gel stained with Ethidium bromide. The gel was run for 30 min at 90 V.  
Lanes 1 and 10: 100bp DNA ladder (GenScript, USA); Lanes 2 – 9, 11 – 19: White 
colonies tested with LMP10F and LMP11R; Lane 20: Negative PCR control with 
LMP10F and LMP11R. 
 1    2     3    4     5     6      7    8    9      
11   12   13   14   15   16  17  18   19   20 
1500 - 
1500 - 
  500 
- 
  500 
- 
   1000 - 
1000 - 
300 - 
  300 - 
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Table 16: NanoDrop results of pET28b(+)/VMO1 isoform 1 construct for 
determination of purification and concentration. 
Sample 260/230 260/280 Concentration (ng/μL) 
pET28b(+)/VMO1 isoform 1 
 
1.68 1.81 175.7 
 
3.8.1 Sequencing of pET28b(+)/VMO1 Isoform 1 Construct 
The extracted pET28b(+)/VMO1 isoform 1 construct was sequenced using the 
Waikato DNA Sequencing Facility and primers were provided to the facility. The 
construct was sequenced using LMP10F, SH1F and LMP11R to cover the entire 
insert. Sequences were analysed using Geneious version 7.1.7. Raw sequences 
using these primers can be found in Appendix Three. The alignment of these three 
sequence files showed that the inner region of the gene had not been sequenced. 
As a result, the primer set SH3F/SH3R was designed to target this region 
(Section 2.2.3). Following sequencing of the construct with these two primers, the 
four sequences from LMP10F, SH1F, SH3F, and SH3R were aligned using the 
ClustalW2 alignment tool to form the consensus sequence as shown in Figure 26. 
Furthermore, Geneious version 7.1.7 was used for annotation of the consensus 
sequence (Figure 27) showing the sections of the sequence that are part of the 
pET28b(+) vector including the His Tag.  
With confirmation of the recombinant VMO1 gene being in-frame with the 
His Tag in the pET28b(+) vector, the DNA construct was transformed into 
electrocompetent E. coli BL21 (DE3) cells for protein induction using IPTG. 
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Figure 26: Alignment of DNA sequences generated using LMP10F, SH3F, SH3R, 
and SH1F primers. This alignment was used to generate the consensus sequence for 
identification of the recombinant VMO1 gene within the pET28b(+) vector. Sequences 
were aligned using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
 
SH3F       ------------------------------------------------------------ 
SH3R       ------------------------------------------------------------ 
LMP10      ATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCA 
SH1F       ------------------------------------------------------------ 
                                                                        
 
SH3F       ------------------------------------------------------------ 
SH3R       ------------------------------------------------------------ 
LMP10      TCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGACTGGTGGACAGCA 
SH1F       ------------------------------------------------------------ 
                                                                        
 
SH3F       ------------------------------------------------------------ 
SH3R       ------------------------------------------------------------ 
LMP10      AATGGGTCGGGATCCCAGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTGCTGCC 
SH1F       ------------------------------------------------------------ 
                                                                        
 
SH3F       ------------------------------------------------------------ 
SH3R       ------------------------------------------------------------ 
LMP10      GCTGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCGGAACGG 
SH1F       --TGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCGGAACGG 
                                                                        
 
SH3F       ------GGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTGGCCTGA 
SH3R       ------------------------------------------------------------ 
LMP10      CTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTGGCCTGA 
SH1F       CTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTGGCCTGA 
                                                                        
 
SH3F       GATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAGGTGGAGCCTCCCCAAGG 
SH3R       ------------------------------------------------------------ 
LMP10      GATGTGTCCCGATGGATTCTTCGCCAGCG------------------------------- 
SH1F       GATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAGGTGGA------------ 
                                                                        
 
SH3F       CATTCCTGGCGACGACACTGCACTGAATGGGATCAGGCTGCACTGCGCGCGCGGGAACGT 
SH3R       --------GCGACGACACTGCACTGAATGGGATCAGGCTGCACTGCGCGCGCGGGAACGT 
LMP10      ------------------------------------------------------------ 
SH1F       ------------------------------------------------------------ 
                                                                        
 
SH3F       CCTAGGCAATACGCACGTGCTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCGGCGGCG 
SH3R       CCTAGGCAATACGCACGTGCTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCGGCGGCG 
LMP10      ------------------------------------------------------------ 
SH1F       ------------------------------------------------------------ 
                                                                        
 
SH3F       CCTACCTAGTGGCTTTCTCGCTTC 
SH3R       CCTACCTAGTGGCTTTCTCGCTTC 
LMP10      ------------------------ 
SH1F       ------------------------ 
  
1
0
5
 
 
 
 
 
Figure 27: Consensus sequence formed from alignment of sequences generated by SH1F, SH3F, SH3R, and LMP10F primers. The 
consensus nucleotide sequence (1-504) was annotated using Geneious version 7.1.7. The start codon is at position 36 and the stop codon at 
position 456 with the yellow line indicating the recombinant protein (AA) that will be expressed within bacterial cells following induction using 
IPTG. The labelled blue line represents the pET28b(+) vector sequence (1-129) and the in-frame His Tag (48-63) that resides within the 
recombinant protein. 
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3.9 Protein Expression in E. coli BL21 (DE3)  
The pET28b(+)/VMO1 isoform 1 construct was transformed into electrocompetent 
E. coli BL21 (DE3) bacterial cells. The transformed cells were then plated on LB 
agar plates with kanamycin for selection of the vector. After overnight growth, the 
plate was inspected for growth and 16 colonies were present. A single colony was 
selected for inoculation of LB broth for protein expression. Two final 
concentrations of IPTG were used for protein induction; 0.4 mM and 1.0 mM, 
respectively. In addition to this, a control broth was grown that was not induced. 
Samples were taken at 0 hour, 3 hours, 6 hours and 24 hours post-induction from 
all broths. Whole cell lysate samples were prepared for each sample taken and 
loaded onto a hand cast 12% separating SDS-PAGE gel with a 4% stacking gel. 
The Plus Protein
™
 Unstained Standards (Bio-Rad Laboratories, Inc, USA) ladder 
was used for determination of protein sizes in the samples. The SDS-PAGE gels 
were run for 45 min at 200 V then fixed with fixing solution and stained with 
Coomassie Blue R250 for visualisation of the bands. Gels were visualised on a 
white light and imaged. The induced recombinant VMO1 protein was expected to 
be 20 kDa in size and represented as a bright band on the SDS-PAGE following 
induction with IPTG. However, no bright bands were seen on the gel at this size 
in the induced samples. Therefore, induction was suspected to have not worked. 
There was a bright band detected at in the 6 hours and 24 hours non-induced 
samples less than 20 kDa in size but it is unknown what protein caused these 
bright bands (Figure 28B, lanes 2 and 5). 
It was decided to transform the pET28b(+)/VMO1 isoform 1 construct into 
E. cloni BL21 (DE3) pLysS cells as these cells contain the pLysS plasmid. This 
107 
 
plasmid acts to prevent expression of genes under the control of the T7 promoter 
prior to induction using IPTG. 
 
 
 
 
 
  
 
 
 
1       2     3     4    5     6    7 
  1    2     3    4    5    6    7 
A 
B 
25 kDa 
-  
25 kDa 
-  
Figure 28: Protein induction of E. coli BL21 (DE3) cells using IPTG. Two final 
concentrations of IPTG were used, 0.4 mM and 1.0 mM as well as a non-induced 
control. Whole cell lysate samples were taken at 0 hours, 3 hours, 6 hours, and 24 hours 
post-induction and loaded onto hand cast 12% separating SDS-PAGE gels. The gels 
were run for 45 min at 200 V and stained with Coomassie Blue R250 for visualisation of 
proteins on a white light and imaged. Gel A) Lane 1: Precision Plus Protein™ 
Unstained Standards ladder (Bio-Rad Laboratories, Inc, USA); Lane 2: Non-induced 
0 hours; Lane 3: 0.4 mM 0 hours: Lane 4: 1.0 mM 0 hours; Lane 5: Non-induced 
3 hours; Lane 6: 0.4 mM 3 hours: Lane 7: 1.0 mM 3 hours. Gel B) Lane 1: Precision 
Plus Protein
™
 Unstained Standards ladder (Bio-Rad Laboratories, Inc, USA); Lane 2: 
Non-induced 6 hours; Lane 3: 0.4 mM 6 hours; Lane 4: 1.0 mM 6 hours: Lane 5: Non-
induced 24 hours; Lane 6: 0.4 mM 24 hours; lane 7: 1.0 mM 24 hours. 
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3.10 Protein Expression in E. cloni BL21 (DE3) pLysS 
The pET28b(+)/VMO1 isoform 1 construct was transformed into chemically 
competent E. cloni BL21 (DE3) pLysS cells as per manufacturer’s instructions. In 
addition to this, a control vector was provided by Dr Emma Andrews that 
contained the PhoH2 gene from M. smegmatis in the pET28b(+) vector. This was 
also transformed into the bacterial cells. The transformations were plated onto LB 
plates containing appropriate antibiotics and grown overnight. The 
pET28b(+)/VMO1 isoform 1 plates were counted for number of colonies and 
found to have 152 colonies present on the plate. Protein expression was induced 
using IPTG at a final concentration of 1.0 mM. A non-induced broth was also 
grown for both protein expression experiments. Samples for whole cell lysate 
were taken at 0 hours, 3 hours, 6 hours, and 24 hours and processed for PAGE 
electrophoresis. Figure 29 shows that non-specific protein expression across all 
four sample timeframes occurred. In addition to this, the positive control, PhoH2 
protein did not show induced expression as the expected protein size was 50 kDa 
was not observed on the PAGE gel (E Andrews, personal communication, 
October, 2014). The recombinant VMO1 protein was also not expressed at high 
levels, as expected, following induction with IPTG.  
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Protein expression in Rosetta™ (DE3) pLysS  
(PAGE gel, western blot images, Ponceau S stain? ) 
 
 
 
 
 
 
 
  1   2   3   4   5   6   7  8   9 
1   2  3   4   5   6  7   8   9 
A 
B 
25 kDa 
-  
25 kDa 
-  
50 kDa 
-  
50 kDa 
-  
Figure 29: Protein induction of E. cloni BL21 (DE3) pLysS cells using IPTG. The 
final concentration of IPTG used was 1.0 mM as well as a non-induced control. In 
addition, a positive control protein, PhoH2 was used. Whole cell lysate samples were 
taken at 0 hours, 3 hours, 6 hours, and 24 hours post-induction and loaded onto hand cast 
12% separating SDS-PAGE gels. The gels were run for 45 min at 200 V and stained with 
Coomassie Blue R250 for visualisation of proteins on a white light and imaged. 
Gel A) Lane 1: Precision Plus Protein
™
 Unstained Standards ladder (Bio-Rad 
Laboratories, Inc, USA); Lane 2: Non-induced PhoH2 0 hours; Lane 3: 1.0 mM IPTG 
PhoH2 0 hours; Lane 4: Non-induced VMO1 0 hours; Lane 5: 1.0 mM IPTG 0 hours; 
Lane 6: Non-induced PhoH2 3 hours; Lane 7: 1.0 mM IPTG PhoH2 3 hours; Lane 8: 
Non-induced VMO1 3 hours; Lane 9: 1.0 mM IPTG 3 hours 
Gel B) Lane 1: Precision Plus Protein
™
 Unstained Standards ladder (Bio-Rad 
Laboratories, Inc, USA); Lane 2: Non-induced PhoH2 6 hours; Lane 3: 1.0 mM IPTG 
PhoH2 6 hours; Lane 4: Non-induced VMO1 6 hours; Lane 5: 1.0 mM IPTG 6 hours; 
Lane 6: Non-induced PhoH2 24 hours; Lane 7: 1.0 mM IPTG PhoH2 24 hours; Lane 8: 
Non-induced VMO1 24 hours; Lane 9: 1.0 mM IPTG 24 hours. 
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3.10.1 Glucose Inhibition for Protein Expression 
Following non-expression of the recombinant VMO1 protein in these bacterial 
cells using standard conditions, glucose at a final concentration of 1% was 
introduced to the LB broth containing selective antibiotics during growth of the 
bacterial cells before induction with 1 mM of IPTG. Introduction of a glucose 
source to bacterial cells leads to low levels of cAMP in the cells. As a result, the 
lac promoter transcription is low as well. Therefore non-specific transcription and 
expression is suppressed until IPTG is introduced to the cells for T7 RNA 
polymerase expression (Novy & Morris, 2001). Samples for whole cell lysate 
were taken at 0 hours and 24 hours and processed for PAGE electrophoresis. 
Samples were loaded onto a 12% hand cast separating gel SDS-PAGE gel with a 
4% stacking gel. Samples were electrophoresed for 45 min at 200 V for separation 
of proteins. The gel was stained with Coomassie Blue R250 Stain and visualised 
under white light. Very little protein was present on the gel, seen as very faint 
bands, in the 0 hour whole cell lysate samples (Figure 30, lanes 2 - 5). This 
indicates that the non-specific protein expression was hindered by the presence of 
the glucose. The 24 hour whole lysate sample failed to show expression of the 
recombinant VMO1 protein when induced with glucose (lane 9) with proteins in 
this sample appearing lower in concentration on the gel. In addition to this, no 
rather bright bands were present at 50 kDa in the positive control of PhoH2 from 
M. smegmatis in the 24 hour post-induction sample (lane 7).  
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Due to non-expression of the recombinant VMO1 protein in these bacterial cells 
using two methods for protein induction, the DNA sequence generated from 
sequencing data (Figure 26) was investigated for the presence of rare codons 
using the RACC (available at http://nihserver.mbi.ucla.edu/RACC/). The VMO1 
nucleotide sequence was found to contain the rare codons AGG, AGA, and CGA, 
which code for arginine as well as the rare isoleucine codon, ATA, and the rare 
leucine codon, CTA. To overcome this codon bias, the bacterial cell line, 
Rosetta
™
 (DE3) pLysS cells (Novagen, USA) was purchased and the 
pET28b(+)/VMO1 isoform 1 construct was transformed into these bacterial cells 
for protein induction.  
Figure 30: Protein induction of E. cloni BL21 (DE3) pLysS cells using IPTG 
and 1% Glucose. The final concentration of IPTG used was 1.0 mM as well as a 
non-induced control. In addition, a positive control protein, PhoH2 was used. 
Whole cell lysate samples were taken at 0 hours and 24 hours post-induction and 
loaded onto hand cast 12% separating SDS-PAGE gels. The gels were run for 
45 min at 200 V and stained with Coomassie Blue R250 for visualisation of 
proteins on a white light and imaged. Lane 1: Precision Plus Protein™ Unstained 
Standards ladder (Bio-Rad Laboratories, Inc, USA); Lane 2: Non-induced PhoH2 
0 hours; Lane 3: 1.0 mM IPTG PhoH2 0 hours; Lane 4: Non-induced VMO1 
0 hours; Lane 5: 1.0 mM IPTG 0 hours; Lane 6: Non-induced PhoH2 24 hours; 
Lane 7: 1.0 mM IPTG PhoH2 24 hours; Lane 8: Non-induced VMO1 24 hours; 
Lane 9: 1.0 mM IPTG 24 hours. 
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3.11 Protein Expression in Rosetta
™
 (DE3) pLysS  
The pET28b(+)/VMO1 Isoform 1 construct was transformed into chemical 
competent Rosetta
™
 (DE3) pLysS cells as per manufacturer’s instructions. The 
cells were plated onto LB agar plates with chloramphenicol and kanamycin for the 
selection of cells containing the construct and pLysS plasmid. Following 
overnight growth of the plates, a single colony was selected for growth in LB 
broth and protein induction using IPTG (final concentration 1.0 mM). Samples 
were taken at 0 hours and 24 hours post-induction for analysis of protein 
expression in the whole cell lysates. In addition to this, samples were taken at 
24 hours post-induction for analysis of proteins in the soluble and insoluble 
fractions. Samples were processed and loaded onto a 4% stacking gel with 12% 
separating gel. The PAGE-MASTER Protein Standard Plus ladder (GenScript, 
USA) was used for determination of protein sizes present in the SDS-PAGE gel. 
The products were electrophoresed for 30 min at 200 V, fixed with fixing solution 
and stained with Coomassie Blue R250 for detection of proteins present on the gel. 
The gel was visualised on a white light and imaged (Figure 31). Bright protein 
bands just under 20 kDa were detected in the 24 hour induced whole cell lysate 
(Figure 30, lane 5) and the 24 hour induced insoluble fraction (Figure 31, lane 9). 
These bands indicated that the recombinant VMO1 protein had been expressed in 
these cells following induction with 1.0 mM IPTG. It also indicated that the 
protein was insoluble.  
Following these results, the protein was tested against antibodies using western 
blotting methodology. 
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3.11.1 Western Blotting of Protein Expression in Rosetta
™
 (DE3) pLysS cells 
 The 24 hour post-induced whole cell lysate, and the 24 hour post-induced 
insoluble and soluble fractions were loaded onto commercial 12% Express PAGE 
gels. Two gels were run, one to be tested against each of the primary antibodies, 
6X His Tag antibody and VMO1 antibody. In addition to these samples, 5 μL 
each of WB-MASTER Protein Standard and PAGE-MASTER Protein Standard 
Plus (GenScript, USA) protein ladders were both loaded into wells for 
determination of protein size. The WB-MASTER Protein Standard consists of 
seven recombinant proteins with each of the proteins containing an IgG banding 
site that is able to bind to primary or secondary antibodies. Samples were loaded 
onto the gels as per Section 2.13 and run for 30 min at 200 V. Prior to loading the 
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Figure 31: Protein induction of Rosetta
™
 (DE3) pLysS cells using 1 mM IPTG. 
Whole cell lysate (WCL) samples were taken at 0 hours and 24 hours post-induction. 
Samples for soluble and insoluble fractions were taken at 24 hours post-induction. 
Samples were loaded onto hand cast 12% separating SDS-PAGE gels. The gels were run 
for 45 min at 200 V and stained with Coomassie Blue R250 for visualisation of proteins 
on a white light and imaged. Lane 1: PAGE-MASTER Protein Standard Plus ladder 
(GenScript, USA); Lane 2: Non-induced 0 hours WCL, Lane 3: 1.0 mM IPTG 0 hours 
WCL; Lane 4: Non-induced 24 hours WCL; Lane 5: 1.0 mM IPTG 24 hours WCL; 
Lane 6: Non-induced 24 hours soluble fraction; Lane 7: 1.0 mM IPTG 24 hours soluble 
fraction; Lane 8: Non-induced 24 hours insoluble fraction; Lane 9: 1.0 mM IPTG 
24 hours insoluble fraction. 
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proteins into the gel, the concentration of the mouse ear protein extract was 
determined using a quick Bradford Assay against BSA standards (Section 2.12). 
The concentration was determined as approximately 1 mg/mL and 10 μL was 
used for preparing the sample for SDS-PAGE gel analysis. 
3.11.1.1 6X His Tag Antibody 
The results of the western blot indicated that the 6X His Tag antibody had bound 
to proteins present in the 24 hour IPTG induced whole cell lysate and 24 hour 
IPTG induced insoluble fraction at 20 kDa, and the purified R343A protein at 
50 kDa and 35 kDa (Figure 32). No binding of the antibody occurred to the BSA 
protein or the 24 hour IPTG induced soluble fraction samples. The membrane was 
then stained using Ponceau S stain to show that the transfer of proteins onto the 
membrane had been successful (Figure 33). Low concentrations of protein were 
present in lane 4, the 24 hour post-induction soluble fraction. The WB-MASTER 
Protein Standard (GenScript, USA) in lane 7 did not stain from the Ponceau S 
Stain which may be due to the proteins present being too low in concentration for 
the stain. The Ponceau S Stain has been demonstrated to detect proteins with a 
concentration between 250 and 500 ng on nitrocellulose membranes (Salinovich 
& Montelaro, 1986). Following these results, a purification protocol of the 
recombinant VMO1 protein was undertaken using the HIS-Select Nickel Affinity 
Gel (Section 2.14.1).  
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Figure 32: Western blot using 6X His Tag antibody. The goat anti-rabbit IgG-HRP 
was used as the secondary antibody. Chemiluminescence was allowed to develop for 
two min using ECL developing solution. The membrane was imaged using the FujiFilm 
Intelligent Dark Box II with the FujiFilm LAS-1000+ camera. Lane 1: PAGE-MASTER 
Protein Standard Plus (GenScript, USA); Lane 2: 24 hour IPTG WCL; Lane 3: 24 hour 
IPTG insoluble fraction; Lane 4: 24 hour IPTG soluble fraction; Lane 5: 4 mg/mL BSA; 
Lane 6: Purified R343A protein; Lane 7: WB-MASTER Protein Standard (GenScript, 
USA). 
 
Figure 33: Staining of PVDF membrane using Ponceau S stain  
Lane 1: PAGE-MASTER Protein Standard Plus (GenScript, USA); Lane 2: 
24 hour IPTG WCL; Lane 3: 24 hour IPTG insoluble fraction; Lane 4: 
24 hour IPTG soluble fraction; Lane 5: 4 mg/mL BSA; Lane 6: Purified 
R343A protein; Lane 7: WB-MASTER Protein Standard (GenScript, USA). 
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3.11.1.2 VMO1 Antibody 
The results of the western blot indicated that the VMO1 antibody had bound to 
proteins present in the 24 hour IPTG induced whole cell lysate and 24 hour IPTG 
induced insoluble fraction at approximately 20 kDa (Figure 34). Additionally, 
there appears to be a smear present at 35 kDa which is of unknown identity in 
lane 2. However, the chemiluminescence was very faint and smeared on the 
membrane due to the transfer of the proteins from the SDS-PAGE gel onto the 
PVDF membrane being affected. In addition to this, the western blot indicated 
that no binding of the antibody occurred to the negative control (BSA protein) as 
expected or the 24 hour IPTG induced soluble fraction samples in lanes 4 and 6 
respectively. Surprisingly, the 1 mg/mL of mouse ear protein extract, provided by 
Miss Blaise Forrester-Gauntlett (UoW), did not show presence of a protein 
binding to the VMO1 antibody as previously demonstrated (Forrester-Gauntlett, 
2013). This may have been due to degradation of the proteins present in the 
sample over a period of time.  
Following western blotting with the antibody, the PVDF membrane was then 
stained using Ponceau S stain to show that the transfer of proteins onto the 
membrane had occurred (Figure 35). Low concentrations of protein were present 
in lanes 2 and 3, which were the 24 hour post-induction whole cell lysate and 
24 hour post-induction insoluble fraction. In particular, the 24 hour post-induction 
soluble fraction in lane 4 was rather light compared to other samples. Lane 5 
which contained the mouse ear sample showed a smear indicated that protein 
degradation had occurred. The negative control protein, BSA, was shown to be a 
bright band present, indicating it had been transferred to the membrane but when 
the membranes were probed with the antibodies, interactions had not occurred as 
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expected. The expected size of BSA is approximately 66.5 kDa; however on the 
PVDF membrane, this was seen as a smear with a bright band of around this size 
indicating that the BSA sample had denatured. 
Following the probing of the PVDF membrane with the VMO1 antibody showing 
that the recombinant VMO1 protein was present in the insoluble fraction, a small 
scale protein purification experiment was undertaken to purify the protein.  
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Western blot using VMO1 antibody. The goat anti-rabbit IgG-HRP was 
used as the secondary antibody. Chemiluminescence was allowed to develop for two min 
using ECL developing solution. The membrane was imaged using the FujiFilm Intelligent 
Dark Box II with the FujiFilm LAS-1000+ camera. Lane 1: PAGE-MASTER Protein 
Standard Plus (GenScript, USA); Lane 2: 24 hour IPTG WCL; Lane 3: 24 hour IPTG 
insoluble fraction; Lane 4: 24 hour IPTG soluble fraction; Lane 5: Mouse Ear protein 
extract; Lane 6: 4 mg/mL BSA; Lane 7: WB-MASTER Protein Standard (GenScript, 
USA). 
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3.12 Protein Purification of Recombinant VMO1 Protein using HIS-Select 
Nickel Affinity Gel 
 A small scale protein purification protocol was undertaken (Section 2.14) to 
purify the recombinant VMO1 protein from the insoluble fraction sample. Briefly, 
the 100 μL of the sample was mixed with the nickel affinity gel and centrifuged. 
The gel was washed with Wash buffer before using the Elution buffer to unbind 
the protein from the gel. Samples were collected following loading of the whole 
insoluble fraction (1), washing of the gel with Wash buffer (2A and 2B), washing 
with the Elution buffer at pH 6.0 (3A and 3B), and washing with Elution buffer at 
pH 4.5 (4A and 4B). Samples were then prepared for SDS-PAGE gel 
electrophoresis and transferred to a PVDF membrane for probing with antibodies 
using western blotting methodology. 
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Figure 35: Staining of PVDF membrane using Ponceau S stain  
Lane 1: PAGE-MASTER Protein Standard Plus (GenScript, USA); Lane 2: 24 hour IPTG 
WCL; Lane 3: 24 hour IPTG insoluble fraction; Lane 4: 24 hour IPTG soluble fraction; 
Lane 5: Mouse Ear protein extract; Lane 6: 4 mg/mL BSA; Lane 7: WB-MASTER 
Protein Standard (GenScript, USA). 
 
119 
 
3.12.1 Western Blot of Protein Purification Samples using 6X His Tag 
Antibody 
Samples were taken during the wash and elution steps to examine if the protein 
had become unbound during the protein purification process. The western blot 
results show that the recombinant VMO1 protein was not present in any of the 
samples taken during the purification process as no His Tag antibody bound to 
any of the protein present (Figure 36). In addition, the antibody did bind to the 
positive control (purified R343A protein in lane 9) as expected and not to the 
negative control protein (BSA in lane 10). However there were two bright bands 
present in lane 9 and it is unknown what the smaller sized product was. It did not 
stain on the membrane with Ponceau S Stain which suggests it was of very low 
concentration. 
 
 
 
 
 
Figure 36: Western blot probing using 6X His Tag antibody. Chemiluminescence was 
allowed to develop for two min using ECL developing solution. The membrane was 
imaged using the FujiFilm Intelligent Dark Box II with the FujiFilm LAS-1000+ camera. 
Lane 1: PAGE-MASTER Protein Standard Plus (GenScript, USA); Lane 2: Sample 1; 
Lane 3: Sample 2A; Lane 4: Sample 2B; Lane 5: Sample 3A; Lane 6: Sample 3B; Lane 7: 
Sample 4A; Lane 8: Sample 4B; Lane 9: Purified R343A; Lane 10: BSA; Lane 11: WB-
MASTER Protein Standard (GenScript, USA). 
1   2   3   4   5   6   7   8  9 10 11   
- 50 
kDa  
- 40 
kDa 
 
 
- 30 
kDa 
120 
 
The membrane was then stained using Ponceau S stain to show proteins present 
on the membrane that were not detected using chemiluminescence (Figure 37). No 
proteins were detected in the lanes containing samples from the protein 
purification. Therefore, it was deduced that the recombinant VMO1 protein had 
not been purified by this protocol. The purified R343A protein and BSA that were 
used as controls were detected on the membrane, which were both seen at the 
correct size. 
 
 
 
 
 
 
 
 
 
 
 
 
3.12.2 Western Blot of Protein Purification Samples using VMO1 Antibody 
Probing of the samples from protein purification was repeated but using the 
VMO1 antibody as the primary antibody. However, a 24 hour control insoluble 
fraction was loaded on the gel as a control instead of the R343A protein. In 
addition, BSA was loaded onto the gel as a negative control. The western blot 
(Figure 38) shows that the VMO1 primary antibody did not detect presence of the 
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Figure 37: Staining of PVDF membrane using Ponceau S stain 
Lane 1: PAGE-MASTER Protein Standard Plus (GenScript, USA); Lane 2: Sample 1; 
Lane 3: Sample 2A; Lane 4: Sample 2B; Lane 5: Sample 3A; Lane 6: Sample 3B; Lane 7: 
Sample 4A; Lane 8: Sample 4B; Lane 9: Purified R343A; Lane 10: BSA; Lane 11: WB-
MASTER Protein Standard (GenScript, USA). 
 
121 
 
recombinant VMO1 protein in any of the samples taken during the protein 
purification process suggesting that the protein was not present or purified as a 
result (Lanes 2 - 8). A protein was detected in lane 9 by the VMO1 antibody that 
was around 50 kDa in size, however it is not known that this protein was as the 
recombinant VMO1 protein was predicted as around 20 kDa in size. The VMO1 
antibody did not detect the BSA in lane 10 as expected.  
 
 
 
 
 
 
Following western blotting, the membrane was stained with Ponceau S stain to 
show presence of proteins in the samples loaded in the gel. The stain detected 
protein in the 24 hour control insoluble fraction and BSA sample as well as the 
PAGE-MASTER Protein Standard Plus ladder (Figure 39). However no 
recombinant VMO1 protein was detected in the samples taken during the protein 
purification process. This indicates that there was no protein present in the 
samples taken throughout the experiment and that the protein was unable to be 
purified using this method.    
Figure 38: Western blot probing using VMO1 antibody [N1C3] (Catalogue number: 
GTX106683) as the primary antibody and goat anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology Inc., USA) as the secondary antibody. Chemiluminescence was allowed 
to develop for two min using ECL developing solution. The membrane was imaged using 
the FujiFilm Intelligent Dark Box II with the FujiFilm LAS-1000+ camera. Lane 1: 
PAGE-MASTER Protein Standard Plus (GenScript, USA); Lane 2: Sample 1; Lane 3: 
Sample 2A; Lane 4: Sample 2B; Lane 5: Sample 3A; Lane 6: Sample 3B; Lane 7: Sample 
4A; Lane 8: Sample 4B; Lane 9: 24 hour control insoluble fraction sample; Lane 10: 
4 mg/mL BSA; Lane 11: WB-MASTER Protein Standard (GenScript, USA). 
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Figure 39: Staining of PVDF membrane using Ponceau S stain 
Lane 1: PAGE-MASTER Protein Standard Plus (GenScript, USA); Lane 2: Sample 1; 
Lane 3: Sample 2A; Lane 4: Sample 2B; Lane 5: Sample 3A; Lane 6: Sample 3B; Lane 7: 
Sample 4A; Lane 8: Sample 4B; Lane 9: 24 hour control insoluble fraction; Lane 10: 
BSA; Lane 11: WB-MASTER Protein Standard (GenScript, USA). 
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CHAPTER FOUR 
Discussion 
The aims of this research were to design and express a recombinant VMO1 
protein containing a His Tag that would allow for purification using a nickel resin 
column. These aims were addressed using a bacterial pET expression system with 
the VMO1 mRNA being isolated from commercially available human cell lines. In 
addition to this, antibodies were tested against the recombinant VMO1 protein for 
validation using western blotting methodology. This chapter will review the 
results achieved from six research objectives that were outlined in Chapter 1 
(Section 1.6) and includes a discussion on the scientific difficulties encountered, 
strategies used to overcome these difficulties, and future research 
recommendations to determine the function of VMO1.  
4.1 Objective 1 – Bioinformatics  
For this research, two isoforms of the VMO1 gene were selected for the 
development of recombinant protein; isoform 1 and isoform 3. The VMO1 
isoform 1 mRNA product is predicted to be a translated protein that is 202 amino 
acids in size with a calculated molecular mass of 21.5 kDa. The isoform 1 
transcript variant contains three exons. The VMO1 isoform 3 mRNA is predicted 
to form a protein with 102 amino acids and a calculated molecular mass of 
10.8 kDa. This transcript variant also has three exons but contains an alternative 
splice site at the 3’ end of the second exon, resulting in a frameshift and a smaller 
protein. Isoform 1 was selected as the commercial antibody used in this research 
was designed to bind specifically to this protein product. Therefore, it is very 
important that the VMO1 antibody is tested against isoform 1 protein to 
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demonstrate antigen specificity, especially since this antibody will be used for 
future studies to determine protein function. In addition, the isoform 3 product 
was selected to test if the antibody was able to recognise and bind to other 
isoforms of the VMO1 protein.  
The pET28b(+) vector is part of the pET expression system which can be used for 
expression of recombinant proteins in bacterial cells. Genes of interest can be 
cloned into the MCS of the vector and be under the control of a T7 promoter for 
expression (Appendix Two). The T7 RNA polymerase which is produced by the 
expression hosts (λDE3 lysogen) binds to the T7 promoter.  
This vector was selected due to the presence of two hexahistidine peptide tags 
which allows for the detection of the expressed recombinant protein using a His 
antibody, and purification using a nickel resin column. The gene of interest, 
VMO1, was inserted into the MCS of the vector which had been digested with the 
two restriction enzymes, EcoRI and BamHI. These enzymes were selected for 
digestion of the vector due to the recognition sites for these enzymes only being 
present once each in the vector so it would only be digested at these sites. The 
selection for inserting the gene into this region also allowed the gene to be 
downstream from the T7 promoter and His Tag and the correct open reading 
frame for both protein expression and purification purposes. 
The primers for targeting the two isoforms were designed with restriction enzyme 
sites near the start and end of the products (Figures 8 and 9). This was to allow for 
digestion of the PCR products with these enzymes to create sticky overhangs on 
the products. This allowed the sticky overhangs to be ligated into their 
complementary overhangs on the pET28b(+) vector. This helped to ensure that the 
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gene was ligated into the vector in the correct direction for translation. Finally, the 
recombinant proteins were designed to have an N-terminal His Tag.  
4.2 Objective 2 – Amplification of VMO1 mRNA from Commercial Human 
Cell Lines  
RNA was provided from two cell lines, SUM149PT (breast cancer) and THP1 
(monocytic leukaemia) and was converted to cDNA using the Tetro cDNA 
synthesis kit. The oligo (dT)18 primers were selected for the conversion as they 
selectively target the poly(A) tail on the 3’ end of mRNA in a total RNA sample. 
This was to ensure that the mRNA coding for protein was selected for. 
Following cDNA synthesis, PCR was performed using the primer set HCC30/31 
for the amplification of VMO1. In addition to this, a positive PCR control, 
GAPDH, was used to test that the cDNA synthesis was successful as the expected 
band of 412 bp was observed on the agarose gel. The results of this PCR 
suggested that the VMO1 gene was expressed in SUM149PT cells as a band of 
354 bp was observed. However, this is not in agreement with previous data 
(Crossan, 2014). The VMO1 gene was not amplified in the THP1 cDNA. The 
PCR results also indicated that the SUM149PT RNA was contaminated with 
genomic DNA due to the presence of a band at 800 bp in size (Figure 10) in the –
RT control sample. Following on from this, gradient PCR was used to determine 
the best annealing temperature with the two primer sets that were designed with 
restriction enzyme sites with SUM149PT cDNA (Figure 11).  
4.2.1 PCR Optimisation 
Gradient PCR was performed using the primer sets SH1F/1R and SH2F/2R to 
determine the best annealing temperature for the primers. Results showed that the 
126 
 
annealing temperature of 60°C was the best for each of the primer sets due to the 
brightness of bands of the expected size on the agarose gel despite multiple bands 
being present in the lanes from non-specific amplification by the primers and 
differing VMO1 isoforms (Figure 11). The band of the expected size could be 
easily gel purified and DNA sequenced for cloning purposes but the band was 
rather faint indicating a low concentration of DNA present in the sample. Loss of 
DNA concentration could occur over the downstream applications such as gel 
purification. However, due to the presence of genomic DNA contamination, a new 
RNA sample was harvested from cultured SUM149PT cells. Therefore, the RNA 
could be DNase-treated to remove this contamination prior to downstream 
applications such as real-time PCR. The new RNA was DNase-treated and 
converted to cDNA as per Section 2.1.4. Prior to cDNA synthesis, the RNA was 
checked for quality and quantity using a NanoDrop Spectrophotometer. The RNA 
was read at wavelengths of 230 nm, 260 nm, and 280 nm. Nucleic acids and 
proteins have absorbance maxima of 260 nm and 280 nm, respectively. The ratio 
of these two wavelengths, the 260/280 ratio, is used to determine the purity of the 
sample. A ratio of around 2.0 is determined as being a pure RNA sample. The 
260/280 ratio was determined as 1.68. This 260/280 ratio indicated that the 
SUM149PT RNA sample was contaminated with proteins absorbing near the 
280 nm wavelength (Table 13).  
Additionally, the 260/230 ratio is often used as an indication of contamination to 
samples with a ratio of 2.0 – 2.2 indicating that RNA is free from organic 
compounds. The 260/280 ratio for the SUM149PT RNA sample was 0.69, which 
is lower than expected. However, it is suggested that the glycogen used as a 
coprecipitate during the TriZol extraction process can be a result of these low 
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ratios. In addition, the TriZol method uses a number of organic compounds and 
chaotropic reagents for the extraction process such as phenol, guanidinium 
thiocyanate, and chloroform (Chomczynski & Sacchi, 1987) which can 
contaminate the sample during the extraction process. These three compounds can 
also affect the 260/230 ratio when present in nucleic acid samples, leading to 
lower readings at these spectra. Contamination could be overcome by using 
commercially available spin-column kits for RNA extraction from cell lines. In 
addition, these kits overcome the use of dangerous chemicals such as chloroform 
and are faster than the traditional method for the RNA extraction of around 
three hours.  
4.2.2 Unexpected PCR Results 
The newly synthesised SUM149PT cDNA as used as a template for PCR using 
the primer sets of SH1F/SH1R and SH2F/2R. Additionally, a PCR positive 
control of GAPDH was used. Furthermore, the primer set HCC30/31 was used as 
a positive control for VMO1 expression since it had been demonstrated to amplify 
SUM149PT cDNA previously (Figure 10). Following amplification, GAPDH 
control showed a presence of a single bright band as expected on the agarose gel 
which indicates that the PCR had not been hindered by any contamination present 
(Figure 12). However, the results were surprising due to a lack of amplification of 
any products by primers designed for VMO1 (SH1F/1R, SH2F/2R, and HCC30/31) 
despite having previously amplifying gene products in other SUM149PT cDNA. 
Alternatively, these discrepancies could be due to RNA degradation, use of 
oligo (dT)18 primers targeting poly(A) mRNA or issues arising from working with 
human cancer cell lines such as misidentification, genetic instability and 
phenotypic drift.  
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RNA may have been degraded by RNases present or due to it being less stable 
than DNA over time. Furthermore, the RNA was not electrophoresed on a 
denaturing agarose gel due to the low yield of RNA obtained. However, if RNA 
was run on a gel, observations of clear bands representing the 28S and 18S 
ribosomal RNA would indicate that the RNA was intact. If the RNA had been 
degraded then there would be a smear present. Alternatively, the RNA could be 
tested using a Bioanalyzer with an RNA kit that tests the integrity of the RNA 
samples and gives it an RNA Integrity Number (RIN) based on the software’s 
algorithms. The scores range from 1 to 10, with 1 representing totally degraded 
RNA and 10 intact RNA (Schroeder et al., 2006). Therefore, it is recommended 
that the RNA be tested for degradation.  
cDNA synthesis was carried out using oligo (dT)18 primers with the Tetro cDNA 
Synthesis Kit. The synthesis of cDNA can also be performed using random 
hexamer primers. These primers bind to a series of random hexameric sequences 
that are found in eukaryotic RNA. However, it was not made clear whether 
previous research involved making cDNA using either oligo (dT)18 primers or 
random hexamer primers. This could be a reason for the discrepancy in the results 
as the VMO1 mRNA may have had a shortened poly(A) tail or lacked one which 
would not have been bound to by the oligo (dT)18 primers during cDNA synthesis. 
Although a majority of the known mRNA in mammalian cells are polyadenylated 
at the 3’ end, a number of other types of RNA are known to lack these tails, such 
as ribosomal RNA (Yang, Duff, Graveley, Carmichael, & Chen, 2011). Therefore, 
the true representation of RNA abundance could have been missed by using 
primers that select for mRNA rather than the total RNA population. As a result, it 
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is recommended to repeat cDNA synthesis using random hexamer primers on the 
SUM149PT RNA extract.   
Misidentification of human cell lines with cross-contamination occurring between 
cell lines can cause misleading results (Masters et al., 2001). This could be 
overcome by authentication of the cell line using an approved DNA method such 
as short tandem repeat (STR) profiling (Geraghty et al., 2014; Masters et al., 
2001). STR profiling amplifies a number of polymorphic STR loci using primers 
that are commercially available. Along with fluorescent detection, the PCR 
products are given a numerical code based on the product length. Reference 
standards have been made for 253 human cell lines including 33 human cancer 
cell lines. Therefore, this allows cell lines to be matched to the reference standards 
for confirmation of the cell line. Therefore, it is recommended to correctly 
identify a cell line using a recommending DNA based method prior to undertaking 
research with it to confirm that it is the intended cell line. 
Alternatively, the differences seen between the two SUM149PT cDNA samples 
could be due to genetic instability and phenotypic drift. This can occur the longer 
a cell line is kept culturing.  
In addition, cancer cell lines can also have defects with p53, a gene responsible 
for repairing DNA damage (Nigro et al., 1989). Therefore, mutations can occur 
more frequently in these cell lines. This results in the genotype of the cell lines 
possibly changing over time with continuous cell line cultures. Finally, 
phenotypic instability can lead to a lack of expression of genes in the cells. This 
can be caused by incorrect culturing conditions leading to losses and gains in 
expression profiles (Geraghty et al., 2014).  
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It is noted that the passage number between the two flasks of sourced 
SUMP149PT cells was less than five passages and the growth conditions were the 
same. ATCC recommends that cell culture should be limited to five passages for 
use in experiments (ATCC, 2013). Therefore, it is most likely that RNA 
degradation, absence or presence of a shorter poly(A) tail in the VMO1 mRNA 
transcript, or cell line misidentification are plausible reasons to explain our data. 
4.2.3 Expression of VMO1 in Human Cell Lines 
To address the discrepancy in gene expression results, it was decided to extract 
RNA from two cell lines that were readily available. The cell lines used were a 
new source of THP1, and A549, a lung carcinoma cell line. The RNA was 
extracted using the TriZol method and DNase-treated. RNA concentration and 
purity was determined using a NanoDrop Spectrophotometer. The 260/230 ratio 
for the A549 RNA was 0.79 and 0.68 THP1 RNA, respectively. These results 
indicate the presence of organic compounds in the extracted RNA samples. Low 
260/230 ratios can also be caused by glycogen which was used for co 
precipitation of the RNA during the extraction protocol.  
Also, the 260/280 ratios were measured. THP1 RNA had a 260/280 ratio of 1.39 
and A549 had a 260/280 ratio of 1.80. These ratios indicated that both samples 
had protein contamination causing a lower than expected ratio for pure RNA 
samples. This could be due to contamination from proteins during phase 
separation with the TriZol and chloroform. 
Finally, the concentrations of the RNA samples were determined with THP1 
having a concentration of 15.4 ng/μL and A549 a concentration of 97.2 ng/μL, 
respectively. From these two RNA samples, cDNA was produced as per 
Section 2.1.4 and used as a template for PCR. The PCR positive control, GAPDH, 
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indicated that the cDNA had been amplified in each of the samples meaning that 
the cDNA quality was suitable for PCR. This was due to the presence of a bright 
band of expected size on an agarose gel following electrophoresis of PCR 
products (Figure 13).  
The cDNA from three cell lines, A549, SUM149PT, and THP1, were amplified 
using a number of primer sets designed to amplify the VMO1 gene (Table 4). PCR 
products were loaded onto an agarose gel for separation of products (Figure 13). 
The results of this PCR were unexpected due to the presence of amplification in 
the THP1 cDNA of PCR products of the correct size. No amplification of VMO1 
was found in the cDNA from A549 and SUM149PT. The products amplified in 
the THP1 cDNA were cut from the gels and purified so they could be ligated into 
vectors. Sequencing was also performed to confirm that the PCR products were in 
fact the VMO1 genes. Following this, the next step was to ligate into the 
expression vector, pET28b(+), to produce a recombinant VMO1 protein. 
4.3 Objective 3 – Cloning of VMO1 cDNA into a Bacterial pET Expression 
System 
Initially, it was attempted to ligate the purified VMO1 isoforms into the pET28b(+) 
vector using T4 DNA Ligase at a concentration of 1 U/μL. Following the ligation 
reaction, the products were transformed into electrocompetent E. coli DH5α. Cells 
were plated onto LB agar plates containing selective antibiotics for growth of cells 
only containing the pET28b(+) vector. A number of colonies on the plate were 
tested for the presence of the insert into the pET28b(+) vector using colony PCR. 
The results indicated that although the vector had been transformed into the cells, 
the insert had not been ligated into it in a number of colonies tested (Figure 17).  
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It was decided to attempt two new approaches for cloning the VMO1 genes. 
Firstly, a new T4 DNA Ligase was sourced from Dr Ray Cursons (UoW). This T4 
DNA Ligase was at a concentration of 5 U/μL. Secondly, it was decided to 
subclone the VMO1 genes into the pBlueScript II SK (+) vector, a T-tailed cloning 
vector. Ligation of the VMO1 isoforms was performed as per Section 2.6 before 
being transformed into chemical competent E. coli DH5α. Colonies grown on an 
LB agar plate with selective antibiotics were tested for the presence of the inserts 
as well as directional colony PCR to confirm the inserts were ligated into the 
pBlueScript II SK (+) vector in the correct direction. Additionally, sequencing 
confirmation that the inserts were VMO1 genes was performed by the Waikato 
DNA Sequencing Facility. Following sequencing confirmation, the VMO1 
isoform 1 gene was digested out of the pBlueScript II SK (+) vector using EcoRI 
and BamHI and ligated into the digested pET28b(+) vector using the T4 DNA 
Ligase at 5 U/μL. Transformation into electrocompetent E. coli DH5α and colony 
PCR confirmed the successful ligation of the gene into the vector (Figure 25). 
Sequencing results also showed it was inserted in-frame of the His Tag of the 
pET28b(+) vector for purification (Figure 27).  
It would be recommended to test the T4 DNA Ligase activity at 1 U/μL by 
digesting Lambda DNA with the HindIII restriction digest enzyme. It is expected 
that the digested products would be ligated back together with the T4 DNA Ligase 
and the results could be visualised on an agarose gel. This would confirm whether 
the T4 DNA Ligase was active or not.  
Additionally, a phosphatase, such as calf-intestinal alkaline phosphatase, can be 
used on the digested pET28b(+) vector prior to ligation. This works to prevent 
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self-ligation of the vector by dephosphorylation of the 5’-phosphorylated termini 
of the vector DNA so the linearised ends of the vector cannot bind back together. 
Finally it would be recommended to ligate the VMO1 isoform 3, as well as other 
isoforms into the pET28b(+) vector to produce other recombinant VMO1 proteins 
for testing against antibodies and functional assays. 
4.3.1 Sequencing Confirmation of VMO1  
DNA sequencing of the recombinant VMO1 isoform 1 DNA clone was performed 
by an Applied Biosystems 3130xl Genetic Analyser which has the capability of 
sequencing 950 bp when a long-read run is performed according to 
manufacturer’s standards. The sequencing data generated from the T7, SH1F, and 
SH1R primers did not cover the entire length of the 1051 bp product. Therefore 
internal primers, SH3F and SH3R, for this isoform were designed to cover the 
inner region of the isoform 1 gene between position 133 and position 568. A 
504 bp consensus sequence was generated from the resulting four overlapping 
contigs, LMP10F, SH1F, SH3F, and SH3R. The VMO1 sequence was from 
position 149 to position 457 which aligned 100% with the VMO1 reference 
sequence (GenBank Accession number: NM_182566.2). The recombinant protein 
sequence was between position 35 and position 457 resulting in a 423 nucleotide 
fragment. In addition, no stop codons were introduced into the open reading frame 
under the influence of the T7 promoter. Therefore, our data shows that VMO1 
gene is expressed in the THP1 cell. 
Following the successful ligation of the VMO1 isoform 1 gene into the pET28b(+) 
vector, the next step was to transform the construct into a E. coli host strain for 
protein expression. 
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4.4 Objective 4 – Expression of Recombinant VMO1 Protein in E. coli 
The expression of recombinant VMO1 protein was accomplished through 
manipulation of E. coli cells using the pET expression system along with 
induction of expression using IPTG. IPTG is a compound that mimics allolactose, 
a lactose metabolite. It is able to bind to the lac repressor in bacterial cells, 
releasing it from the lac operator. This allows the lac operon to begin transcription 
of genes under control of this operon (Marbach & Bettenbrock, 2012).  
Initially, the pET28b(+)/VMO1 isoform 1 construct was transformed into 
electrocompetent E. coli BL21 (DE3) cells. Protein induction using two final 
concentrations of IPTG (0.4 mM and 1.0 mM) were tested as per Section 2.10.1. 
These two concentrations were used as per recommendations by Novagen (2000). 
In addition, a control was used that was not induced with IPTG to compare 
expression of proteins between non-induced and induced cells. Following 
induction with IPTG, samples were taken at a number of time points (0 - 24 hrs) 
from each of the non-induced control, 0.4 mM IPTG induction, and 1.0 mM IPTG 
induction. Samples were prepared for SDS-PAGE analysis and protein expression 
was assessed following staining of the gel. An expected VMO1 protein of around 
20 kDa in size was expected on the gel as a rather bright band in induced cells 
following expression induction using IPTG. However, this was not seen. To 
address this, an alternative E. coli host strain was investigated. 
The pET28b(+)/VMO1 isoform 1 construct was transformed into E. cloni BL21 
(DE3) pLysS cells. These cells contain the pLysS plasmid which prevents the 
basal expression from the T7 promoter using T7 lysozyme. The T7 lysozyme 
inhibits the transcription of the T7 RNA polymerase which plays a role in 
promoting expression of genes downstream from the T7 promoter. Following 
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induction with IPTG, the DE3 lysogen expresses the T7 RNA polymerase which 
can bind to the T7 promoter for expression (Zhang & Studier, 1997). Protein 
expression was induced as per Section 2.10.2 with IPTG at a final concentration 
of 1.0 mM along with a non-induced control sample. The samples were run on an 
SDS-PAGE gel for protein separation. Analysis of the protein samples indicated 
that the recombinant protein was not expressed in these cells. Therefore, glucose 
was introduced to the LB broth and the expression induction repeated. The use of 
glucose in the broth was aimed to control non-specific expression and up-regulate 
the expression of the recombinant VMO1 protein (Novy & Morris, 2001; Pan & 
Malcolm, 2000). However, upon analysis of the protein extracts run on an SDS-
PAGE gel (Figure 30), it found that the glucose greatly inhibited protein 
expression over the time course with very low concentrations of protein visualised 
on the gel after 24 hours of expression induction. Additionally, the positive 
control that was transformed into the bacterial cells did not show expression of the 
expected 50 kDa sized PhoH2 protein. This protein had previously been expressed 
in these bacterial cells using the same conditions for the expression of the 
recombinant VMO1 protein. Therefore due to non-expression, the temperature of 
the incubator was checked using a thermometer and new IPTG was made. It has 
been found that the incubator has fluctuations in the temperature and does not stay 
at the set temperature (Sari Karppinen, personal communication, March 2015). 
Due to time constraints, it was not possible to induce and express the 50 KDa 
positive control protein construct. Finally, the recombinant VMO1 protein did not 
appear to be over-expressed in any of the samples based on the protein expression 
shown on the PAGE gel. 
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Finally, a third E. coli strain, Rosetta
™
 (DE3) pLysS cells, was used for the 
expression of the recombinant VMO1 protein. This strain was selected to 
overcome the issues of potential codon bias. Codon bias occurs in E. coli cells 
with major codons being used for highly expressed genes in the cells and rare 
codons in genes that are expressed at low levels. If a heterologous gene is 
introduced to the E. coli cells and expression is induced using a reagent such as 
IPTG, the cells can encounter issues with not having the appropriate transfer 
RNAs (tRNA) present to keep up with translation (Kane, 1995). The VMO1 
nucleotide sequence contained rare codons for the amino acids arginine, 
isoleucine, and leucine. Following transformation of the pET28b(+)/VMO1 
isoform 1 construct into these bacterial cells, induction of protein expression was 
carried out and the proteins analysed using SDS-PAGE gels. The gels indicated 
over-expression of a protein approximately 20 kDa in size in both the 24 hour 
post-induction whole cell lysate and the 24 hour post-induction insoluble fraction. 
This indicated that the VMO1 protein was insoluble and found in inclusion bodies 
formed inside the bacterial cells. 
The next step was to test the protein samples against both the VMO1 antibody and 
His antibody for confirmation that the recombinant VMO1 protein had been 
produced in these bacterial cells. This was performed using western blotting 
methodology. 
4.5 Objective 5 – Purification of Recombinant VMO1 Protein 
Purification of the recombinant VMO1 protein was attempted using a HIS-Select
®
 
Nickel Affinity Gel (Sigma-Aldrich, USA). A small scale purification was 
attempted first to determine the right conditions for purification. Protease 
inhibitors were used during sample preparation to prevent the degradation of 
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proteins present in the sample. Additionally, the sample was treated with DNase I 
to remove genomic DNA contamination from the protein sample. DNA present in 
the sample can cause it to have high viscosity which can prevent protein analysis.  
Two differing pHs of Elution buffer were used for the protein purification. Elution 
of the protein samples from the gel was first attempted with an Elution buffer at 
pH 6.0, followed by an Elution buffer at pH 4.0. This is due to some recombinant 
proteins with a His Tag not eluting at pH 6.0 so a pH as low as 4.5 can be 
attempted.  
Samples were collected throughout the purification process and prepared for SDS-
PAGE separation of proteins and western blotting. Probing of the membrane with 
the VMO1 antibody indicated that the recombinant protein was not present in any 
of the samples collected during the protein purification (Figure 38). Additionally, 
probing with the His antibody did not bind to protein in the samples collected 
from the protein purification experiment (Figure 36). Furthermore, Ponceau S 
staining of the membrane failed to detect protein on the membranes in the 
purification samples despite detecting the presence of the controls for the western 
blotting (Figures 37 and 39). The recombinant protein not binding to the gel could 
be due to a number of issues. Firstly, recombinant protein was not correctly folded 
into its native confirmation and the epitope was hidden. Secondly, the conditions 
of the purification were optimal for binding by the protein and therefore it would 
be recommended to repeat the small scale purification and check the protein 
sample pH was between 7.0 and 8.0. Additionally, the protein sample from which 
an aliquot was loaded onto the affinity gel showed the presence of a white 
precipitate a day later following storage of the sample at room temperature. 
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Therefore, it is likely that the protein precipitated out of solution during the 
purification process.  
Over expression of the heterologous protein in the E. coli cells can lead to their 
aggregation in the cytoplasm, forming an insoluble inclusion body (Tsumoto, 
Ejima, Kumagai, & Arakawa, 2003). These inclusion bodies must be solubilised 
and the protein refolded correctly. Solubilisation of the inclusion body can be 
achieved through the use of detergents such as urea and guadinium hydrochloride. 
Following solubilisation proteins in the inclusion body, the proteins need to be 
correctly folded using dialysis and buffers for refolding of the protein (Tsumoto et 
al., 2003). Therefore, it would be recommended to attempt such strategies to 
solubilise the inclusion bodies for successful protein purification. 
Protein refolding and solubility of the protein can be improved through the use of 
molecular chaperones which are co-expressed in the E. coli cells with the 
recombinant protein (Sørensen & Mortensen, 2005). However these methods can 
still prevent the correct folding of the recombinant protein due to properties of the 
protein. The E. coli cytoplasm is in a reducing state where disulfide bonds are 
prevented from forming. This is through two pathways, the thioredoxin system 
and the glutathione system. These pathways contribute to preventing the 
formation of disulfide bonds in proteins (Hannig & Makrides, 1998). As shown by 
Kido et al. (1995), there are disulfide bridges holding together β-sheets together in 
the chicken VMO1 protein. Furthermore, Forrester-Gauntlett (2013) found 
through bioinformatics analysis that the presence of the eight cysteine residues for 
forming the disulfide bonds in the chicken VMO1 protein are in identical places 
in both the mouse and human VMO1. Therefore, the presence of these cysteines 
that play a role in the correct folding of the VMO1 protein may have been 
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prevented from forming disulfide bridges. This prevention of disulfide bonds can 
be overcome by disrupting the trxB and gor genes that encode for the two 
pathways and there are E. coli strains available that lack these genes. Therefore, it 
would be recommended to trial these strains to determine if the recombinant 
protein can be folded correctly in these cells (Sørensen & Mortensen, 2005).   
4.6 Objective 6 – Validation of the VMO1 Antibody against the Recombinant 
VMO1 Protein 
The VMO1 antibody was validated against both non-purified and purified protein 
samples for detection of the presence of the recombinant VMO1 protein. Firstly, 
western blotting performed on both the 24 hour IPTG induced insoluble fraction 
and whole cell lysate indicated the presence of a protein that bound to the VMO1 
antibody at approximately 20 kDa (Figure 34). There was a protein of 35 kDa size 
detected in the whole cell lysate sample, however, it is unknown what this protein 
could be. The identity of this protein could be identified using mass spectrometry 
to determine its amino acid sequence.  
As demonstrated in the western blot image (Figure 34), the VMO1 antibody did 
not bind to the mouse ear extract provided by Miss Blaise Forrester-Gauntlett 
(UoW). Previously, this sample was demonstrated to be bound to by the VMO1 
antibody. This sample was made from inner ears extracted from four mice 
specimens aged 28 days or older. The inner ears were pooled together to increase 
the protein yield during the extraction process (Forrester-Gauntlett, 2013). Due to 
the absence of binding of the antibody to the protein, it is possible that there has 
been degradation of the sample over time. Therefore, it would be recommended to 
extract a new mouse ear protein lysate as per the protocol outlined by Forrester-
Gauntlett (2013) and probe this new sample with the VMO1 antibody.  
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Western blotting performed on the purified protein samples using the VMO1 
antibody was not able to detect the presence of the recombinant protein 
(Figure 38). This indicated that the protein had not been purified during this 
process. Therefore, it is recommended that protein purification be repeated to 
obtain a pure recombinant VMO1 protein to validate against the VMO1 antibody. 
Furthermore, a protein of around 50 kDa in size was detected in lane 9 on the 
membrane by the VMO1 antibody in the 24 hour control insoluble fraction. It is 
unknown what this protein could be or why it was not detected on the western blot 
of the non-purified protein samples (Figure 34). Mass spectrometry could be used 
to determine what this protein was based on the amino acid sequence. 
4.7 Future Recommendations 
There are three goals that need to be addressed to continue the investigation of 
VMO1 function. Firstly, the discrepancies between the results reported in this 
thesis and published data regarding the expression of the VMO1 gene in human 
cell lines. Secondly, the large scale purification of recombinant VMO1 isoform 1 
protein. Thirdly, the function of VMO1 protein needs to be determined through a 
number of assays. These three goals are discussed in more detail below. 
4.7.1 Characterisation of VMO1 in Human Cell Lines  
The Human Protein Atlas is a publicly available on-line database with access 
available to millions of high-resolution images of proteins distributed in 44 
different human tissues, 20 different cancer cell tissues from patients, and 46 
human cell lines (Pontén, Jirström, & Uhlen, 2008; Uhlén et al., 2015). Data 
provided by the Human Protein Atlas shows that RNA-Seq has identified the 
presence of VMO1 mRNA in eight of the 46 human cell lines that data is available 
for. RNA expression is measured as number of Fragments Per Kilobase gene 
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model and Million reads (FPKM). This value is calculated and an average FPKM 
value is assigned based on replicate values to give an abundance score. These 
FPKM thresholds are categorised into low, medium, or high RNA abundance. 
Within cell lines, non-detection is indicated with a score of 0 – 1, low 1 – 20, 
medium 20 – 50, and high >50.  
Interestingly, the Human Protein Atlas indicates that the VMO1 mRNA is present 
in the A549 cell lines based on RNA-Seq data. The FPKM score for this data was 
given as 2 based on two samples tested. This indicates that the VMO1 mRNA is at 
low abundance in these alveolar basal epithelial cells. In comparison, data from 
the protein atlas suggests that VMO1 mRNA is not present in HeLa cells, yet a 
commercial antibody available from ProteinTech was validated using protein 
extracted from HeLa cells (cervical cancer) and HEK-293 cells (Human 
Embryonic Kidney), resulting in the observation of a 22 kDa protein 
(ProteinTech, 2015).  
Our PCR data suggests that VMO1 is expressed in SUM149PT and THP1 cell 
lines. The Human Protein Atlas has data on two breast adenocarcinoma cancer 
cell lines; MCF7 and SK-BR-3 – IHC. Interestingly, MCF is positive for VMO1 
RNA, whereas SK-BR-3 is not. Additionally, the THP1 cell line reported an 
FPKM of 0.0 and 0.2 respectively for two samples analysed using RNA-Seq. This 
indicates that there was no detection of VMO1 RNA in the samples from this cell 
line. Furthermore, there has been no antibody probing data made available for 
these cell lines. 
In addition to this, the VMO1 protein was stained for using a VMO1 antibody 
(Sigma-Aldrich, USA, Product name: HPA023038) on 48 normal human tissue 
samples as well as human cancer samples of the 20 most common cancer types. 
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Results showed that the VMO1 protein was present in five of the 12 breast cancer 
tissue samples at high levels and seven of the 12 breast cancer tissue samples at 
medium levels. However, it is noted that the Protein Atlas VMO1 antibody differs 
to the one used for the purposes of this study.  
In conclusion, it would be recommended in the future to purchase this new 
antibody and test both antibodies on protein lysate extracted from the three human 
cell lines used in this study; SUM149PT, A549, and THP1 but also include HeLa 
and HEK-293 cells. In addition, harvest RNA from these cultured cells, run 
extracted RNA on a denaturing agarose gel, synthesise cDNA using random 
hexamer primers and design new VMO1 primers to target the four isoforms. The 
outcome of this may resolve the true expression of VMO1 in human cell lines and 
the discrepancies in the results presented in this thesis and current data available 
on-line. Alternatively, with human ethics approval RNA could be extracted from a 
snap-frozen or a formalin-fixed, paraffin-embedded biopsy tissue specimen. 
4.7.2 Recommendations for Purifying Recombinant VMO1 Protein 
A number of recommendations were outlined in Section 4.5 to solubilise the 
inclusion bodies for successful protein purification. Following optimisation of 
small scale protein expression and purification of the VMO1 protein from 
inclusion bodies, the next step would complete a large scale protein induction, 
extraction and purification experiment. It would then be advisable to make the 
protein more specific through cleavage at the thrombin site of the purified 
recombinant protein. This cleavage site is located between the hexahistidine tag 
and the start of the VMO1 protein and would remove 13 amino acids from the 
beginning of the recombinant protein. This step would form a protein with no 
additional tags and therefore closely resembles the native protein (Hefti, Dixon, & 
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Vervoort, 2001). The resulting protein could then be concentrated and purified 
using a size exclusion column which would remove the cleaved His Tag peptide 
and protease from the sample. Finally, a Bradford assay would be performed to 
determine the concentration of the purified protein against BSA standards, and a 
western blot run to confirm that the VMO1 antibody recognises the further 
purified recombinant protein.  
4.7.3 Future Determination of VMO1 Protein Function 
Once the recombinant VMO1 protein has been concentrated and purified, a 
number of studies can be investigated to determine the function of the VMO1 
protein and if it plays a significant role in the mechanism of hearing. Firstly, the 
stability of the protein needs to be determined. This will address the ideal 
conditions that the VMO1 protein can be stored at to prevent degradation or 
precipitation of the protein out of solution. For example, this would involve the 
implementation of Circular dichroism spectroscopy (Greenfield, 2006). 
Secondly, it is recommended that the transferase activity of VMO1 be assessed. It 
has been found that the chicken VMO1 protein possesses the ability to synthesise 
N-acetylchitooligosaccharides from hexasaccharides of N-acetylglucosamines 
which is similar to the function of the lysozyme (Kido et al., 1995). Therefore it 
would be interesting to determine whether the recombinant human VMO1 has the 
same or similar properties.  
Thirdly, to determine protein partners of VMO1, a pull-down assay is 
recommended. The pull-down assay is a technique which can be used to 
determine the physical interactions between proteins and for determining protein-
protein interactions. This could be used to determine which proteins interact with 
VMO1. The technique is a form of affinity purification where the “bait” protein, 
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VMO1, is captured to an affinity ligand that is immobilised. The VMO1 protein 
would then be incubated with “prey” proteins in a cell lysate. Unbound protein is 
washed away that has not interacted with the captured VMO1 protein. The 
captured VMO1 protein along with its protein partners are eluted using a number 
of methods such as competitive analytes, low pH, or reducing buffers and the 
products are analysed using SDS-PAGE gels (Golemis & Adams, 2002).  
Finally, it would be recommended to test inner ear protein extracts from mice 
exposed to loud noise compared to control mice. Previous studies using RNA-Seq 
of rat cochleae has shown that Vmo1 had a 51.77 fold increase in expression 
following exposure to loud noise in comparison to the control group (Patel et al., 
2013). The aim of this study was to determine the changes in gene expression 
following acoustic trauma. Therefore, it would be recommended to repeat this 
experiment in another animal model, such as the mouse whose Vmo1 protein is 92% 
similar to the rat Vmo1 amino acid sequence, to see if similar results are obtained 
in regards to changes of gene expression for the Vmo1 gene in the inner ear. 
Finally, protein samples could be obtained from the separate groups for analysis 
by SDS-PAGE and western blotting methodology to test for presence of the 
VMO1 protein in the samples. 
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CHAPTER FIVE 
Conclusion 
The first aim of this research was to design, clone, and express a recombinant 
VMO1 protein. This was achieved through the use of the pET28b(+) expression 
system and VMO1 mRNA amplified from the THP1 human cell line. Sequencing 
data confirmed that the VMO1 gene was expressed in this cell line despite data 
from the Human Protein Atlas suggesting otherwise. 
The second aim was to purify the recombinant VMO1 protein using a nickel resin 
column. Although this aim was not achieved due to complications with the 
purification procedure, a number of techniques to overcome these issues have 
been discussed for future purification attempts.  
Lastly, the third aim was to validate a commercially available VMO1 protein 
against the recombinant protein. It was demonstrated that the antibody was able to 
bind to the recombinant protein using western blotting methodology, indicating 
that the antibody was able to identify the recombinant protein and could be 
reproduced successfully.  
In conclusion, the findings presented in this thesis suggest that VMO1 mRNA of 
both 387 bp and 691 bp is expressed in THP1 human cell line and insoluble 
VMO1 recombinant protein of approximately 20 kDa in size can expressed and be 
recognised by two antibodies; VMO1 and His Tag. With optimisation and 
purification, a large scale induction of recombinant protein would be beneficial 
for future functional assays such as a pull-down assay to identify interacting 
protein partners. This may provide further insight into the function of VMO1 in 
the inner ear and the role it may play in hearing.   
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APPENDIX ONE 
Buffers and Solutions 
A549 growth medium 
To make 100 mL: 
89 mL  RPMI-1640 Media 
10 mL  Fetal Bovine Serum 
1 mL  100X Penicillin/Streptomycin 
37:1 Acrylamide: BIS (22%) 
22.2 g  Acrylamide 
0.6 g  Bisacrylamide 
Make up to 100 mL with ddH2O, store at 4°C in a light protected bottle 
50 mg/mL Ampicillin 
50 mg  Ampicillin 
1 mL  mQH2O  
Filter sterilise, store at -20°C. 
100 mg/mL Ampicillin 
100 mg Ampicillin 
1 mL  mQH2O 
Filter sterilise, store at -20°C. 
10% Ammonium persulfate (APS) 
0.1 g  Ammonium persulfate 
1 mL  ddH2O 
Store at -20°C. 
10% Blocking solution 
2.5 g  Nonfat Dry Milk powder 
Make up to 25 mL in 1X TBST. Store at 4°C for up to three days. 
75% Ethanol 
750 mL 100% reagent grade ethanol 
250 mL 0.1% DEPC mQH2O 
CaCl2/PEG solution 
To make 10 mL: 
9.9 mL  0.1 M CaCl2 
10 μL  1% PEG8000 
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Chloramphenicol 
34 mg  Chloramphenicol 
1 mL  Ethanol 
Filter sterilise, store at -20°C 
2X cOmplete, Mini, EDTA-free Protease Inhibitor solution 
1 tablet 2X cOmplete, Mini, EDTA-free Protease Inhibitor  
5 mL  mQH2O 
Store at 4°C for one week or freeze aliquots at -20°C for long term storage 
Coomassie blue stain 
0.25 g  Coomassie blue brilliant stain R-250 
90 mL  Methanol 
10 mL  Glacial acetic acid 
Make up to 200 mL with ddH2O 
Cracking Buffer 
3.6 g  Urea 
Make up to 10 mL with 2X SDS Loading Buffer 
0.5M EDTA 
186.1 g disodium EDTA.2H2O 
Add to 800 mL of mQH2O and stir with magnetic mixer. Adjust pH to 8.0 with 
NaOH and adjust volume to 1 L with mQH2O. Autoclave. 
Elution Buffer pH 4.5 
0.1M  Sodium phosphate 
8 M  Urea 
Dissolve in ddH2O. Adjust pH to 4.5 with appropriate acids or bases. 
Elution Buffer pH 6.0 
0.1M  Sodium phosphate 
8 M  Urea 
Dissolve in ddH2O. Adjust pH to 4.5 with appropriate acids or bases. 
Equilibration Buffer 
0.1 M  Sodium phosphate  
8 M  Urea 
Dissolve in ddH2O. Adjust pH to 8.0 with appropriate acids or bases. 
20% Glucose 
To make 10 mL 
2 g  D-Glucose 
10 mL  mQH2O 
Filter sterilise. Aliquot into 2 mL tubes, store at -20°C 
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10% Glycerol 
100 mL Glycerol 
900 mL mQH2O 
Autoclave 
80% Glycerol 
160 mL Glycerol 
40 mL  mQH2O 
Autoclave 
100mM IPTG 
2.38 g  IPTG 
100 mL ddH2O 
Filter sterilise and aliquot into 1 mL tubes. Store at -20°C. 
Kanamycin 
30 mg  Kanamycin 
1 mL  mQH2O 
Filter sterilise, store at -20°C. 
LB broth  
25.0 g  LB 
Add to 1 L of distilled H2O and autoclave. 
LB plates 
25 g  LB  
15 g  Agar 
Make up to 1 L with mQH2O. Autoclave. Cool to ~50°C. Add antibiotics if 
necessary and pour. Once set, refrigerate upside down.   
6X Loading Dye 
3 mL  Glycerol 
25 mg  Bromophenol Blue 
20 μL  Xylene Cyanole 
Make up to 10 mL with sterile mQH2O. 
Lysis Buffer 
1 mL  1 M Tris-HCl pH 7.5 
6.25 mL 4 M NaCl 
5 mL  Glycerol 
50 μL  TritonX-100 
Make up to 50 mL with ddH2O 
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Lysis Buffer (NaCl - free) 
0.2 mL  1 M Tris-HCl pH 7.5 
1 mL  Glycerol 
10 μL  TritonX-100 
Make up to 5 mL with ddH2O 
1X Phosphate buffered saline (PBS) 
8 g  NaCl 
0.25 g  KCl 
0.2 g  KH2PO4 
1.15 g  Na2HPO4 
Make to 1 L with mQH2O 
Ponceau S stain 
0.1 g  Ponceau S 
0.1 g  Acetic acid 
Make to 1 L with mQH2O 
Ponceau S Destaining solution 
2.5 mL  Acetic acid 
Make up to 250 mL with sterile mQH2O 
0.4 M Sodium phosphate  
2.839 g Disodium phosphate (anhydrous) 
50 mL  Sterile ddH2O 
Use at final concentration of 0.1 M. 
10% SDS 
1 g  SDS 
Dissolve in 8 mL of mQH2O then make to 10 mL. 
2X SDS Loading Buffer 
To make 10 mL: 
1 mL  1 M Tris.HCl pH 6.8 
3 mL  100% Glycerol 
4 mL  10% SDS 
10 mg  Bromophenol Blue 
Make up to 10 mL with sterile mQH2O 
Prior to use, add 20 μL of β-Mercaptoethanol to 1 mL of 2X SDS Loading Buffer 
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SUM149PT growth medium 
To make 50 mL: 
46.2 mL Ham’s F12 Nutrient Mixture 
2.5 mL  Fetal Bovine Serum 
500 μL  1 M HEPES 
250 μL  1 mg/mL Insulin 
50 μL  1 mg/mL Hydrocortisone 
500 μL  100 X Penicillin/Streptomycin 
THP1 growth medium 
To make 100 mL: 
89 mL  RPMI-1640 Media 
10 mL  Fetal Bovine Serum 
1 mL  100X Penicillin/Streptomycin 
1X TAE Buffer 
20 mL  50X TAE Buffer 
980 mL ddH2O 
50X TAE Buffer 
242 g  Tris 
57.1 mL Glacial Acetic acid 
100 mL 0.5 M EDTA, pH 8 
Make to final volume of 1 L with ddH2O 
1X Tris Buffered Saline (TBS)  
100 mL 10X TBS 
900 mL Sterile mQH2O 
10X Tris Buffered Saline (TBS) 
24.2 g  Tris base 
80 g  NaCl 
Adjust pH to 7.6 with HCl. Make up to 1 L with sterile mQH2O.  
1X TBST 
100 mL 10X TBS 
1 mL  Tween20 
Make up to 1 L with sterile mQH2O. 
1X Tris-EDTA buffer pH 8.0 
To make 200 mL: 
2 mL  1M Tris 
0.4 mL  0.5M EDTA 
Make up to 200 mL with mQH2O. Check pH and adjust with acid/base if 
necessary. 
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5X Tris-EDTA Buffer pH 8.0 
12.5 mL 1 M Tris-HCl pH 8.0 
2.5 mL  0.5 M EDTA pH 8.0 
Adjust volume to 250 mL with mQH2O, autoclave 
1X Tris-Glycine running buffer 
100 mL 10X Tris-Glycine Buffer 
900 mL ddH2O 
10X Tris-Glycine Buffer 
30 g  Tris 
144 g  Glycine 
10 g  SDS 
Make up to 1 L using ddH2O. 
1M Tris-HCl pH 8.0 
121.1 g Tris base 
Make up to 800 mL of mQH2O and adjust to correct pH. Autoclave.  
8M Urea 
4.8048 g Urea 
10 mL  Sterile ddH2O 
Wash Buffer 
0.1M  Sodium phosphate 
8 M  Urea 
Dissolve in ddH2O. Adjust pH to 6.3 with appropriate acids or bases. 
X-Gal 
20 mg  X-Gal 
1 mL  Dimethyl formamide 
Store at -20°C. 
 
 
  
160 
 
APPENDIX TWO 
Vector Maps 
pET28b(+) Vector 
This vector is an expression system that is designed to produce protein within the 
bacterial host cell it was transformed into through induction with IPTG. The 
VMO1 gene was cloned into the vector between the EcoRI and BamHI restriction 
enzyme sites prior to transformation. 
 
 
 
 
Figure 40: pET28b(+) vector map. Depicted is the multiple cloning site, restriction 
enzyme sites, sequencing primer sites (green), and kanamycin antibiotic resistance 
gene (red)  (AddGene). 
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pBlueScript II SK (+) Vector 
The pBlueScript II SK (+) plasmid is a cloning vector that can be used for blue 
and white colony screening for presence of the gene insert using IPTG and X-Gal. 
It also contains an ampicillin resistance gene used for growth selection of cells 
containing the plasmid on LB agar plates with ampicillin. This vector was used 
due to difficulties cloning the VMO1 gene directly into the pET28b(+) vector.  
 
  
 
Figure 41: pBlueScript II SK (+) vector map. Shown is the multiple cloning site 
positions of restriction enzyme sites, sequencing primer sites (green), ampicillin 
antibiotic resistance gene (red) (AddGene). 
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APPENDIX THREE 
Sequencing Data 
 
Sequencing was provided by the Waikato DNA Sequencing Facility of UoW. 
Sequencing was carried out on an Applied Biosystems 3130xl Genetic Analyser. 
Sequence outputs were analysed using Geneious version 7.1.7 
(http://www.geneious.com, Kearse et al., 2012).  
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Figure 42: Sequencing results of pET28b(+)/VMO1 isoform 1 construct using LMP10F. The sequence has been edited for quality and 
used to form a consensus sequence for confirmation of the ligation into the vector and to check it is in-frame with the His Tag for 
purification. Sequencing was provided by Waikato DNA Sequencing Facility and edited using Geneious version 7.1.7. 
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Figure 43: Sequencing results of pET28b(+)/VMO1 isoform 1 construct using SH1F. The sequence has been edited for quality and used 
to form a consensus sequence for confirmation of the ligation into the vector and to check it is in frame with the His Tag for purification. 
Sequencing was provided by Waikato DNA Sequencing Facility and edited using Geneious version 7.1.7. 
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Figure 44: Sequencing results of pET28b(+)/VMO1 isoform 1 construct using SH3F. The sequence has been edited for quality and used to 
form a consensus sequence for confirmation of the ligation into the vector and to check it is in-frame with the His Tag for purification. 
Sequencing was provided by Waikato DNA Sequencing Facility and edited using Geneious version 7.1.7. 
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Figure 45: Sequencing results of pET28b(+)/VMO1 isoform 1 construct using SH3R. The sequence has been edited for quality and used to 
form a consensus sequence for confirmation of the ligation into the vector and to check it is in-frame with the His Tag for purification. 
Sequencing was provided by Waikato DNA Sequencing Facility and edited using Geneious version 7.1.7. 
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Figure 46: Sequencing results of pET28b(+)/VMO1 isoform 1 construct using LMP11R. The sequence was used for confirmation of the 
ligation into the vector and to check it is in-frame with the His Tag for purification. Sequencing was provided by Waikato DNA Sequencing 
Facility and data interpreted using Geneious version 7.1.7. 
